Compounds and uses thereof
Compounds targeting BRG1 and BRM proteins within the BAF complex are developed to modulate its activity, effectively inhibiting cancer cell growth and inducing apoptosis, even in drug-resistant cancers.
Patent Information
- Application Number
- JP2024122975
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-11
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-06
AI Technical Summary
Current treatments for disorders associated with alterations in the BRG1 and BRM proteins, such as cancer, are inadequate in effectively modulating the BAF complex activity and addressing drug resistance.
Development of compounds that modulate the BAF complex by targeting BRG1 and/or BRM proteins, which can be used alone or in combination with other pharmaceutically active agents to treat such disorders, including cancer.
The compounds effectively inhibit the activity of BRG1 and BRM, leading to reduced cancer cell proliferation and apoptosis, even in drug-resistant cases, and can be used to treat various types of cancer and viral infections.
Smart Images

Figure 2024156779000422 
Figure 2024156779000423 
Figure 2024156779000424
Abstract
Description
[Technical Field]
[0001] The present invention relates to compounds useful for modulating the BRG1 or BRM-associated factor (BAF) complex. In particular, the present invention relates to compounds useful for treating disorders associated with BAF complex function. [Background technology]
[0002] Chromatin regulation is essential for gene expression, and ATP-dependent chromatin remodeling is the mechanism by which such gene expression occurs. The human switch / sucrose non-fermenting (SWI / SNF) chromatin remodeling complex, also known as the BAF complex, contains two SWI2-like ATPases known as BRG1 (Brahma-related gene-1) and BRM (Brahma). The transcriptional activator BRG1, also known as the ATP-dependent chromatin remodeler SMARCA4, is encoded by the SMARCA4 gene on chromosome 19. BRG1 is overexpressed in some cancer tumors and is required for cancer cell proliferation. BRM, also known as the likely global transcriptional activator SNF2L2 and / or the ATP-dependent chromatin remodeler SMARCA2, is encoded by the SMARCA2 gene on chromosome 9 and has been shown to be essential for tumor cell proliferation in cells characterized by loss-of-function mutations in BRG1. Deactivation of BRG and / or BRM leads to downstream effects in cells, including cell cycle arrest and tumor suppression. Summary of the Invention
[0003] The present invention features compounds useful for modulating the BAF complex. In some embodiments, the compounds are useful for treating disorders associated with alterations in the BAF complex, such as disorders associated with alterations in one or both of the BRG1 and BRM proteins. The compounds of the present invention can be used alone or in combination with other pharmaceutically active agents to treat such disorders.
[0004] In one aspect, the present invention provides a compound having the structure: [ka] During the ceremony, m is 0, 1, 2, or 3; n is 0, 1, 2, 3, or 4; p is 0, 1, 2, or 3; X 1 But, O, NR 5 , or (C(R 5 )(R 6 )) and Z 1 and Z 2 each of which is independently absent or (C(R 9 )2) or O, but X 1 If is O, then Z 1 and Z 2 each of which is independently absent or (C(R 9 )2) and X 2 But N or CR 8 and Each R X1 are independently deuterium, optionally substituted C-C alkyl, or halo, or two geminal R X1 groups combine with the atoms to which they are attached to form a carbonyl, L 1 is an optionally substituted 9- or 10-membered bicyclic heterocyclyl, an optionally substituted 9- or 10-membered bicyclic heteroaryl, an optionally substituted 6-membered monocyclic heteroarylvinyl, an optionally substituted 6-membered monocyclic heteroaryl-C3-C8-cycloalkyl, or an optionally substituted 6-membered monocyclic heteroarylethynyl; L 2 but absent or optionally substituted C3-C 10 Cycloalkyl, optionally substituted C-C 10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 4- to 10-membered heterocyclyl; R 1is hydrogen or optionally substituted C1-C6 alkyl; Each R 2 and each R 3 are independently hydrogen, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl; R 4 is hydrogen, halo, optionally substituted C1-C6 alkyl, or optionally substituted C3-C 10 is cycloalkyl, R 5 is hydrogen, deuterium, or optionally substituted C1-C6 alkyl; R 6 is hydrogen, deuterium, optionally substituted C-C alkyl, or halo, and each R 9 are independently hydrogen, deuterium, optionally substituted C-C alkyl, or halo, or R 6 and one adjacent R 9 together with the atoms to which they are attached form an optionally substituted C3-C8 cycloalkyl, and the remaining R 9 groups, if present, are independently deuterium, optionally substituted C1-C6 alkyl, or halo; Each R 7 are independently selected from optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, halo, optionally substituted C3-C 10 cycloalkyl, optionally substituted 5- to 10-membered heteroaryl, optionally substituted 4- to 10-membered heterocyclyl, -N(R 7A )2, or -OR 7A and each R 7A are independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C 10 Cycloalkyl, optionally substituted C-C 10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 4- to 10-membered heterocyclyl, or two geminal R 7Agroups, together with the atoms to which they are attached, combine to form an optionally substituted 5- to 10-membered heteroaryl or an optionally substituted 4- to 10-membered heterocyclyl; R 8 is hydrogen, halo, cyano, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C 10 is cycloalkyl, R 10 is hydrogen or halo, or a pharmaceutically acceptable salt thereof.
[0005] In some embodiments, Z 1 is (C(R 9 )2). In some embodiments, Z 1 is absent. In some embodiments, Z 1 is O.
[0006] In some embodiments, Z 2 is (C(R 9 )2). In some embodiments, Z 2 is absent. In some embodiments, Z 2 is O.
[0007] In some embodiments, X 1 is O. In some embodiments, X 1 is NR 5 In some embodiments, X 1 is (C(R 5 )(R 6 )
[0008] In some embodiments, X 2 is CR 8 is.
[0009] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0010] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0011] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0012] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0013] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0014] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0015] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0016] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0017] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0018] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0019] In some embodiments, R 8 is hydrogen. In some embodiments, R 8is halo (e.g., fluoro). In some embodiments, R 8 is an optionally substituted C-C alkynyl. In some embodiments, R 8 is an optionally substituted C1-C6 heteroalkyl. In some embodiments, R 8 is an optionally substituted C3-C 10 It is cycloalkyl.
[0020] In some embodiments, X 2 is N.
[0021] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0022] In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is a halogen.
[0023] In some embodiments, R 10 is hydrogen. In some embodiments, R 10 is a halogen.
[0024] In some embodiments, at least one R X1 is optionally substituted C-C alkyl. In some embodiments, at least one R X1 is halo. In some embodiments, at least one R X1 is deuterium.
[0025] In some embodiments, p is 3. In some embodiments, p is 2. In some embodiments, p is 1. In some embodiments, p is 0.
[0026] In some embodiments, L 1 is an optionally substituted 9- or 10-membered bicyclic heteroaryl. In some embodiments, L 1 is [ka] During the ceremony, X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 each independently represents N or CR L1 That is, Each R L1 is independently H, halo, optionally substituted C1-C6 alkyl; A 1 But -(C(R 2 )(R 3 )) m - is a bond to A 2 But, L 2 is a bond to
[0027] In some embodiments, L 1 is as follows: [ka] In some embodiments, R L1 is hydrogen.
[0028] In some embodiments, L 1 is as follows: [ka]
[0029] In some embodiments, L 1 is as follows: [ka]
[0030] In some embodiments, L 1 is an optionally substituted monocyclic 6-membered heteroarylvinyl.
[0031] In some embodiments, L 1 is [ka] During the ceremony, X 3 , X 4 , and X 5 each independently represents N or CR L1 and Each R L1 is independently H, halo, optionally substituted C1-C6 alkyl; A 1 But -(C(R 2 )(R 3 )) m - is a bond to A 2 But, L 2 is a bond to
[0032] In some embodiments, L 1 is as follows: [ka]
[0033] In some embodiments, L 1 is an optionally substituted monocyclic 6-membered heteroarylethynyl.
[0034] In some embodiments, L 1 is [ka] During the ceremony, X 3 , X 4 , and X 5 each independently represents N or CR L1 and Each R L1 is independently H, halo, optionally substituted C1-C6 alkyl; A 1 But -(C(R 2 )(R 3 )) m - is a bond to A 2 But, L 2 is a bond to
[0035] In some embodiments, L 1 is as follows: [ka]
[0036] In some embodiments, L 1 is an optionally substituted monocyclic 6-membered heteroaryl-C3-C8-cycloalkyl.
[0037] In some embodiments, L 1 is [ka] During the ceremony, X 3 , X 4 , and X 5 each independently represents N or CR L1 and Each R L1 is independently H, halo, optionally substituted C1-C6 alkyl; A 1 But -(C(R 2 )(R 3 )) m - is a bond to A 2 But, L 2 is a bond to
[0038] In some embodiments, L 1 is as follows: [ka]
[0039] In some embodiments, L 1 is an optionally substituted 9 or 10 membered bicyclic heterocyclyl.
[0040] In some embodiments, the compound has the following structure: [ka]
[0041] In some embodiments, L 2 is an optionally substituted 5-10 membered heteroaryl.
[0042] In some embodiments, -L 2 -(R 7 ) n is a group of the following structure: [ka] [ka]
[0043] In some embodiments, -L 2 -(R 7 ) n is a group of the following structure: [ka]
[0044] In some embodiments, -L 2 -(R 7 ) n is a group of the following structure: [ka]
[0045] In some embodiments, -L 2-(R 7 ) n is a group of the following structure: [ka]
[0046] In some embodiments, -L 2 -(R 7 ) n is a group of the following structure: [ka]
[0047] In some embodiments, -L 2 -(R 7 ) n is a group of the following structure: [ka]
[0048] In some embodiments, L 2 is an optionally substituted C6-C 10 In some embodiments, L is aryl. 2 is an optionally substituted phenyl.
[0049] In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3.
[0050] In some embodiments, R 7 is an optionally substituted C1-C6 alkyl. In some embodiments, R 7 is an optionally substituted C1-C6 heteroalkyl. In some embodiments, R 7 is an optionally substituted 4-10 membered heterocyclyl. In some embodiments, R 7 is optionally substituted azetidinyl or optionally substituted morpholinyl. In some embodiments, R 7is an optionally substituted C3-C 10 In some embodiments, R 7 is optionally substituted cyclopropyl or optionally substituted cyclobutyl. In some embodiments, R 7 is -N(R 7A )2. In some embodiments, R 7 is an optionally substituted N-azetidinyl or an optionally substituted N-morpholinyl. In some embodiments, two geminal R 7 The groups, together with the atoms to which they are attached, combine to form an optionally substituted 4- to 10-membered heterocyclyl. In some embodiments, at least one R 7 -OR 7A In some embodiments, R 7A is an optionally substituted C 1-6 It is alkyl.
[0051] In some embodiments, n is 0.
[0052] In some embodiments, at least one R 7is difluoromethyl, cyclopropyl, 2,2-difluorocyclopropyl, difluoromethoxy, 2,6-dimethylmorpholin-4-yl, N-azetidinyl, 3-fluorocyclobutyl, 2-methoxyethyl, ethoxy, methoxy, 2,2-difluoroethoxy, 2,2-difluoroethyl, trifluoromethyl, isopropyl, methyl, acetyl, fluoro, chloro, 1-methylpyrazol-3-yl, dimethylamino, N-methyl-N-(2-methoxyethyl)-amino, N-ethyl-N-(2-methoxyethyl)-amino, N-(2-propyl)-N-(2-methoxyethyl)-amino, 2-methoxyethylamino, 3-aza-8-oxa-bicyclo[ 4.3.0]non-3-yl, 3-aza-7-oxa-bicyclo[4.3.0]non-3-yl, 1-fluorocyclobut-1-yl, 3-fluoropyrrolidin-1-yl, 3-methoxypyrrolidin-1-yl, oxetan-3-yl, N-methylindolin-4-yl, 2,2-difluoro-3-methylcycloprop-1-yl, 3-methoxyazetidin-1-yl, 3-methoxypiperidin-1-yl, 1,2-dimethyl-7-azaindol-4-yl, 1-methyl-7-azaindol-4-yl, 2,3-methylenedioxyphenyl, N-methyl-N-(3-oxetanyl)amino, 3-oxetanyloxy, 1,1-difluoro-5-azaspiro[2.3]hex-5-yl, 1-fluoromethyl-cyclopropyl, N-(3-tetrahydrofuranyl)methylamino, N-indolinyl, N-1,4-oxazepanyl, 2-fluoro-2-propyl, 1,1-difluoro-2-propyl, 2,2-difluoro-1-methylcycloprop-1-yl, 1-methylcyclopropyl, 4,4-difluoropiperidin-1-yl, 2-methoxyethoxy, 3,3-difluorocyclobut-1-yl, N-methyl-N-1-methoxyprop-2-ylamino, 1-methoxyprop-2-ylamino, 1-methoxyethyl, 4-methylpiperazinyl, 3-methylmorpholinyl, 2,2-difluoropropoxy, 3- Methoxycyclobutyl, methylamino, 4-dimethylamino-3,3-difluoropiperidinyl, 4-methylamino-3,3-difluoropiperidinyl, 3,3-difluoropyrrolidinyl, N-methyl-N-3-methoxycyclobutylamino, 1-methylpyrazol-5-yl, 6-oxa-3-azabicyclo[3.1.1]hept-3-yl, cyclopropyloxy, 2,6-dimethylpyrid-4-yl, 2-methylpyrrolidinyl, 4-oxabicyclo[4.1.0]hept-1-yl, N-methyl-N-(2,6-dimethyltetrahydropyran-4-yl)amino, or N-methyl-N-3-methyloxetan-3-ylmethylamino.
[0053] In some embodiments, R 1 is hydrogen.
[0054] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0055] In some embodiments, the group [ka] is a group of the following structure: [ka]
[0056] In some embodiments, the compound is a compound selected from the group consisting of compounds 1-523 and pharmaceutically acceptable salts thereof. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12] [Table 1-13] [Table 1-14]
Table 1-15
Table 1-16
Table 1-17
Table 1-18
Table 1-19
Table 1-20
Table 1-21
Table 1-22
Table 1-23
Table 1-24
Table 1-25
Table 1-26
Table 1-27
Table 1-28
Table 1-29
Table 1-30
Table 1-31
Table 1-32
Table 1-33
Table 1-34
Table 1-35
Table 1-36
Table 1-37
Table 1-38
Table 1-39
Table 1-40
Table 1-41
Table 1-42
Table 1-43
Table 1-44
Table 1-45
Table 1-46
Table 1-47
Table 1-48
Table 1-49
Table 1-50
Table 1-51
Table 1-52
Table 1-53
Table 1-54
Table 1-55
Table 1-56
Table 1-57
Table 1-58
Table 1-59
Table 1-60
Table 2-1
Table 2-2
Table 2-3
Table 2-4
Table 2-5
Table 2-6
Table 2-7
Table 2-8
Table 2-9
Table 2-10
Table 2-11
Table 2-12
Table 2-13
Table 2-14
Table 2-15
Table 2-16
Table 2-17
Table 2-18
Table 2-19
Table 2-20
Table 2-21
Table 2-22
[0057] In some embodiments, the compound is 50 and BRM IC 50 to a BRG1 IC of at least 5. In some embodiments, the compound 50 and BRM IC 50 to a BRG1 IC of at least 7. In some embodiments, the compound 50 and BRM IC 50 to a BRG1 IC of at least 10. In some embodiments, the compound 50 and BRM IC 50 In some embodiments, the compound has a BRG1 IC 50 and BRM IC 50 In some embodiments, the compound has a BRG1 IC 50 and BRM IC 50 In some embodiments, the compound has a BRG1 IC 50 and BRM IC 50 The ratio of
[0058] In another aspect, the invention features a pharmaceutical composition including any one of the above compounds and a pharmaceutically acceptable excipient.
[0059] In another aspect, the invention features a method for decreasing the activity of a BAF complex in a cell, the method comprising contacting the cell with an effective amount of any of the aforementioned compounds or a pharmaceutical composition thereof.
[0060] In some embodiments, the cells are cancer cells.
[0061] In another aspect, the invention features a method of treating a BAF complex-associated disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of any of the aforementioned compounds or a pharmaceutical composition thereof.
[0062] In some embodiments, the BAF complex-associated disorder is cancer.
[0063] In a further aspect, the invention features a method of inhibiting a BRM, the method including contacting a cell with an effective amount of any of the aforementioned compounds or a pharmaceutical composition thereof. In some embodiments, the cell is a cancer cell.
[0064] In another aspect, the invention features a method of inhibiting BRG1, the method including contacting a cell with an effective amount of any of the aforementioned compounds or a pharmaceutical composition thereof. In some embodiments, the cell is a cancer cell.
[0065] In a further aspect, the invention features a method of inhibiting BRM and BRG1, the method including contacting a cell with an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof. In some embodiments, the cell is a cancer cell.
[0066] In another aspect, the invention features a method of treating a disorder associated with a loss-of-function mutation in BRG1 in a subject in need thereof, the method comprising administering to the subject an effective amount of any of the aforementioned compounds or a pharmaceutical composition thereof.
[0067] In some embodiments, the disorder associated with BRG1 loss-of-function mutation is cancer. In other embodiments, the subject is determined to have a BRG1 loss-of-function disorder, for example, determined to have a BRG1 loss-of-function cancer (for example, determined to comprise cancer cells with BRG1 loss-of-function).
[0068] In another aspect, the invention features a method of inducing apoptosis in a cell, the method comprising contacting the cell with an effective amount of any of the aforementioned compounds or a pharmaceutical composition thereof. In some embodiments, the cell is a cancer cell.
[0069] In a further aspect, the invention features a method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of any of the aforementioned compounds or a pharmaceutical composition thereof.
[0070] In some embodiments of any of the aforementioned methods, the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary site, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, esophagogastric cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin's lymphoma, small cell lung cancer, prostate cancer, embryonal tumors, germ cell tumors, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumors, uterine sarcoma, gastrointestinal stromal tumors, CNS cancer, thymic tumor, adrenocortical carcinoma, appendix cancer, small intestine cancer, or penile cancer.
[0071] In some embodiments of any of the aforementioned methods, the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, or penile cancer.
[0072] In some embodiments of any of the foregoing methods, the cancer is a drug-resistant cancer or has not responded to previous therapies (e.g., vemurafenib, dacarbazine, CTLA4 inhibitors, PD1 inhibitors, interferon therapy, BRAF inhibitors, MEK inhibitors, radiation therapy, temozolimide, irinotecan, CAR-T therapy, Herceptin, Perjeta, tamoxifen, Xeloda, docetaxel, platinum agents such as carboplatin, taxanes such as paclitaxel and docetaxel, ALK inhibitors, MET inhibitors, Alimta, Abraxane, Adriamycin®, gemcitabine, Avastin, Halaven, neratinib, PARP inhibitors, ARN810, mTOR inhibitors, topotecan, Gemzar, VEGFR2 inhibitors, folate receptor antagonists, demcizumab, fosbretabulin, or PDL1 inhibitors).
[0073] In some embodiments of any of the aforementioned methods, the cancer has or has been determined to have a BRG1 mutation. In some embodiments of any of the aforementioned methods, the BRG1 mutation is homozygous. In some embodiments of any of the aforementioned methods, the cancer does not have or has been determined to not have an epidermal growth factor receptor (EGFR) mutation. In some embodiments of any of the aforementioned methods, the cancer does not have or has been determined to not have an anaplastic lymphoma kinase (ALK) driver mutation. In some embodiments of any of the aforementioned methods, the cancer has or has been determined to have a KRAS mutation. In some embodiments of any of the aforementioned methods, the BRG1 mutation is in the ATPase catalytic domain of the protein. In some embodiments of any of the aforementioned methods, the BRG1 mutation is a deletion at the C-terminus of BRG1.
[0074] In another aspect, the present disclosure provides a method of treating a BAF-associated disorder (e.g., cancer or viral infection) in a subject in need thereof, comprising contacting a cell with an effective amount of any of the aforementioned compounds or pharmaceutically acceptable salts thereof, or any of the aforementioned pharmaceutical compositions. In some embodiments, the disorder is a viral infection caused by a virus selected from the Retroviridae family, such as lentiviruses (e.g., human immunodeficiency virus (HIV) and deltaretroviruses (e.g., human T-cell leukemia virus type I (HTLV-I)), human T-cell leukemia virus type II (HTLV-II)), Hepadnaviridae family (e.g., hepatitis B virus (HBV)), Flaviviridae family (e.g., hepatitis C virus (HCV)), Adenoviridae family (e.g., human adenovirus), Herpesviridae family (e.g., human cytomegalovirus (HCMV), Epstein-Barr virus, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), human herpesvirus type 6 (HHV-6), herpesvirus K*, CMV, varicella-zoster virus), Papillomaviridae family (e.g., human papillomavirus (HPV), HPV E1), Parvoviridae (e.g., parvovirus B19), Polyomaviridae (e.g., JC virus and BK virus), Paramyxoviridae (e.g., measles virus), or Togaviridae (e.g., rubella virus). In some embodiments, the disorder is coffin schisis, neurofibromatosis (e.g., NF-1, NF-2, or schwannoma), or multiple meningiomas.
[0075] In another aspect, the disclosure provides a method for treating a viral infection in a subject in need thereof, the method comprising administering to the subject an effective amount of any of the foregoing compounds, or a pharmaceutically acceptable salt thereof, or any of the foregoing pharmaceutical compositions. In some embodiments, the viral infection is caused by a virus selected from the Retroviridae family, such as lentivirus (e.g., human immunodeficiency virus (HIV) and deltaretrovirus (e.g., human T-cell leukemia virus type I (HTLV-I)), human T-cell leukemia virus type II (HTLV-II)), Hepadnaviridae family (e.g., hepatitis B virus (HBV)), Flaviviridae family (e.g., hepatitis C virus (HCV)), Adenoviridae family (e.g., human adenovirus), Herpesviridae family (e.g., human cytomegalovirus (HCMV), Epstein-Barr virus, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), human herpesvirus type 6 (HHV-6), herpesvirus K*, CMV, varicella-zoster virus), Papillomaviridae family (e.g., human papillomavirus (HPV), HPV), E1), Parvoviridae (e.g., parvovirus B19), Polyomaviridae (e.g., JC virus and BK virus), Paramyxoviridae (e.g., measles virus), or Togaviridae (e.g., rubella virus).
[0076] In another aspect, the invention features a method of treating melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematological cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of any of the aforementioned compounds or a pharmaceutical composition thereof.
[0077] In another aspect, the invention features a method of reducing melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematological cancer tumor growth in a subject in need thereof, the method comprising administering to the subject an effective amount of any of the aforementioned compounds or a pharmaceutical composition thereof.
[0078] In another aspect, the invention features a method of inhibiting metastatic progression of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematological cancer in a subject, comprising administering an effective amount of any of the preceding compounds or a pharmaceutical composition thereof.
[0079] In another aspect, the invention features a method of inhibiting metastatic colonization of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or hematological cancer in a subject, the method comprising administering an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof.
[0080] In another aspect, the invention features a method for reducing the level and / or activity of BRG1 and / or BRM in melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, blood cancer cells, or esophageal cancer cells, comprising contacting the cells with an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof.
[0081] In some embodiments of any of the above aspects, the melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, or blood cells are in the subject.
[0082] In some embodiments of any of the above aspects, an effective amount of a compound reduces the level and / or activity of BRG1 by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) compared to a reference substance. In some embodiments, an effective amount of a compound reduces the level and / or activity of BRG1 by at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) compared to a reference substance. In some embodiments, an effective amount of a compound reduces the level and / or activity of BRG1 by at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%).
[0083] In some embodiments, an effective amount of a compound reduces BRG1 levels and / or activity by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) for at least 12 hours (e.g., 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours, or more) compared to a reference substance. In some embodiments, an effective amount of a compound that reduces the level and / or activity of BRG1 by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) for at least 4 days (e.g., 5 days, 6 days, 7 days, 14 days, 28 days, or more) compared to a reference substance.
[0084] In some embodiments of any of the above aspects, an effective amount of compound reduces the level and / or activity of a BRM by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) compared to a reference substance. In some embodiments, an effective amount of compound reduces the level and / or activity of a BRM by at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) compared to a reference substance. In some embodiments, an effective amount of compound reduces the level and / or activity of a BRM by at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%).
[0085] In some embodiments, an effective amount of a compound reduces the level and / or activity of a BRM by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) for at least 12 hours (e.g., 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours, or more) compared to a reference substance. In some embodiments, an effective amount of a compound that reduces the level and / or activity of a BRM by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) for at least 4 days (e.g., 5 days, 6 days, 7 days, 14 days, 28 days, or more) compared to a reference substance.
[0086] In some embodiments, the subject has cancer. In some embodiments, the cancer expresses BRG1 and / or BRM protein, and / or the cell or subject has been identified as expressing BRG1 and / or BRM. In some embodiments, the cancer expresses BRG1 protein, and / or the cell or subject has been identified as expressing BRG1. In some embodiments, the cancer expresses BRM protein, and / or the cell or subject has been identified as expressing BRM. In some embodiments, the cancer is melanoma (e.g., uveal melanoma, mucosal melanoma, or cutaneous melanoma). In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is a hematological cancer, such as multiple myeloma, large cell lymphoma, acute T-cell leukemia, acute myeloid leukemia, myelodysplastic syndrome, immunoglobulin A lambda myeloma, diffuse mixed histiocytic and lymphocytic lymphoma, B-cell lymphoma, acute lymphoblastic leukemia (e.g., T-cell acute lymphoblastic leukemia or B-cell acute lymphoblastic leukemia), diffuse large cell lymphoma, or non-Hodgkin's lymphoma. In some embodiments, the cancer is breast cancer (e.g., ER-positive breast cancer, ER-negative breast cancer, triple-positive breast cancer, or triple-negative breast cancer). In some embodiments, the cancer is bone cancer (e.g., Ewing's sarcoma). In some embodiments, the cancer is renal cell carcinoma (e.g., microphthalmia transcription factor (MITF) family translocation renal cell carcinoma (tRCC)). In some embodiments, the cancer is metastatic (e.g., the cancer has spread to the liver). A metastatic cancer may comprise cells exhibiting migratory cell migration and / or invasion, and / or may comprise cells exhibiting endothelial recruitment and / or angiogenesis. In other embodiments, the migratory cancer is a cell migration cancer. In yet other embodiments, the cell migration cancer is a non-metastatic cell migration cancer. A metastatic cancer may be a cancer that spreads via seeding the surfaces of the peritoneum, pleura, pericardium, or subarachnoid space. Alternatively, a metastatic cancer may be a cancer that spreads via the lymphatic system or hematogenously. In some embodiments, an effective amount of a compound of the present invention is an amount effective to inhibit metastatic colonization of a cancer in the liver.
[0087] In some embodiments, the cancer harbors a mutation in GNAQ. In some embodiments, the cancer harbors a mutation in GNA11. In some embodiments, the cancer harbors a mutation in PLCB4. In some embodiments, the cancer harbors a mutation in CYSLTR2. In some embodiments, the cancer harbors a mutation in BAP1. In some embodiments, the cancer harbors a mutation in SF3B1. In some embodiments, the cancer harbors a mutation in EIF1AX. In some embodiments, the cancer harbors a TFE3 translocation. In some embodiments, the cancer harbors a TFEB translocation. In some embodiments, the cancer harbors a MITF translocation. In some embodiments, the cancer harbors an EZH2 mutation. In some embodiments, the cancer harbors a SUZ12 mutation. In some embodiments, the cancer harbors an EED mutation.
[0088] In some embodiments of any of the foregoing methods, the method further comprises administering to the subject an anti-cancer therapy or contacting the cells with an anti-cancer therapy, e.g., a chemotherapeutic or cytotoxic agent, immunotherapy, surgery, radiation therapy, hyperthermia, or photocoagulation, or a combination thereof. In some embodiments, the anti-cancer therapy is a chemotherapeutic or cytotoxic agent, such as an antimetabolite, an antimitotic, an anti-tumor agent, an antibiotic, an asparagine-specific enzyme, a bisphosphonate, an anti-neoplastic agent, an alkylating agent, a DNA repair enzyme inhibitor, a histone deacetylase inhibitor, a corticosteroid, a demethylating agent, an immunomodulatory agent, a Janus-related kinase inhibitor, a phosphinositide 3-kinase inhibitor, a proteasome inhibitor, or a tyrosine kinase inhibitor, or a combination thereof.
[0089] In some embodiments of any of the aforementioned methods, the compound of the invention is used in combination with another anti-cancer therapy used to treat uveal melanoma, such as surgery, a MEK inhibitor, and / or a PKC inhibitor. For example, in some embodiments, the method further comprises performing surgery before, after, or simultaneously with the administration of the compound of the invention. In some embodiments, the method further comprises administering a MEK inhibitor and / or a PKC inhibitor before, after, or simultaneously with the administration of the compound of the invention.
[0090] In some embodiments, the anti-cancer therapy and the compound of the invention are administered within 28 days of each other, and each in an amount together effective to treat the subject.
[0091] In some embodiments, the subject or cancer has and / or has been identified as having a loss-of-function mutation in BRG1.
[0092] In some embodiments, the cancer is resistant to one or more chemotherapeutic or cytotoxic agents (e.g., the cancer has been determined to be resistant to a chemotherapeutic or cytotoxic agent (e.g., by a genetic marker) or has been determined to be likely to be resistant to a chemotherapeutic or cytotoxic agent (e.g., a cancer that has failed to respond to a chemotherapeutic or cytotoxic agent)). In some embodiments, the cancer has failed to respond to one or more chemotherapeutic or cytotoxic agents. In some embodiments, the cancer is resistant to or has failed to respond to dacarbazine, temozolomide, cisplatin, treosulfan, fotemustine, IMCgp100, CTLA-4 inhibitors (e.g., ipilimumab), PD-1 inhibitors (e.g., nivolumab or pembrolizumab), PD-L1 inhibitors (e.g., atezolizumab, avelumab, or durvalumab), mitogen-activated protein kinase (MEK) inhibitors (e.g., selumetinib, binimetinib, or trametinib), and / or protein kinase C (PKC) inhibitors (e.g., sotrastaurin or IDE196).
[0093] In some embodiments, the cancer is resistant to or has not responded to previously administered therapeutic agents used to treat uveal melanoma, such as MEK inhibitors or PKC inhibitors. For example, in some embodiments, the cancer is resistant to or has not responded to mitogen-activated protein kinase (MEK) inhibitors (e.g., selumetinib, binimetinib, or tametinib) and / or protein kinase C (PKC) inhibitors (e.g., sotrastaurin or IDE196).
[0094] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in therapy.
[0095] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in decreasing the activity of a BAF complex in a cell.
[0096] In some embodiments, the BAF complex is in a cancer cell.
[0097] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in the treatment of a BAF complex-associated disorder.
[0098] In some embodiments, the BAF complex-associated disorder is cancer or a viral infection.
[0099] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in inhibiting a BRM in a cell.
[0100] In some embodiments, the cells are cancer cells.
[0101] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in the treatment of a disorder associated with a loss-of-function mutation in BRG1.
[0102] In some embodiments, the disorder associated with a loss-of-function mutation in BRG1 is cancer.
[0103] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in inducing apoptosis in a cell.
[0104] In some embodiments, the cells are cancer cells.
[0105] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in the treatment of cancer.
[0106] In some embodiments, the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary site, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, esophagogastric cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin's lymphoma, small cell lung cancer, prostate cancer, embryonal tumors, germ cell tumors, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumors, uterine sarcoma, gastrointestinal stromal tumors, CNS cancer, thymic tumor, adrenocortical carcinoma, appendix cancer, small intestine cancer, or penile cancer.
[0107] In some embodiments, the cancer is non-small cell lung cancer, colon cancer, bladder cancer, cancer of unknown primary origin, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, or penile cancer.
[0108] In some embodiments, the cancer is non-small cell lung cancer. In some embodiments, the cancer is soft tissue sarcoma.
[0109] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in the treatment of a cancer selected from the group consisting of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, and hematological cancer.
[0110] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in reducing tumor growth of a cancer selected from the group consisting of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, and hematological cancer.
[0111] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in inhibiting the metastatic progression of a cancer selected from the group consisting of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, and hematological cancer.
[0112] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in inhibiting metastatic colonization of a cancer selected from the group consisting of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, and hematological cancer.
[0113] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in reducing the level and / or activity of a BRM in a cancer cell selected from the group consisting of melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, and hematological cancer.
[0114] In some embodiments, the cell is in a subject.
[0115] In some embodiments, the cancer is metastatic.
[0116] In some embodiments, the use further includes an anti-cancer therapy.
[0117] In some embodiments, the anti-cancer therapy is a chemotherapeutic or cytotoxic agent, immunotherapy, surgery, radiation therapy, hyperthermia, or photocoagulation.
[0118] In some embodiments, the anti-cancer therapy is surgery.
[0119] In some embodiments, the anti-cancer therapy is a chemotherapeutic or cytotoxic agent.
[0120] In some embodiments, the chemotherapeutic or cytotoxic agent is an antimetabolite, an antimitotic, an antitumor antibiotic, an asparagine-specific enzyme, a bisphosphonate, an anti-neoplastic agent, an alkylating agent, a DNA repair enzyme inhibitor, a histone deacetylase inhibitor, a corticosteroid, a demethylating agent, an immunomodulatory agent, a Janus-related kinase inhibitor, a phosphinositide 3-kinase inhibitor, a proteasome inhibitor, or a tyrosine kinase inhibitor.
[0121] In some embodiments, the one or more chemotherapeutic or cytotoxic agents are dacarbazine, temozolomide, cisplatin, treosulfan, fotemustine, IMCgp100, a CTLA-4 inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a mitogen-activated protein kinase inhibitor, and / or a protein kinase C inhibitor.
[0122] In some embodiments, the anti-cancer therapy and the compound of any one of claims 1-93 or the pharmaceutical composition of claim 94 are administered within 28 days of each other, and each in an amount effective to treat the subject.
[0123] In some embodiments, the subject or cancer has and / or has been identified as having a loss-of-function mutation in BRG1.
[0124] In some embodiments, the cancer has failed to respond to or progressed after administration of one or more chemotherapeutic or cytotoxic agents.
[0125] In some embodiments, the cancer is resistant or predicted to be resistant to one or more chemotherapeutic agents.
[0126] In some embodiments, the one or more chemotherapeutic or cytotoxic agents are dacarbazine, temozolomide, cisplatin, treosulfan, fotemustine, IMCgp100, a CTLA-4 inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a mitogen-activated protein kinase inhibitor, and / or a protein kinase C inhibitor.
[0127] In some embodiments, the cancer is melanoma. In some embodiments, the melanoma is uveal melanoma. In some embodiments, the melanoma is mucosal melanoma. In some embodiments, the melanoma is cutaneous melanoma. In some embodiments, the cancer is a hematological cancer. In some embodiments, the hematological cancer is multiple myeloma, large cell lymphoma, acute T-cell leukemia, acute myeloid leukemia, myelodysplastic syndrome, immunoglobulin A lambda myeloma, diffuse mixed histiocytic and lymphocytic lymphoma, B-cell lymphoma, acute lymphoblastic leukemia, diffuse large cell lymphoma, or non-Hodgkin's lymphoma. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is breast cancer. In some embodiments, the breast cancer is ER-positive breast cancer, ER-negative breast cancer, triple-positive breast cancer, or triple-negative breast cancer. In some embodiments, the cancer is bone cancer. In some embodiments, the bone cancer is Ewing's sarcoma. In some embodiments, the cancer is renal cell carcinoma. In some embodiments, the renal cell carcinoma is microphthalmia transcription factor (MITF) family translocation renal cell carcinoma.
[0128] In one aspect, the present invention provides a compound disclosed herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition disclosed herein, for use in the treatment of a viral infection.
[0129] In some embodiments, the viral infection is an infection with a virus of the family Retroviridae, Hepadnaviridae, Flaviviridae, Adenoviridae, Herpesviridae, Papillomaviridae, Parvoviridae, Polyomaviridae, Paramyxoviridae, or Togaviridae.
[0130] In one aspect, the invention provides the use of any of the foregoing compounds (e.g., a BRM / BRG1 dual inhibitor compound or a BRM-selective compound), or a pharmaceutically acceptable salt thereof, or any of the foregoing pharmaceutical compositions, in the manufacture of a medicament. In some embodiments, the use is as described for the methods described herein.
[0131] chemical terms The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
[0132] For any of the following chemical definitions, the number following an atomic symbol indicates the total number of atoms of that element present in a particular chemical moiety. As understood, other atoms, such as H atoms, or substituents described herein, may be present, as needed, to satisfy the valence of an atom. For example, an unsubstituted C alkyl group has the formula —CHCH. When used with groups defined herein, references to the number of carbon atoms include divalent carbons in acetal and ketal groups, but do not include the carbonyl carbon in acyl, ester, carbonate, or carbamate groups. References to the number of oxygen, nitrogen, or sulfur atoms in heteroaryl groups include only those atoms that form part of the heterocyclic ring.
[0133] The term "acyl," as used herein, represents an H or alkyl group, as defined herein, attached to the parent molecular group through a carbonyl group, and is exemplified by formyl (i.e., a carboxaldehyde group), acetyl, trifluoroacetyl, propionyl, and butanoyl. Exemplary unsubstituted acyl groups contain 1 to 6, 1 to 11, or 1 to 21 carbons.
[0134] As used herein, the term "alkyl" refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of 1 to 20 carbon atoms (e.g., 1 to 16 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms, or 1 to 3 carbon atoms).
[0135] Alkylene is a divalent alkyl group. As used herein, the term "alkenyl," alone or in combination with other groups, refers to a straight-chain or branched hydrocarbon residue having a carbon-carbon double bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6 carbon atoms, or 2 carbon atoms).
[0136] As used herein, the term "alkynyl," alone or in combination with other groups, refers to a straight-chain or branched hydrocarbon residue having a carbon-carbon triple bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6 carbon atoms, or 2 carbon atoms).
[0137] As used herein, the term “amino” refers to —N(R N1 )2, and each R N1 are independently H, OH, NO2, N(R N2 )2, SO2OR N2 , SO2R N2 , SOR N2 , an N-protecting group, alkyl, alkoxy, aryl, arylalkyl, cycloalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), and these enumerated R N1Each of the groups may be optionally substituted, or two R N1 combine to form an alkylene or heteroalkylene, and each R N2 are independently H, alkyl, or aryl. The amino groups of the present invention can be unsubstituted amino (i.e., —NH) or substituted amino (i.e., —N(R N1 )2).
[0138] As used herein, the term "aryl" refers to an aromatic mono- or polycarbocyclic radical of 6 to 12 carbon atoms having at least one aromatic ring. If polycyclic, the aryl group contains two or three rings. Examples of such groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, indanyl, and 1H-indenyl.
[0139] As used herein, the term "arylalkyl" refers to an alkyl group substituted with an aryl group. Unsubstituted arylalkyl groups include those having 7 to 30 carbons (e.g., C-C alkyl, C-C alkyl), such as benzyl and phenethyl. 10 Aryl, C1-C 10 Alkyl C6-C 10 Aryl, or C1-C 20 Alkyl C6-C 10 In some embodiments, alkyl and aryl each contain 1, 2, 3, or 4 substituents, depending on valence, as defined herein for each group.
[0140] As used herein, the term "azido" refers to an -N3 group.
[0141] As used herein, the term "bridged cyclyl" refers to a bridged polycyclic group of 5 to 20 carbons containing 1 to 3 bridges. Bridged polycycloalkyl groups can be unsubstituted or substituted as defined herein for cycloalkyl.
[0142] As used herein, the term "cyano" refers to a -CN group.
[0143] As used herein, the term "carbocyclyl" refers to a non-aromatic C-C ring in which the ring is formed by carbon atoms. 12 It refers to a monocyclic, bicyclic, or tricyclic structure. The carbocyclyl structure includes a cycloalkyl group and an unsaturated carbocyclyl radical.
[0144] As used herein, the term "cycloalkyl" refers to a saturated non-aromatic monovalent monocyclic, bicyclic, or tricyclic radical of 3 to 10, preferably 3 to 6, carbon atoms. Cycloalkyl groups can be fully saturated or contain one or more double or triple bonds, provided that none of the rings are aromatic. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl.
[0145] As used herein, the term "halo" means a fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo) radical.
[0146] As used herein, the term "heteroalkyl" refers to an alkyl group, as defined herein, in which one or more of the constituent carbon atoms has been replaced with nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkyl group is further substituted with one, two, three, or four substituents, as described herein for alkyl groups. An example of a heteroalkyl group is "alkoxy," which, as used herein, refers to alkyl-O- (e.g., methoxy and ethoxy). Heteroalkylene is a divalent heteroalkyl group. As used herein, the term "heteroalkenyl" refers to an alkenyl group, as defined herein, in which one or more of the constituent carbon atoms has been replaced with nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl group is further substituted with one, two, three, or four substituents, depending on the valency, as described herein for alkenyl groups. An example of a heteroalkenyl group is "alkenoxy," which, as used herein, refers to alkenyl-O-. Heteroalkenylene is a divalent heteroalkenyl group. As used herein, the term "heteroalkynyl" refers to an alkynyl group, as defined herein, in which one or more of the constituent carbon atoms has been replaced with nitrogen, oxygen, or sulfur. In some embodiments, heteroalkynyl groups are further substituted with 1, 2, 3, or 4 substituents, depending on valency, as described herein for alkynyl groups. An example of a heteroalkynyl group is "alkynoxy," which, as used herein, refers to alkynyl-O-. Heteroalkynylene is a divalent heteroalkynyl group.
[0147] As used herein, the term "heteroaryl" refers to a monocyclic, bicyclic, or tricyclic radical of 5 to 12 atoms having at least one aromatic ring and containing one, two, or three ring atoms selected from nitrogen, oxygen, and sulfur, with the remaining ring atoms being carbon. One or two ring carbon atoms of a heteroaryl group may be replaced by a carbonyl group. Examples of heteroaryl groups are pyridyl, pyrazolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, imidazolyl, oxazolyl, and thiazolyl.
[0148] As used herein, the term "heteroarylalkyl" refers to an alkyl group substituted with a heteroaryl group. Unsubstituted heteroarylalkyl groups include groups with 7 to 30 carbons (e.g., C1-C6 alkyl, C2-C9 heteroaryl, C1-C 10 alkyl C2-C9 heteroaryl, or C1-C 20 alkyl (e.g., C2-C9 heteroaryl, 7-16 or 7-20 carbons). In some embodiments, alkyl and heteroaryl are each further substituted with 1, 2, 3, or 4 substituents, depending on valency, as defined herein for each group.
[0149] As used herein, the term "heteroarylcycloalkyl" refers to a cycloalkyl group substituted with a heteroaryl group. Exemplary unsubstituted heteroarylcycloalkyl groups are 5 to 30 carbons (e.g., 5 to 17 carbons, such as C2-C9 heteroaryl C3-C8 cycloalkyl). In some embodiments, cycloalkyl and heteroaryl can each be further substituted with 1, 2, 3, or 4 substituents, as defined herein for each group.
[0150] As used herein, the term "heteroarylethynyl" refers to a group of the formula -R A -R B - group, where R A is heteroaryl and R Bis ethynyl. Optionally substituted heteroarylethynyl is heteroarylethynyl where the heteroaryl portion is optionally substituted as defined for heteroaryl.
[0151] As used herein, the term "heteroarylvinyl" refers to a heteroaryl group of the formula -R A -R B - group, where R A is heteroaryl and R B is vinyl. An optionally substituted heteroarylvinyl is a heteroarylvinyl in which the heteroaryl portion is optionally substituted as defined for heteroaryl.
[0152] As used herein, the term "heterocyclyl" refers to a monocyclic, bicyclic, or tricyclic radical having 3 to 12 atoms with at least one ring containing 1, 2, 3, or 4 ring atoms selected from N, O, or S, and the ring is not aromatic. Examples of heterocyclyl groups include, but are not limited to, morpholinyl, thiomorpholinyl, furyl, piperazinyl, piperidinyl, pyranyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, and 1,3-dioxanyl.
[0153] As used herein, the term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl group. Unsubstituted heterocyclylalkyl groups include groups of 7 to 30 carbons (e.g., C1-C6 alkyl, C2-C9 heterocyclyl, C1-C 10 alkyl C2-C9 heterocyclyl, or C1-C 20 and alkyl C2-C9 heterocyclyl (7 to 16 or 7 to 20 carbons). In some embodiments, the alkyl and heterocyclyl are each further substituted with 1, 2, 3, or 4 substituents, as defined herein for each group.
[0154] As used herein, the term "hydroxyalkyl" refers to an alkyl group substituted with an --OH group.
[0155] As used herein, the term "hydroxyl" refers to an --OH group.
[0156] As used herein, the term "N-protecting group" refers to a group intended to protect an amino group against undesired reactions during synthetic procedures. Commonly used N-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis," 3rd Edition (John Wiley & Sons, New York, 1999).N-protecting groups include, but are not limited to, acyl, aryloyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and chiral auxiliaries such as protected or unprotected D,L, or D,L-amino acids such as alanine, leucine, and phenylalanine; sulfonyl-containing groups such as benzenesulfonyl and p-toluenesulfonyl; benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-20 dimethoxybenzyl Oxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenylyl)-1-methylethoxycarbonyl, α,α-dimethyl 3,5-dimethoxybenzyloxycarbonyl, benzhydryloxycarbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl, methoxycarbonyl Examples of N-protecting groups include carbamate-forming groups such as aryl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl, adamantyloxycarbonyl, cyclohexyloxycarbonyl, and phenylthiocarbonyl, arylalkyl groups such as benzyl, triphenylmethyl, and benzyloxymethyl, and silyl groups such as trimethylsilyl. Preferred N-protecting groups are alloc, formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).
[0157] As used herein, the term "nitro" refers to the group --NO.sub.2.
[0158] As used herein, the term "oxo" refers to a divalent oxygen atom (e.g., the structure of oxo may be depicted as =0). For example, a carbonyl group is a carbon (e.g., an alkyl carbon, alkenyl carbon, alkynyl carbon, heteroalkyl carbon, heteroalkenyl carbon, heteroalkynyl carbon, carbocyclyl carbon, etc.) substituted with an oxo. Alternatively, sulfur may be substituted with one or two oxo groups (e.g., -SO- or -SO2- in a substituted heteroalkyl, heteroalkenyl, heteroalkynyl, or heterocyclyl group).
[0159] As used herein, the term "thiol" refers to a -SH group.
[0160] Alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl (e.g., cycloalkyl), aryl, heteroaryl, and heterocyclyl groups can be substituted or unsubstituted, and if substituted, there will be 1, 2, 3, 4, or 5 substituents present, unless otherwise specified, depending on the valence. The 1 to 5 substituents are each independently selected from the group consisting of acyl, alkyl (e.g., unsubstituted and substituted, where the substituents include any group described herein, e.g., aryl, halo, hydroxy), alkenyl, alkynyl, aryl (e.g., substituted and unsubstituted phenyl), carbocyclyl (e.g., substituted and unsubstituted cycloalkyl), halo (e.g., fluoro), hydroxyl, heteroalkyl (e.g., substituted and unsubstituted methoxy, ethoxy, or thioalkoxy), heteroalkenyl, heteroalkynyl, heteroaryl, heterocyclyl, amino (e.g., NH or mono- or dialkylamino), azido, cyano, nitro, thiol, and oxo. Each of the substituents is unsubstituted or substituted with an unsubstituted substituent as defined herein for each respective group. In some embodiments, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, and heteroalkynyl are optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of aryl (e.g., substituted and unsubstituted phenyl), carbocyclyl (e.g., substituted and unsubstituted cycloalkyl), halo (e.g., fluoro), hydroxyl, heteroaryl, heterocyclyl, amino (e.g., NH or mono- or dialkylamino), azido, cyano, nitro, thiol, and oxo. Each of the substituents is unsubstituted or substituted with an unsubstituted substituent as defined herein for each respective group. In some embodiments, the substituents are themselves unsubstituted.
[0161] The compounds of the present invention may have one or more asymmetric carbon atoms and may exist in the form of optically pure enantiomers, mixtures of enantiomers such as racemates, optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates, or mixtures of diastereomeric racemates. Optically active forms can be obtained, for example, by resolution of racemates, asymmetric synthesis, or asymmetric chromatography (chromatography using a chiral adsorbent or eluent). Thus, certain disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are most commonly pairs of stereoisomers whose mirror images are not superimposable because they contain asymmetrically substituted carbon atoms that function as chiral centers. An enantiomer refers to one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are most commonly stereoisomers that are not related as mirror images because they contain two or more asymmetrically substituted carbon atoms and represent the configuration of substituents around one or more chiral carbon atoms. Enantiomers of a compound can be prepared, for example, by separating an enantiomer from a racemate using one or more well-known techniques and methods, such as chiral chromatography and separation methods based thereon. Suitable techniques and / or methods for separating enantiomers of the compounds described herein from a racemic mixture can be readily determined by one of ordinary skill in the art. A "racemate" or "racemic mixture" refers to a compound containing two enantiomers; such mixtures do not exhibit optical activity, i.e., they do not rotate the plane of polarized light. A "geometric isomer" refers to isomers that differ in the orientation of substituent atoms relative to a carbon-carbon double bond, a cycloalkyl ring, or a bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond can be in the E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration. "R," "S," "S*," "R*," "E," "Z," "cis," and "trans" refer to configurations relative to the core molecule. Certain disclosed compounds may exist in atropisomeric forms.Atropisomers are stereoisomers resulting from hindered rotation around a single bond, where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers. The compounds of the present invention can be prepared as individual isomers by isomer-specific synthesis or by resolution from an isomeric mixture. Traditional resolution techniques include forming a salt of the free base of each isomer of the isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming a salt of the acid form of each isomer of the isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each isomer of the isomeric pair using an optically pure acid, amine, or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either the starting material or the final product using a variety of well-known chromatographic methods. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by weight relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% optically pure by weight. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by weight. Percent optical purity is the weight of the enantiomer, or the ratio of the weight of the enantiomer to the weight of its optical isomer. Diastereomeric purity by weight is the ratio of the weight of one diastereomer to the weight of all diastereomers. When the stereochemistry of a disclosed compound is named or shown by structure, the named or shown stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by mole fraction relative to the other stereoisomers.When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by mole fraction. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% pure by mole fraction. Percent purity by mole fraction is the ratio of moles of enantiomer, or moles of enantiomer to moles of its optical isomer. Similarly, percent purity by mole fraction is the ratio of moles of diastereomer, or moles of diastereomer to moles of its isomer. When a disclosed compound is named or depicted by structure without indicating stereochemistry, and the compound has at least one chiral center, the name or structure should be understood to encompass any enantiomer of the compound free of the corresponding optical isomer, a racemic mixture of the compound, a mixture of the compound, or a mixture enriched in one enantiomer with respect to its corresponding optical isomer. When a disclosed compound is named or depicted by structure without indicating stereochemistry, and the compound has two or more chiral centers, the name or structure should be understood to encompass any diastereomer free of the other diastereomer, any diastereomer free of other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers enriched in one diastereomer with respect to the other, or mixtures of diastereomers enriched in one or more diastereomers with respect to the other. The present invention encompasses all of these forms.
[0162] The compounds of the present disclosure also include all isotopes of atoms present in the intermediate or final compounds. "Isotopes" refer to atoms having the same atomic number but different mass numbers resulting from different numbers of neutrons in the nucleus. For example, isotopes of hydrogen include tritium and deuterium.
[0163] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that can be incorporated into the compounds of the invention include: 2 H, 3 H, 11 C. 13 C. 14 C. 13 N, 15 N, 15 O. 17 O. 18 O. 32 P, 33 P, 35 S, 18 F, 36 Cl, 123 I, and 125 Isotopically labeled compounds (e.g., 3 H and 14 C) can be useful in compound or substrate tissue distribution assays. 3 H) and carbon-14 (i.e., 14 C) isotopes can be useful for their ease of preparation and detectability. Additionally, deuterium (i.e., 2 Substitution with heavier isotopes, such as H, may afford certain therapeutic benefits (e.g., increased in vivo half-life or reduced dosage requirements) due to greater metabolic stability. In some embodiments, one or more hydrogen atoms are 2 H or 3 H or one or more carbon atoms are replaced by 13 C or 14 replaced by C-enriched carbon. 15 O. 13 N, 11 C, and 18Positron-emitting isotopes such as F are useful in positron emission tomography (PET) studies to examine substrate receptor occupancy. The preparation of isotopically labeled compounds is known to those skilled in the art. For example, isotopically labeled compounds can generally be prepared by following procedures similar to those disclosed for the compounds of the present invention described herein, substituting non-isotopically labeled reagents for isotopically labeled reagents.
[0164] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials for use in the present disclosure are described herein. Other suitable methods and materials known in the art may also be used. These materials, methods, and examples are illustrative only and are not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
[0165] definition In this application, unless otherwise clear from the context, (i) the term "a" may be understood to mean "at least one," (ii) the term "or" may be understood to mean "and / or," and (iii) the terms "including" and "including" may be understood to encompass the listed elements or steps, whether presented by themselves or together with one or more additional elements or steps.
[0166] As used herein, the terms "about" and "approximately" refer to values within 10% above and below the stated value. For example, the term "about 5 nM" indicates a range of 4.5 to 5.5 nM.
[0167] As used herein, the term "administration" refers to the administration of a composition (e.g., a compound or a preparation comprising a compound as described herein) to a subject or system. Administration to an animal subject (e.g., to a human) can be by any suitable route. For example, in some embodiments, administration can be bronchial (including by bronchial infusion), buccal, enteral, interdermal, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intratumoral, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal infusion), transdermal, vaginal, and intravitreal.
[0168] As used herein, the term "BAF complex" refers to the BRG1 or HBRM-associated factor complex in human cells.
[0169] As used herein, the term "BAF complex-associated disorder" refers to a disorder caused by or affected by the level of activity of the BAF complex.
[0170] As used herein, the term "BRG1 loss-of-function mutation" refers to a mutation in BRG1 that results in a protein with reduced activity (e.g., at least a 1% reduction in BRG1 activity, e.g., a 2%, 5%, 10%, 25%, 50%, or 100% reduction in BRG1 activity). Exemplary BRG1 loss-of-function mutations include, but are not limited to, homozygous BRG1 mutations and deletions at the C-terminus of BRG1.
[0171] As used herein, the term "BRG1 loss-of-function disorder" refers to a disorder (e.g., cancer) that exhibits a reduction in BRG1 activity (e.g., at least a 1% reduction in BRG1 activity, e.g., a 2%, 5%, 10%, 25%, 50%, or 100% reduction in BRG1 activity).
[0172] The term "cancer" refers to conditions caused by the proliferation of malignant cells, such as tumors, neoplasms, carcinomas, sarcomas, leukemias, and lymphomas.
[0173] As used herein, "combination therapy" or "administered in combination" means that two (or more) different agents or treatments are administered to a subject as part of a defined treatment regimen for a particular disease or condition. The treatment regimen defines the dosage and periodicity of administration of each agent so that the effects of the separate agents on the subject overlap. In some embodiments, delivery of two or more agents may be simultaneous or concurrent, or the agents may be co-formulated. In some embodiments, two or more agents are not co-formulated but are administered in a sequential manner as part of a prescribed regimen. In some embodiments, the administration of two or more agents or combined treatments is such that the reduction in symptoms or other parameters associated with the disorder is greater than that observed with one agent or treatment delivered alone or in the absence of the other. The effect of the two treatments may be partially additive, fully additive, or greater than additive (e.g., synergistic). The sequential or substantially simultaneous administration of each therapeutic agent can occur by any suitable route, including, but not limited to, oral, intravenous, intramuscular, and direct absorption through mucosal tissue. The therapeutic agents can be administered by the same route or by different routes, for example, a first therapeutic agent of the combination may be administered by intravenous injection, while a second therapeutic agent of the combination may be administered orally.
[0174] "Determining the level" of protein or RNA refers to detecting the protein or RNA, either directly or indirectly, by methods known in the art. "Directly determining" means performing a process to obtain a physical entity or value (e.g., performing an assay or test on a sample, or "analyzing a sample," as that term is defined herein). "Indirectly determining" refers to receiving a physical entity or value from another party or source (e.g., a third-party laboratory that directly obtained the physical entity or value). Methods for measuring protein levels generally include, but are not limited to, Western blotting, immunoblotting, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), immunoprecipitation, immunofluorescence, surface plasmon resonance, chemiluminescence, fluorescence polarization, phosphorescence, immunohistochemistry, matrix-assisted laser desorption / ionization time-of-flight (MALDI-TOF) mass spectrometry, liquid chromatography (LC) mass spectrometry, microcytometry, microscopy, fluorescence-activated cell sorting (FACS), and flow cytometry, as well as assays based on protein properties, including, but not limited to, enzymatic activity or interactions with other protein partners. Methods for measuring RNA levels are known in the art and include, but are not limited to, quantitative polymerase chain reaction (qPCR) and Northern blot analysis.
[0175] A "decreased level" or "increased level" of protein or RNA refers to a decrease or increase, respectively, in protein or RNA levels compared to a reference substance (e.g., about a 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, about 150%, about 200%, about 300%, about 400%, about 500%, or more decrease or increase). , a decrease or increase of more than about 10%, about 15%, about 20%, about 50%, about 75%, about 100%, or about 200% compared to a reference material, a decrease or increase of less than about 0.01-fold, about 0.02-fold, about 0.1-fold, about 0.3-fold, about 0.5-fold, about 0.8-fold, or less, or an increase of about 1.2-fold, about 1.4-fold, about 1.5-fold, about 1.8-fold, about 2.0-fold, about 3.0-fold, about 3.5-fold, about 4.5-fold, about 5.0-fold, about 10-fold, about 15-fold, about 20-fold, about 30-fold, about 40-fold, about 50-fold, about 100-fold, more than about 1000-fold, or more. Protein levels can be expressed as mass / volume (e.g., g / dL, mg / mL, μg / mL, ng / mL) or as a percentage of total protein in the sample.
[0176] "Reducing the activity of the BAF complex" means reducing the level of activity associated with the BAF complex or an associated downstream effect. A non-limiting example of reducing the activity of the BAF complex is activation of Sox2. The activity level of the BAF complex can be measured using any method known in the art, for example, the method described in Kadoch et al. Cell, 2013, 153, 71-85, which is incorporated herein by reference.
[0177] As used herein, the term "inhibiting BRM" refers to blocking or reducing the level or activity of the ATPase catalytic binding domain or bromodomain of a protein. BRM inhibition can be determined using methods known in the art, such as a BRM ATPase assay, a Nano DSF assay, or a BRM luciferase cellular assay.
[0178] As used herein, the term "LXS196," also known as IDE196, refers to a PKC inhibitor having the following structure: [ka] or a pharmaceutically acceptable salt thereof.
[0179] As used herein, the term "pharmaceutical composition" refers to a composition comprising a compound described herein, formulated with a pharmaceutically acceptable excipient and suitable for administration to a mammal, e.g., a human. Typically, a pharmaceutical composition is manufactured or sold, with the approval of a government regulatory agency, as part of a therapeutic regimen for the treatment of a mammalian disease. A pharmaceutical composition can be formulated, for example, for oral administration in a unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup), for topical administration (e.g., as a cream, gel, lotion, or ointment), for intravenous administration (e.g., as a sterile solution free of particulate embolic agents and in a solvent system suitable for intravenous use), or in any other pharmaceutically acceptable formulation.
[0180] As used herein, "pharmaceutically acceptable excipient" refers to any component of a compound described herein (e.g., a vehicle capable of suspending or dissolving an active compound) that has the properties of being substantially non-toxic and non-inflammatory in a patient. Excipients may include, for example, anti-adherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film-forming or coating agents, flavors, fragrances, glidants (glidants), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, and water for hydration.
[0181] As used herein, the term "pharmaceutically acceptable salt" refers to any pharmaceutically acceptable salt of a compound, for example, any compound of Formula I. Pharmaceutically acceptable salts of any of the compounds described herein may include salts that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, or allergic reaction, commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in Berge et al., J. Pharmaceutical Sciences 66:1-19, 1977 and Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. Salts can be prepared in situ during the final isolation and purification of the compounds described herein, or separately by reacting the free base group with a suitable organic acid.
[0182] The compounds of the present invention may have ionizable groups so that they can be prepared as pharmaceutically acceptable salts. These salts may be acid addition salts, including inorganic or organic acids, or salts may be prepared from inorganic or organic bases when the compounds of the present invention are in acidic form. Frequently, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases, as well as methods for preparing suitable salts, are well known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases, including inorganic and organic acids and bases.
[0183] "Reference material" refers to any useful reference material used to compare protein or RNA levels. A reference material can be any sample, standard, standard curve, or level used for comparison purposes. A reference material can be a normal reference sample or reference standard or level. A "reference sample" can be, for example, a control, e.g., a predetermined negative control value such as a "normal control," or a previous sample taken from the same subject; a sample from a normal healthy subject, such as normal cells or normal tissue; a sample (e.g., cell or tissue) from a subject without a disease; a sample from a subject diagnosed with a disease but not yet treated with a compound of the present invention; a sample from a subject being treated with a compound of the present invention; or a sample of purified protein or RNA (e.g., any of those described herein) with a known normal concentration. A "reference standard or level" refers to a value or numerical value derived from a reference sample. A "normal control value" is a predetermined value indicative of a non-disease state, e.g., a value expected in a healthy control subject. Typically, a normal control value is expressed as a range ("between X and Y"), a high threshold ("below X"), or a low threshold ("above X"). A subject having a measured value within the normal control value for a particular biomarker is typically referred to as being "within the normal range" for that biomarker. A normal reference standard or level can be a value or number derived from a normal subject who does not have a disease or disorder (e.g., cancer); a subject who has been treated with a compound of the invention. In preferred embodiments, the reference sample, standard, or level is matched to the sample subject sample by at least one of the following criteria: age, weight, sex, stage of disease, and overall health. A standard curve of purified protein or RNA levels within the normal reference range, such as any of those described herein, can also be used as a reference.
[0184] As used herein, the term "subject" refers to any organism to which a composition according to the invention can be administered, for example, for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include any animal (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans). A subject may be a human or animal seeking or in need of treatment, requesting treatment, undergoing treatment, will undergo treatment in the future, or being treated by a trained professional for a particular disease or condition.
[0185] As used herein, the terms "treat," "treated," or "treating" refer to therapeutic treatment or any procedure where the purpose is to slow (alleviate) an undesirable physiological condition, disorder, or disease, or to obtain a beneficial or desired clinical result. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; attenuation of the severity of the condition, disorder, or disease; stabilization (i.e., non-worsening) of the condition, disorder, or disease; delay in the onset or slowing of progression of the condition, disorder, or disease; improvement or remission (partial or complete) of the condition, disorder, or disease state; improvement in at least one measurable physical parameter not necessarily discernible by the patient; or enhancement or amelioration of the condition, disorder, or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival compared to expected survival if not receiving treatment. The compounds of the invention may also be used to "prophylactically treat" or "prevent" disorders, for example, in subjects at increased risk of developing the disorder.
[0186] As used herein, the terms "variant" and "derivative" are used interchangeably and refer to naturally occurring, synthetic, and semi-synthetic analogs of the compounds, peptides, proteins, or other substances described herein. Variants or derivatives of the compounds, peptides, proteins, or other substances described herein may retain or improve the biological activity of the original material.
[0187] The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. [Brief explanation of the drawings]
[0188] [Figure 1] 1 is a graph showing the inhibition of cell proliferation of several cancer cell lines by a BRG1 / BRM inhibitor (Compound A). [Figure 2A] 1 is a graph showing the inhibition of cell proliferation of uveal melanoma cell line 92-1 by a BRG1 / BRM inhibitor (Compound A), a MEK inhibitor (selumetinib), and a PKC inhibitor (LXS196). [Figure 2B] 1 is a graph showing the inhibition of cell proliferation of the uveal melanoma cell line MP41 by a BRG1 / BRM inhibitor (Compound A), a MEK inhibitor (selumetinib), and a PKC inhibitor (LXS196). [Figure 3] 1 is a graph showing the inhibition of cell proliferation of several cancer cell lines by a BRG1 / BRM inhibitor (Compound B). [Figure 4A] 1 is a graph showing the area under the curve (AUC) calculated from the dose-response curves of cancer cell lines treated with BRG1 / BRM inhibitors. [Figure 4B] 1 is a graph showing the area under the curve (AUC) calculated from the dose-response curves of cancer cell lines treated with BRG1 / BRM inhibitors. [Figure 5] 1 is a graph showing the inhibition of cell proliferation of uveal melanoma and non-small cell lung cancer cell lines by a BRG1 / BRM inhibitor (Compound B). [Figure 6A]1 is a graph showing the inhibition of cell proliferation of uveal melanoma cell line 92-1 by a BRG1 / BRM inhibitor (Compound B), a MEK inhibitor (selumetinib), and a PKC inhibitor (LXS196). [Figure 6B] 1 is a graph showing the inhibition of cell proliferation of the uveal melanoma cell line MP41 by a BRG1 / BRM inhibitor (Compound B), a MEK inhibitor (selumetinib), and a PKC inhibitor (LXS196). [Figure 7A] 1 is a graph showing the inhibition of cell proliferation of parental and PKC inhibitor-refractory uveal melanoma cell lines by a PKC inhibitor (LXS196). [Figure 7B] 1 is a graph showing the inhibition of cell proliferation of parental and PKC inhibitor-refractory uveal melanoma cell lines by a BRG1 / BRM inhibitor (Compound B). [Figure 8A] 1 is a graph showing the inhibition of tumor growth in mice implanted with a uveal melanoma cell line by a BRG1 / BRM inhibitor (Compound C). [Figure 8B] FIG. 1 shows the size of tumors derived from mice implanted with a uveal melanoma cell line and administered a BRG1 / BRM inhibitor (Compound C). [Figure 8C] 1 is a graph showing changes in body weight of mice transplanted with a uveal melanoma cell line and administered a BRG1 / BRM inhibitor (Compound C). DETAILED DESCRIPTION OF THE INVENTION
[0189] The present disclosure features compounds useful for inhibiting BRM and optionally BRG1. These compounds may be used to modulate the activity of the BAF complex, for example, for the treatment of BAF-associated disorders (e.g., loss-of-function disorders of BRG1), such as cancer. Exemplary compounds described herein include compounds having a structure according to Formula I: [ka] During the ceremony, m is 0, 1, 2, or 3; n is 0, 1, 2, 3, or 4; p is 0, 1, 2, or 3; X 1 But, O, NR 5 , or (C(R 5 )(R 6 )) and Z 1 and Z 2 each of which is independently absent or (C(R 9 )2) or O, but X 1 If is O, then Z 1 and Z 2 each of which is independently absent or (C(R 9 )2) and X 2 But N or CR 8 and Each R X1 are independently deuterium, optionally substituted C-C alkyl, or halo, or two geminal R X1 groups combine with the atoms to which they are attached to form a carbonyl, L 1 is an optionally substituted 9- or 10-membered bicyclic heterocyclyl, an optionally substituted 9- or 10-membered bicyclic heteroaryl, an optionally substituted 6-membered monocyclic heteroarylvinyl, an optionally substituted 6-membered monocyclic heteroaryl-C3-C8-cycloalkyl, or an optionally substituted 6-membered monocyclic heteroarylethynyl; L 2 but absent or optionally substituted C3-C 10 Cycloalkyl, optionally substituted C-C 10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 4- to 10-membered heterocyclyl; R 1 is hydrogen or optionally substituted C1-C6 alkyl; Each R 2 and each R 3 are independently hydrogen, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl; R4 is hydrogen, halo, optionally substituted C1-C6 alkyl, or optionally substituted C3-C 10 is cycloalkyl, R 5 is hydrogen, deuterium, or optionally substituted C1-C6 alkyl; R 6 is hydrogen, deuterium, optionally substituted C-C alkyl, or halo, and each R 9 are independently hydrogen, deuterium, optionally substituted C-C alkyl, or halo, or R 6 and one adjacent R 9 together with the atoms to which they are attached form an optionally substituted C3-C8 cycloalkyl, and the remaining R 9 groups, if present, are independently deuterium, optionally substituted C1-C6 alkyl, or halo; Each R 7 are independently selected from optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, halo, optionally substituted C3-C 10 cycloalkyl, optionally substituted 5- to 10-membered heteroaryl, optionally substituted 4- to 10-membered heterocyclyl, -N(R 7A )2, or -OR 7A and each R 7A are independently selected from H, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C3-C 10 Cycloalkyl, optionally substituted C-C 10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 4- to 10-membered heterocyclyl, or two geminal R 7A groups, together with the atoms to which they are attached, combine to form an optionally substituted 5- to 10-membered heteroaryl or an optionally substituted 4- to 10-membered heterocyclyl; R 8is hydrogen, halo, cyano, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 heteroalkyl, or optionally substituted C3-C 10 is cycloalkyl, R 10 is hydrogen or halo, or a pharmaceutically acceptable salt thereof.
[0190] In some embodiments, the compound, or a pharmaceutically acceptable salt thereof, has the structure of any one of compounds 1-330 in Table 1.
[0191] Other embodiments, and exemplary methods for synthesis of the production of these compounds, are described herein.
[0192] Pharmaceutical use The compounds described herein are useful in the methods of the invention and, without being bound by theory, are believed to exert their ability by modulating the level, status, and / or activity of the BAF complex, i.e., by inhibiting the activity of BRG1 and / or BRM proteins within the mammalian BAF complex. BAF complex-associated disorders include, but are not limited to, disorders associated with loss-of-function mutations in BRG1.
[0193] One aspect of the invention relates to a method of treating a disorder associated with a loss-of-function mutation in BRG1, such as cancer (e.g., non-small cell lung cancer, colon cancer, bladder cancer, cancer of unknown primary site, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, or penile cancer) in a subject in need thereof. In some embodiments, the compound is administered in an amount and for a time effective to result in one or more (e.g., two or more, three or more, four or more) of: (a) a reduction in tumor size; (b) a reduction in tumor growth rate; (c) an increase in tumor cell death; (d) a reduction in tumor progression; (e) a reduction in the number of metastases; (f) a reduction in the rate of metastasis; (g) a reduction in tumor recurrence; (h) an increase in the subject's survival rate; or (i) an increase in the subject's progression-free survival.
[0194] Treating cancer can result in a reduction in tumor size or volume. For example, after treatment, tumor size is reduced by 5% or more (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more) relative to its size before treatment. Tumor size may be measured by any reproducible means of measurement. For example, tumor size may be measured as the diameter of the tumor.
[0195] Treating cancer may also result in a reduction in tumor number. For example, after treatment, tumor number is reduced by 5% or more (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more) compared to the number before treatment. The number of tumors may be measured by any reproducible means of measurement; for example, the number of tumors may be measured by counting tumors visible to the naked eye or at a particular magnification (e.g., 2x, 3x, 4x, 5x, 10x, or 50x).
[0196] Treatment of cancer can result in a reduction in the number of metastatic nodules in other tissues or organs distant from the primary tumor site. For example, after treatment, the number of metastatic nodules is reduced by 5% or more (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more) compared to the number before treatment. The number of metastatic nodules may be measured by any reproducible means of measurement. For example, the number of metastatic nodules may be measured by counting metastatic nodules visible to the naked eye or at a particular magnification (e.g., 2x, 10x, or 50x).
[0197] Treating cancer may result in an increase in the average survival time of a population of subjects treated according to the present invention compared to a population of untreated subjects. For example, the average survival time is increased by more than 30 days (more than 60 days, 90 days, or 120 days). The increase in average survival time of a population may be measured by any reproducible means. The increase in average survival time of a population may be measured, for example, by calculating the average length of survival for a population after the start of treatment with a compound of the present invention. The increase in average survival time of a population may also be measured, for example, by calculating the average length of survival for a population after the completion of the first round of treatment with a pharmaceutically acceptable salt of a compound of the present invention.
[0198] Treating cancer may also result in a reduction in mortality in a population of treated subjects compared to an untreated population. For example, mortality is reduced by more than 2% (e.g., more than 5%, 10%, or 25%). The reduction in mortality in a population of treated subjects may be measured by any reproducible means, for example, by calculating the average number of disease-related deaths per unit time for the population after initiation of treatment with a pharmaceutically acceptable salt of the present invention. The reduction in mortality in a population may also be measured, for example, by calculating the average number of disease-related deaths per unit time for the population after completion of the first round of treatment with a pharmaceutically acceptable salt of the present invention.
[0199] Exemplary cancers that may be treated by the present invention include, but are not limited to, non-small cell lung cancer, small cell lung cancer, colon cancer, bladder cancer, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, esophagogastric cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin's lymphoma, prostate cancer, embryonal tumors, germ cell tumors, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumors, uterine sarcoma, gastrointestinal stromal tumors, CNS cancer, thymic tumors, adrenocortical carcinoma, appendix cancer, small intestine cancer, and penile cancer.
[0200] Combination preparations and their uses The compounds of the invention can be combined with one or more therapeutic agents. In particular, the therapeutic agents can be those that treat or prophylactically treat any of the cancers described herein.
[0201] Combination therapy The compounds of the present invention can be used alone or in combination with additional therapeutic agents, such as other drugs for treating cancer or related symptoms, or in combination with other types of treatment for cancer. In combination therapy, the dosage of one or more therapeutic compounds may be reduced from the standard dosage when administered alone. For example, dosages may be empirically determined from drug combinations and permutations, or estimated by isobolographic analysis (e.g., Black et al., Neurology 65:S3-S6, 2005). In this case, the dosage of the combined compounds should provide a therapeutic effect.
[0202] In some embodiments, the second therapeutic agent is a chemotherapeutic agent (e.g., a cytotoxic agent or other compound useful in the treatment of cancer). These include alkylating agents, antimetabolites, folic acid analogs, pyrimidine analogs, purine analogs and related inhibitors, vinca alkaloids, epipodophyllotoxins, antibiotics, L-asparaginase, topoisomerase inhibitors, interferons, platinum coordination complexes, anthracenedione-substituted ureas, methylhydrazine derivatives, adrenocorticosteroids, progestins, estrogens, antiestrogens, androgens, antiandrogens, and gonadotropin-releasing hormone analogs. Also included are 5-fluorouracil (5-FU), leucovorin (LV), irenotecan, oxaliplatin, capecitabine, paclitaxel, and doxetaxel. Non-limiting examples of chemotherapeutic agents include alkylating agents, such as thiotepa and cyclophosphamide; alkylsulfonates, such as busulfan, improsulfan, and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethyleneimines and methylamelamines, such as altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphate, and methylamelamine. Acid amides and trimethylolmelamine; acetogenins (especially bullatacin and bullatacinone); camptothecin (including the synthetic analog topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin, and bizelesin synthetic analogs); cryptophycins (especially cryptophycin 1 and cryptophycin 8); dolastatins; duocarmycins (including the synthetic analogs KW-2189 and CBI-TMI); eluterobin; pancrustatin; sarcodictyin; spongistatins;Nitrogen mustards, such as chlorambucil, chlornaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine hydrochloride oxide, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics, such as enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gamma II and calicheamicin omega II (see, e.g., Agnew, Chem. Intl. Ed. Engl. 33:183-186 (1994); dynemicins, including dynemicin A; bisphosphonates, such as clodronate; esperamicin; and neocarzinostatin chromophore and related enediyne antibiotic chromophores), antibiotics such as aclacinomycin, actinomycin, authramycin, azaserine, bleomycin, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, Adriamycin® (morpholino-doxorubicin, cyanomorpholino-doxorubicin), doxorubicin, including 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcelomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycin, peplomycin, potfilomycin, puromycin, chelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine;Pyrimidine analogues, such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens, such as calsterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; antiadrenal agents, such as aminoglutethimide, mitotane, trilostane; folic acid replacements, such as furoic acid; aceglatone; aldophosphamide glycosides; aminolevulinic acid; eniluracil; amsacrine; bestravcil; bisantrene; edatrexa acetamide; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; epothilon; etoglucide; gallium nitrate; hydroxyurea; lentinan; lonidynin; maytansinoids, such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidanmol; nitraelin; pentostatin; fenameth; pirarubicin; losoxantrone; podophyllic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin; schizofiran; spirogermanium; tenuazonic acid; triazicon; 2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, veraculin A, roridin A, and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, such as Taxol® paclitaxel (Bristol-Myers Squibb Oncology, Princeton, NJ), ABraxane®, a chromophore-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), and Taxotere® doxetaxel (Rhone-Poulenc Rorer, Antony, France); chlorambucil;These include Gemzar® gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes, such as cisplatin, oxaliplatin, and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; Navelbine® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11); topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids, such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids, or derivatives of any of the above. Two or more chemotherapeutic agents can be used in a cocktail administered in combination with the first therapeutic agent described herein. Suitable dosing regimens for combination chemotherapy are known in the art and are described, for example, in Saltz et al. (1999) Proc ASCO 18:233a and Douillard et al. (2000) Lancet 355:1041-7.
[0203] In some embodiments, the second therapeutic agent is a therapeutic agent that is a biologic, such as a cytokine (e.g., an interferon or an interleukin (e.g., IL-2)) used in cancer treatment. In some embodiments, the biologic is an anti-angiogenic agent, such as an anti-VEGF agent, e.g., bevacizumab (Avastin®). In some embodiments, the biologic is an immunoglobulin-based biologic, e.g., a monoclonal antibody (e.g., a humanized antibody, fully human antibody, Fc fusion protein, or functional fragment thereof) that agonizes a target to stimulate an anti-cancer response or antagonizes an antigen important to cancer. Such medications include Rituxan (rituximab), Zenapax (daclizumab), Simulect (basiliximab), Synagis (palivizumab), Remicade (infliximab), Herceptin (trastuzumab), Mylotarg (gemtuzumab ozogamicin), Campath (alemtuzumab), Zevalin (ibritumomab tiuxetan), Humira (adalimumab), Xolair (omalizumab), Bexxar (tositumomab-I-131), Raptiva (efalizumab), Erbitux (cetuximab), Avastin (bevacizumab), Tysabri (natalizumab), and Actemra (tosi Antibody-drug conjugates are also included.
[0204] The second agent may be a therapeutic agent that is a non-drug treatment, for example, the second therapeutic agent is radiation therapy, cryotherapy, thermotherapy, and / or surgical removal of tumor tissue.
[0205] The second agent may be a checkpoint inhibitor. In one embodiment, the checkpoint inhibitor is an inhibitory antibody (e.g., a monospecific antibody such as a monoclonal antibody). The antibody can be, for example, humanized or fully human. In some embodiments, the checkpoint inhibitor is a fusion protein, e.g., an Fc receptor fusion protein. In some embodiments, the checkpoint inhibitor is an agent, such as an antibody, that interacts with a checkpoint protein. In some embodiments, the checkpoint inhibitor is an agent, such as an antibody, that interacts with a ligand of the checkpoint protein. In some embodiments, the checkpoint inhibitor is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of CTLA-4 (e.g., an anti-CTLA4 antibody such as ipilimumab / Yervoy or tremelimumab). In some embodiments, the checkpoint inhibitor is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of PD-1 (e.g., nivolumab / Opdivo®; pembrolizumab / Keytruda®; pidilizumab / CT-011). In some embodiments, the checkpoint inhibitor is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of PDL1 (e.g., MPDL3280A / RG7446; MEDI4736; MSB0010718C; BMS 936559). In some embodiments, the checkpoint inhibitor is an inhibitor (e.g., an inhibitory antibody or Fc fusion or small molecule inhibitor) of PDL2 (e.g., a PDL2 / Ig fusion protein such as AMP 224). In some embodiments, the checkpoint inhibitor is an inhibitor (e.g., an inhibitory antibody or small molecule inhibitor) of B7-H3 (e.g., MGA271), B7-H4, BTLA, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK1, CHK2, A2aR, a B-7 family ligand, or a combination thereof.
[0206] In any of the combination embodiments described herein, the first and second therapeutic agents are administered simultaneously or sequentially, in either order. The first therapeutic agent can be administered immediately before, immediately after, up to 1 hour, up to 2 hours, up to 3 hours, up to 4 hours, up to 5 hours, up to 6 hours, up to 7 hours, up to 8 hours, up to 9 hours, up to 10 hours, up to 11 hours, up to 12 hours, up to 13 hours, 14 hours, up to 16 hours, up to 17 hours, up to 18 hours, up to 19 hours, up to 20 hours, up to 21 hours, up to 22 hours, up to 23 hours, up to 24 hours, or up to 1-7, 1-14, 1-21, or 1-30 days before or after the second therapeutic agent.
[0207] Pharmaceutical Compositions The compounds of the invention are preferably formulated into pharmaceutical compositions for administration to mammals, preferably humans, in a biologically compatible form suitable for administration in vivo. Thus, in one aspect, the invention provides a pharmaceutical composition comprising a compound of the invention in admixture with a suitable diluent, carrier, or excipient.
[0208] The compounds of the present invention may be used in the form of free base, salt, solvate, and prodrug. All forms are within the scope of the present invention. According to the method of the present invention, as will be understood by those skilled in the art, the described compounds, or their salts, solvates, or prodrugs, can be administered to patients in various forms depending on the selected route of administration. The compounds of the present invention may be administered, for example, orally, parenterally, bucally, sublingually, nasally, rectally, via patch, pump, or transdermal administration, and the pharmaceutical composition will be formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal, and topical modes of administration. Parenteral administration may also be by continuous infusion over a selected period of time.
[0209] The compounds of the present invention can be administered orally, for example, with an inert diluent or an assimilable edible carrier, or enclosed in hard or soft shell gelatin capsules, or compressed into tablets, or incorporated directly with dietary food. For oral therapeutic administration, the compounds of the present invention can be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers. The compounds of the present invention can also be administered parenterally. Solutions of the compounds of the present invention can be prepared in water suitably mixed with a surfactant. These preparations may contain a preservative to prevent microbial growth under ordinary storage and use conditions. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003, 20th ed.) and The United States Pharmacopeia: The National Formulary, published in 1999 (USP 24 NF19). Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and sufficiently fluid for easy administration via syringe. Compositions for nasal administration can be conveniently formulated as aerosols, drops, gels, and powders. Aerosol formulations typically contain a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually provided in single or multi-dose sterile form in a sealed container, which can be in the form of a cartridge or refill for use with a spray device. Alternatively, the sealed container can be a single-dispensing device, such as a single-dose nasal inhaler or aerosol dispenser fitted with a metering valve, intended for disposal after use. When the dosage form includes an aerosol dispenser, it contains a propellant, which can be a compressed gas such as compressed air or an organic propellant. The aerosol dosage form can also be in the form of a pump-atomizer.Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles in which the active ingredient is formulated with a carrier. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base. The compounds described herein may be administered intratumorally, for example, by intratumoral injection. Intratumoral injection is a direct injection into the tumor vasculature and is particularly intended for individual, solid, accessible tumors. Local, regional, or systemic administration may also be appropriate. The compounds described herein can be advantageously contacted by administering an injection or multiple injections to the tumor, for example, spaced approximately 1 cm apart. In the case of surgical intervention, the present invention can be used before surgery, such as to prepare an inoperable tumor for resection. Continuous administration can also be applied, where appropriate, for example, by implanting a catheter into the tumor or tumor vasculature.
[0210] The compounds of the invention, as described herein, can be administered to animals, e.g., humans, alone or in combination with pharmaceutically acceptable carriers, the ratios being determined by the solubility and chemical properties of the compounds, the chosen route of administration, and standard pharmaceutical practice.
[0211] Dosage The dosage of the compounds of the present invention and / or compositions containing the compounds of the present invention can vary depending on many factors, including the pharmacodynamic properties of the compound; the mode of administration; the age, health, and weight of the recipient; the nature and severity of symptoms; the frequency of treatment and the type of concomitant treatment, if any; and the clearance rate of the compound in the treated animal. Those skilled in the art can determine the appropriate dosage based on the above factors. The compounds of the present invention may be administered initially at a suitable dosage, which may be adjusted as necessary depending on the clinical response. In general, satisfactory results can be obtained when the compounds of the present invention are administered to humans at a daily dose of, for example, 0.05 mg to 3000 mg. The dosage range includes, for example, 10 to 1000 mg.
[0212] Alternatively, the patient's body weight can be used to calculate the dosage. For example, the dose of the compound or pharmaceutical composition thereof administered to the patient may be in the range of 0.1 to 100 mg / kg. [Example]
[0213] Definitions used in the scheme below and elsewhere in this specification are as follows: [Table 3-1] [Table 3-2]
[0214] material Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. All reactions involving air- or moisture-sensitive reagents were performed under a nitrogen atmosphere.
[0215] Example 1. Preparation of Compounds (2R)-2,6-Difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxylic acid [ka] Step 1: Preparation of methyl 4-bromo-2-fluoro-6-sulfanyl-2-benzoate [ka] To a solution of methyl 4-bromo-2,6-difluorobenzoate (100 g, 398.37 mmol) in DMF (1000 mL) was added Na2S (34.54 g, 398.37 mmol, 90% purity), and the mixture was stirred at 30 °C for 16 hours. The reaction mixture was poured into water (1500 mL) and extracted with MTBE (1500 mL * 2). The aqueous phase was adjusted to pH = 2 with 1 N HCl and extracted with MTBE (1500 mL * 3). The combined organic layers were washed with water (2000 mL * 2) and brine (5000 mL), dried over Na2SO4, filtered, and concentrated to give methyl 4-bromo-2-fluoro-6-sulfanyl-2-benzoate (105 g, crude) as a yellow oil. LCMS (ESI) m / z: [Br 79 M+H] + =232.9
[0216] Step 2: Preparation of 3-(4-bromo-2-fluoro-6-sulfanyl-phenyl)methanol [ka] To a solution of methyl 4-bromo-2-fluoro-6-sulfanyl-2-benzoate (105 g, 396.08 mmol) in THF (1000 mL) was added LiAlH (15.03 g, 396.08 mmol) at 0 °C under N. The mixture was stirred at 0 °C for 1 h. The mixture was poured into 1 N HCl (1000 mL) and extracted with EtOAc (1000 mL*2). The combined organic phase was washed with brine (2000 mL), dried over anhydrous NaSO, filtered, and concentrated in vacuo to give 3-(4-bromo-2-fluoro-6-sulfanyl-phenyl)methanol (93 g, crude) as a yellow oil.
[0217] Step 3: Preparation of 5-(4-bromo-2-fluoro-6-vinylsulfanyl-phenyl)methanol [ka] To a solution of methyl 4-bromo-2-fluoro-6-sulfanyl-2-benzoate (93 g, 392.26 mmol) in DMF (1800 mL) were added K2CO3 (162.64 g, 1.18 mol) and 1,2-dibromoethane (221.07 g, 1.18 mol, 88.78 mL), and the mixture was stirred at 30 °C for 16 h. The reaction was quenched with water (2000 mL). The mixture was extracted with ethyl acetate (2000 mL*3). The combined organic layers were dried over Na2SO4 and concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10:1 to 1:1), and the solution was concentrated to give 5-(4-bromo-2-fluoro-6-vinylsulfanyl-phenyl)methanol (56 g, 212.83 mmol) as a yellow oil. 1 H NMR(400MHz,CDCl3) δ=7.33(s,1H),7.19-7.17(m,1H),6.50-6.44(m,1H),5.54-5.42(m,2H),4.78(d,J=1.2Hz,2H),2.13(s,1H) ppm
[0218] Step 4: Preparation of 4-bromo-2-fluoro-6-vinylsulfinyl-phenyl)methanol [ka] To a solution of 5-(4-bromo-2-fluoro-6-vinylsulfanyl-phenyl)methanol (10 g, 38.00 mmol) in MeOH (100 mL) and HO (100 ml) was added Oxone (11.68 g, 19.00 mmol), and the mixture was stirred at 30 °C for 16 h. The reaction mixture was poured into water (1 L), the solution was extracted with EA (1 L * 3), and the combined organic layers were washed with saturated NaSO (1 L) and brine (1 L), dried over NaSO, filtered, and concentrated to give 6-(4-bromo-2-fluoro-6-vinylsulfinyl-phenyl)methanol (10.61 g, crude) as a yellow oil. LCMS (ESI) m / z: [Br 79 M+H] + =263.0
[0219] Step 5: Preparation of 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide [ka] To a solution of 6-(4-bromo-2-fluoro-6-vinylsulfinyl-phenyl)methanol (10.6 g, 37.98 mmol) in THF (110 mL) was added NaH (3.04 g, 75.95 mmol, 60% purity) at 0 °C, and the mixture was stirred at 20 °C for 1 h. The reaction mixture was poured into NHCl (500 mL), and the solution was extracted with EA (500 mL * 3). The combined organic layers were washed with brine (1000 mL), dried over NaSO, filtered, and concentrated to give a brown residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10:1 to 1:1), and the solution was concentrated to give 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide (5.5 g, 19.70 mmol, 51.89% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=7.78-7.75(m,1H),7.62(s,1H),4.96(d,J=15.2Hz,1H),4.54-4.50(m,1H),4.33-4.24(m,2H),3.41-3.39(m,2H) ppm
[0220] Step 6: Preparation of 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide and 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin [ka] To a solution of 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide (1.9 g, 6.81 mmol) in DCM (40 mL) was added SbCl (46.58 mg, 204.21 μmol), followed by DAST (2.19 g, 13.61 mmol, 1.80 mL). The mixture was stirred at 20 °C for 16 h. Next, DAST (5.49 g, 34.03 mmol, 4.50 mL) was added, and the mixture was stirred at 20 °C for 16 h. SbCl (1.55 g, 6.81 mmol) and DAST (10.97 g, 68.07 mmol, 8.99 mL) were added, and the mixture was stirred at 20 °C for 16 h. The reaction mixture was poured into NaHCO3 solution (200 mL), and the solution was extracted with EA (200 mL * 3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20:1 to 5:1), and peak 1 eluate was concentrated to give 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide (1.2 g, 4.56 mmol, 67.00% yield) as a yellow oil. 1 H NMR(400MHz,CDCl3) δ=7.54-7.51(m,1H),7.18-7.15(m,1H),4.91-4.89(m,2H),4.17-4.14(m,2H),2.89-2.86(m,2H) ppm The peak 2 eluate was concentrated to give 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin (600 mg, 2.13 mmol, 31.36% yield) as a yellow solid. 1 H NMR(400MHz, CDCl3) δ=7.55-7.54(m,1H),7.27-7.24(m,1H),5.63-5.51(m,1H),5.25(d,J=13.6Hz,1H),4.69-4.65(m,1H),4.43-4.41(m,1H),4.13-4.05(m,1H) ppm
[0221] Step 7: Preparation of 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin [ka] To a solution of 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide (peak 1 above) (1.2 g, 4.56 mmol) in MeCN (25 mL) was added Select F (2.02 g, 5.70 mmol) followed by DAST (147.02 mg, 912.11 μmol, 120.51 μL) under ice bath. The solution was stirred at 20 °C for 1 h. Next, DIEA (884.11 mg, 6.84 mmol, 1.19 mL) was added to the mixture at 0 °C, and the mixture was stirred at 20 °C for 1 h. The reaction mixture was poured into NaHCO3 solution (200 mL) and extracted with EA (200 mL * 3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 20:1 to 5:1), and the solution was concentrated to give 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiep- ine (500 mg, 1.78 mmol, yield 39.00%) as a yellow solid. 1 H NMR(400MHz, CDCl3) δ=7.54(m,1H),7.27-7.24(m,1H),5.63-5.51(m,1H),5.25(d,J=13.6Hz,1H),4.70-4.66(m,1H),4.43-4.42(m,1H),4.13-4.05(m,1H) ppm
[0222] Step 8: Preparation of 2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin-8-carboxylic acid [ka] To a solution of 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin (1.3 g, 4.62 mmol) in DMSO (20 mL) and HO (4 mL) was added KCO (958.71 mg, 6.94 mmol), bicyclohexyl(3-bicyclohexylphosphaniumylpropyl)phosphonium; ditetrafluoroborate (283.13 mg, 462.44 µmol), and Pd(OAc) (103.82 mg, 462.44 µmol). The suspension was degassed under vacuum and purged with CO several times. The mixture was stirred at 100 °C under CO (15 psi) for 2 h. The reaction mixture was poured into NaHCO solution (100 mL) and extracted with EA (100 mL * 2). The aqueous phase was adjusted to pH=1 with 1N HCl and extracted with EA (50 mL*2), and the combined organic layers were dried over Na2SO4, filtered, and concentrated to give 2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin-8-carboxylic acid (1.1 g, crude) as a yellow solid, which was used without purification.
[0223] Step 9: 2,6-Difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ 6 Preparation of benzoxathiepin-8-carboxylic acid [ka] To a solution of 2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin-8-carboxylic acid (1.1 g, 4.47 mmol) in MeOH (12 mL) and HO (12 mL) was added Oxone (5.49 g, 8.93 mmol), and the mixture was stirred at 20° C. for 16 h. The reaction mixture was poured into water (100 mL), the solution was extracted with EA (100 mL*3), and the combined organic layers were washed with brine (200 mL), dried over NaSO, filtered, and concentrated to give 2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ as a white solid. 6 -benzoxathiepin-8-carboxylic acid (1.1 g, 3.95 mmol, 88.50% yield). 1H NMR(400MHz,DMSO-d6) δ=14.03-13.95(m,1H),8.34(d,J=1.2Hz,1H),8.13-8.11(m,1H),6.27-6.16(m,1H),5.25-5.21(m,1H),4.91-4.86(m,1H),4.47-4.38(m,2H) ppm.
[0224] Step 10: (2R)-2,6-Difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ 6 -benzoxathiepin-8-carboxylic acid (intermediate 1) and (2S)-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ 6 Preparation of benzoxathiepin-8-carboxylic acid [ka] 2,6-Difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ 6 -Benzoxathiepin-8-carboxylic acid (1.1 g, 3.95 mmol) was separated by chiral SFC (column: Daicel ChiralPak IG (250*30 mm, 10 μm); mobile phase: [0.1% NH3H2O MEOH]; B%: 20% to 20%, 4.75; 310 min) to give two peaks. Peak 1 eluate was concentrated to give a colorless residue, which was diluted with water (100 mL) and adjusted to pH=2 with 4N HCl solution. The solution was extracted with EA (100 mL*2). The combined organic layer was dried over Na2SO4, filtered, and concentrated to give (2R)-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ as a white solid. 6 -benzoxathiepin-8-carboxylic acid (intermediate 1) (350 mg, 1.25 mmol, 31.69% yield) was obtained. 1 H NMR(400MHz,DMSO-d6) δ=14.17-13.92(m,1H),8.33(s,1H),8.13-8.11(m,1H),6.27-6.17(m,1H),5.25-5.21(m,1H),4.91-4.86(m,1H),4.47-4.35(m,2H) ppm Chiral SFC:IG-3_5CM_MEOH(DEA)_5_40_3ML_T35.M;Rt=1.408 min,ee%=98.14%.
[0225] The peak 2 eluate was concentrated to give a residue, which was diluted with water (100 mL) and adjusted to pH=2 with 4N HCl solution, the solution was extracted with EA (100 mL*2), the combined organic layer was dried over Na2SO4, filtered and concentrated to give (2S)-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ as a white solid. 6 -benzoxathiepin-8-carboxylic acid (500 mg, 1.66 mmol, 41.94% yield). 1 H NMR(400MHz,DMSO-d6) δ=14.27-13.55(m,1H),8.34(d,J=1.2Hz,1H),8.13-8.10(m,1H),6.27-6.16(m,1H),5.26-5.21(m,1H),4.91-4.86(m,1H),4.47-4.38(m,2H) ppm.Chiral SFC:IG-3_5CM_MEOH(DEA)_5_40_3ML
[0226] Preparation of (R)-2,6-difluoro-N-((2-(7-methyl-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)-2,3-dihydro-5H-benzo[e][1,4]oxathiepin-8-carboxamide 1,1-dioxide (Compound 6) [ka] Step 1: Preparation of 7-methyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine [ka] To a solution of 7-bromo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (350 mg, 1.63 mmol) and methylboronic acid (292.28 mg, 4.88 mmol) in dioxane (5.6 mL) and HO (1.4 mL) was added di-tert-butyl(cyclopentyl)phosphane; dichloropalladium; iron (106.07 mg, 162.76 mmol), and KPO (1.04 g, 4.88 mmol). The reaction was stirred at 80 °C for 2 h. The reaction mixture was poured into HO (5 mL), and the solution was extracted with EA (5 mL * 2). The combined organic layers were washed with brine (6 mL), dried over NaSO, filtered, and concentrated to give a residue. The residue was purified by flash silica gel chromatography using a gradient of 0 to 80% ethyl acetate / petroleum. The desired eluate was concentrated in vacuo to give 7-methyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (200 mg, 1.33 mmol, 81.83% yield) as a yellow oil. LCMS (ESI) m / z: [M+H] + =151.1.
[0227] Step 2: Preparation of tert-butyl ((2-(7-methyl-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)carbamate [ka] To a solution of tert-butyl N-[(2-chloro-1,6-naphthyridin-7-yl)methyl]carbamate (200 mg, 680.86 μmol) and 7-methyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (122.70 mg, 817.03 μmol) in dioxane (4 mL) was added CsCO (1.11 g, 3.40 mmol), Xantphos (78.79 mg, 136.17 μmol), and Pd(dba) (62.35 mg, 68.09 μmol, 0.1 equiv). The reaction was stirred at 100 °C for 12 h. The reaction mixture was filtered. The filtrate was concentrated in vacuo to give the crude material. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient elution @ 36 mL / min). The eluate was concentrated in vacuo to give tert-butyl ((2-(7-methyl-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)carbamate (250 mg, 531.33 μmol, 78.04% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] + =408.1.
[0228] Step 3: Preparation of (2-(7-methyl-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methanamine [ka] To a solution of tert-butyl ((2-(7-methyl-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)carbamate (250 mg, 613.55 umol) in dioxane (1 mL) was added HCl / dioxane (4 M, 4 mL). The reaction mixture was stirred at 25° C. for 1 hour. The reaction mixture was concentrated in vacuo to give (2-(7-methyl-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methanamine (150 mg, crude, HCl) as a yellow solid, which was used directly in the next step without further purification. LCMS (ESI) m / z: [M+H] + =308.1.
[0229] Step 4: Preparation of (R)-2,6-difluoro-N-((2-(7-methyl-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)-2,3-dihydro-5H-benzo[e][1,4]oxathiepin-8-carboxamide 1,1-dioxide (Compound 6) [ka] To a solution of (2R)-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxylic acid (Intermediate 1, above) (40.46 mg, 145.43 μmol) in DCM (1 mL) was added (2-(7-methyl-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methanamine (50 mg, 145.43 μmol), DIEA (187.95 mg, 1.45 mmol, 253.31 μL), EDCI (55.76 mg, 290.86 μmol), and HOBt (39.30 mg, 290.86 μmol). The reaction was stirred at 25° C. for 2 hours. The reaction mixture was poured into water (5 mL), and the mixture was extracted with EtOAc (5 mL*3). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, filtered, and concentrated in vacuo to give a residue. The residue was purified by preparative HPLC (FA conditions; column: Phenomenex Synergi C18 150*25 mm*10 um; mobile phase: [water (FA)-ACN]; B%: 17% to 50%, 11 min). The desired fractions were lyophilized to give (R)-2,6-difluoro-N-((2-(7-methyl-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)-2,3-dihydro-5H-benzo[e][1,4]oxathiepin-8-carboxamide 1,1-dioxide (34.84 mg, 56.78 μmol, 39.04% yield, FA) as a yellow solid. LCMS (ESI) m / z: [M+H] + =568.2. 1 H NMR(400MHz,DMSO-d6) δ=9.71-9.68(m,1H),9.08(s,1H),8.47(d,J=1.2Hz,1H),8.39-8.22(m,4H),7.77-7.76(m,1H),7.53(s,1H),7.20-7.20(m,1H), 6.31-6.15(m,1H),5.24(d,J=14.8Hz,1H),4.91-4.87(m,1H),4.74(d,J=6.0Hz,2H),4.48-4.35(m,2H),4.33(s,4H),2.25(s,3H) ppm.
[0230] The following examples in Table 2 were prepared using standard chemical manipulations and procedures similar to those used to prepare compound 6. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6] [Table 4-7]
[0231] Preparation of (2R)-N-[[2-[3-(difluoromethoxy)phenyl]-1,6-naphthyridin-7-yl]methyl]-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxamide (compound 297) [ka] Step 1: Preparation of tert-butyl ((2-(3-(difluoromethoxy)phenyl)-1,6-naphthyridin-7-yl)methyl)carbamate [ka] A mixture of tert-butyl N-[(2-chloro-1,6-naphthyridin-7-yl)methyl]carbamate (208.40 mg, 709.46 μmol), [3-(difluoromethoxy)phenyl]boronic acid (200 mg, 1.06 mmol), ditert-butyl(cyclopentyl)phosphane; dichloropalladium; iron (46.24 mg, 70.95 μmol), and KPO (451.78 mg, 2.13 mmol) in dioxane (3 mL) and HO (1 mL) was degassed and purged with N three times. The mixture was then stirred at 80 °C under a N atmosphere for 14 h. The reaction mixture was diluted with HO (15 mL) and extracted with EA (15 mL*3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 1 / 2), and the fractions were concentrated under reduced pressure to give tert-butyl ((2-(3-(difluoromethoxy)phenyl)-1,6-naphthyridin-7-yl)methyl)carbamate (255 mg, 635.27 μmol, 89.54% yield) as a brown oil. LCMS (ESI) m / z: [M+H] + =402.1. 1 H NMR(400MHz,DMSO-d6) δ=9.36(s,1H),8.68(d,J=8.4Hz,1H),8.32(d,J=8.4Hz,1H),8.19(d,J=8.0Hz,1H),8.11(d,J=2 .0Hz,1H),7.77(s,1H),7.67-7.59(m,2H),7.58-7.21(m,2H),4.45(d,J=6.0Hz,2H),1.44(s,9H) ppm.
[0232] Step 2: Preparation of (2-(3-(difluoromethoxy)phenyl)-1,6-naphthyridin-7-yl)methanamine [ka] To a solution of tert-butyl ((2-(3-(difluoromethoxy)phenyl)-1,6-naphthyridin-7-yl)methyl)carbamate (250 mg, 622.81 umol) in TFA (1 mL) and DCM (3 mL). The mixture was stirred at 25°C for 0.5 h. The mixture was poured into aqueous NaHCO3 (10 mL) and then extracted with EA (10 mL*3). The combined organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to give (2-(3-(difluoromethoxy)phenyl)-1,6-naphthyridin-7-yl)methanamine (185 mg, 614.03 umol, 98.59% yield) as a brown solid. LCMS (ESI) m / z: [M+H] + =302.1.
[0233] Step 3: Preparation of (2R)-N-[[2-[3-(difluoromethoxy)phenyl]-1,6-naphthyridin-7-yl]methyl]-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxamide [ka] To a solution of (2-(3-(difluoromethoxy)phenyl)-1,6-naphthyridin-7-yl)methanamine (50 mg, 165.95 μmol) in DCM (1 mL) was added (2R)-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxyl (46.17 mg, 165.95 μmol), EDCI (47.72 mg, 248.93 μmol), HOBt (33.64 mg, 248.93 μmol), and DIEA (107.24 mg, 829.76 μmol). The mixture was stirred at 25 °C for 14 h. The reaction mixture was diluted with HO (5 mL) and extracted with DCM (5 mL*3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by reverse-phase HPLC (0.1% FA, acetonitrile and water). The solution was then concentrated under reduced pressure and lyophilized to give (2R)-N-[[2-[3-(difluoromethoxy)phenyl]-1,6-naphthyridin-7-yl]methyl]-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxamide (20.83 mg, 37.10 μmol, 22.35% yield) as an off-white solid. LCMS (ESI) m / z: [M+H] + =562.2. 1 H NMR(400MHz,DMSO-d6) δ=9.76-9.73(m,1H),9.41(s,1H),8.69(d,J=8.8Hz,1H),8.47(s,1H),8 .33(d,J=8.4Hz,1H),8.26(d,J=10.4Hz,1H),8.19(d,J=7.6Hz,1H),8.10 (s,1H),7.92-7.82(m,1H),7.65-7.61(m,1H),7.57-7.17(m,2H),6.33-6 .10(m,1H),5.25(d,J=14.4Hz,1H),4.95-4.68(m,3H),4.53-4.32(m,2H) ppm. Chiral SFC: OJ-3-MeOH(DEA)-5-40-3 mL-35 T. lcm; Rt = 2.427 min, ee% = 100.00%.
[0234] The following examples in Table 3 were prepared using standard chemical manipulations and procedures similar to those used to prepare compound 297. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6]
[0235] Preparation of the intermediate 2(4R)-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid [ka] Step 1: Preparation of 3-chlorosulfonyl-5-fluoro-4-hydroxy-benzoic acid [ka] To a solution of HOSO2Cl (175.00 g, 1.50 mol, 100 mL) was added 3-fluoro-4-hydroxybenzoic acid (12 g, 76.87 mmol) in 10 portions at 0 °C. The mixture was stirred at 30 °C for 16 hours and then at 80 °C for 2 hours. The reaction solution was added dropwise to ice water (100 mL). The mixture was filtered, and the filter cake was washed with water (3 × 10 mL) and dried under vacuum to obtain 3-chlorosulfonyl-5-fluoro-4-hydroxybenzoic acid (15 g, 55.97 mmol, 72.81% yield) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ = 11.52-11.09 (m, 1H), 7.90-7.85 (m, 1H), 7.65-7.62 (m, 1H) ppm.
[0236] Step 2: Preparation of 3-fluoro-4-hydroxy-5-sulfanyl-benzoic acid [ka] To a solution of 3-chlorosulfonyl-5-fluoro-4-hydroxybenzoic acid (15 g, 58.91 mmol) in toluene (300 mL) was added PPh (54.08 g, 206.19 mmol) at 30 °C, and the mixture was stirred at 90 °C for 16 h. The reaction mixture was quenched by adding saturated NaHCO (100 mL) and extracted with MTBE (100 mL * 3). The aqueous layer was adjusted to pH = 3 with 12 N HCl and extracted with EA (100 mL * 3). The EA layer was dried over NaSO, filtered, and concentrated under reduced pressure to give 3-fluoro-4-hydroxy-5-sulfanyl-benzoic acid (8.5 g, 45.17 mmol, 76.68% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=12.96-12.89(m,1H),11.57-11.51(m,1H),7.82-7.74(m,1H),7.61-7.42(m,1H) ppm.
[0237] Step 3: Preparation of methyl 3-fluoro-4-hydroxy-5-sulfanyl-benzoate [ka] To a solution of 3-fluoro-4-hydroxy-5-sulfanyl-benzoic acid (8 g, 42.51 mmol) in MeOH (80 mL) was added H2SO4 (14.72 g, 150.08 mmol, 8 mL). The mixture was stirred at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure to remove MeOH. The residue was diluted with H2O (100 mL). The pH was adjusted to 3 with aqueous NaHCO3 (100 mL*3) and extracted with EA (100 mL*3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® silica flash column, 0-100% ethyl acetate / petroleum ether gradient elution @ 100 mL / min) and the eluate was concentrated under reduced pressure to give 3-fluoro-4-hydroxy-5-sulfanyl-benzoic acid ester (8 g, 19.78 mmol, 93.06% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =202.9. 1 H NMR(400MHz,DMSO-d6) δ=12.27-11.29(m,1H),7.86-7.78(m,1H),7.65-7.43(m,1H),3.81(d,J=8.4Hz,3H) ppm.
[0238] Step 4: Preparation of methyl 9-fluoro-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylate [ka] To a solution of methyl 3-fluoro-4-hydroxy-5-sulfanylbenzoate (7 g, 34.62 mmol) and 1,3-dibromopropane (6.99 g, 34.62 mmol, 3.53 mL) in DMF (350 mL) was added CsCO (56.40 g, 173.09 mmol). The mixture was stirred at 25 °C for 12 h. The mixture was diluted with HO (200 mL) and extracted with MTBE (200 mL * 2). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 1 / 0 to 5 / 1). The eluate was concentrated to give methyl 9-fluoro-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylate (7.5 g, 30.96 mmol, 89.42% yield) as a yellow oil. LCMS(ESI) m / z:[M+H] + =242.9. 1 H NMR(400MHz,CDCl3) δ=7.81(s,1H),7.60-7.57(m,1H),4.45-4.43(m,2H),3.89(s,3H),3.08-3.05(m,2H),2.34-2.29(m,2H) ppm.
[0239] Step 5: Preparation of methyl 9-fluoro-5-oxo-3,4-dihydro-2H-1,5λ4-benzoxathiepin-7-carboxylate [ka] To a solution of methyl 9-fluoro-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylate (7 g, 28.89 mmol) in MeOH (140 mL) and HO (70 mL) was added Oxone (9.77 g, 15.89 mmol) at 0 °C. The mixture was stirred at 30 °C for 12 h. The mixture was diluted with HO (300 mL) and extracted with EA (300 mL * 2). The combined organic layers were washed with saturated NaSO (300 mL), dried over anhydrous NaSO, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). The eluate was concentrated to give methyl 9-fluoro-5-oxo-3,4-dihydro-2H-1,5λ4-benzoxathiepin-7-carboxylate (7 g, 27.10 mmol, 93.81% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =258.9. 1 H NMR(400MHz, CDCl3) δ=8.19-8.18(m,1H),7.90-7.87(m,1H),4.57-4.53(m,1H),3.93(s,3H),3.91-3.89 (m,1H),3.32-3.29(m,1H),3.23-3.19(m,1H),2.70-2.66(m,1H),2.40-2.39(m,1H) ppm.
[0240] Step 6: Preparation of methyl 4,9-difluoro-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylate [ka] To a solution of methyl 9-fluoro-5-oxo-3,4-dihydro-2H-1,5λ4-benzoxathiepin-7-carboxylate (500 mg, 1.94 mmol) in CHCl3 (5 mL) was added DAST (6.10 g, 37.84 mmol, 5.00 mL). The mixture was stirred at 50 °C for 96 h. For workup, the reaction mixture was combined with another four batches. The reaction mixture was added to saturated NaHCO3 (200 mL) at 0 °C and extracted with DCM (200 mL * 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 10 / 1). The eluate was concentrated to give methyl 4,9-difluoro-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylate (1.3 g, 5.00 mmol, 51.60% yield) as a yellow solid. 1 H NMR(400MHz, CDCl3) δ=7.94-7.93(m,1H),7.76-7.73(m,1H),5.96-5.83(m,1H),4.63-4.58(m,1H),4.16-4.10(m,1H),3.91(s,3H),2.64-2.57(m,2H) ppm.
[0241] Step 7: Preparation of 4,9-difluoro-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylic acid [ka] To a mixture of methyl 4,9-difluoro-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylate (1.95 g, 7.49 mmol) in THF (10 mL), MeOH (5 mL), and HO (5 mL) was added NaOH (599.41 mg, 14.99 mmol). The mixture was stirred at 25 °C for 2 h. The mixture was diluted with HO (50 mL) and adjusted to pH 3 with 1 N HCl, followed by extraction with EA (50 mL * 2). The combined organic layer was dried over anhydrous NaSO, filtered, and concentrated to give 4,9-difluoro-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylic acid (1.8 g, 7.31 mmol, 97.57% yield) as a white solid, which was used directly in the next step.
[0242] Step 8: 4,9-Difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carvone Preparation of the acid [ka] To a solution of 4,9-difluoro-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylic acid (1.8 g, 7.31 mmol) in MeOH (40 mL) and HO (20 mL) was added Oxone (13.48 g, 21.93 mmol) at 0 °C. The mixture was stirred at 30 °C for 12 h. The mixture was diluted with HO (100 mL) and extracted with DCM (100 mL * 2). The combined organic layer was washed with aqueous NaSO (100 mL), dried over anhydrous NaSO, filtered, and concentrated to give 4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid (1.9 g, 6.83 mmol, 93.42% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=8.33-8.25(m,1H),8.19-8.15(m,1H),6.33-6.20(m,1H),4.63-4.59(m,1H),4.19-4.13(m,1H),2.84-2.74(m,1H),2.61-2.57(m,1H) ppm.
[0243] Step 9: Preparation of intermediate 2 (4R)-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid and (4S)-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid [ka] 4,9-Difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid (1.88 g, 6.76 mmol) was separated by chiral SFC (column: DAICEL CHIRALPAK AD-H (250 mm * 30 mm, 5 μm); mobile phase: [0.1% NH3HO MEOH]; B%: 15% to 15%, 8.5 min; 750 min).
[0244] Intermediate 2: (4R)-4,9-Difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid. The eluate of peak 1 was concentrated to give a residue. The residue was diluted with HO (50 mL) and adjusted to pH 2 with 1N HCl, followed by extraction with DCM (50 mL * 2). The combined organic layer was dried over anhydrous NaSO, filtered, and concentrated to give (4R)-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid (Intermediate 2) (850 mg, 2.99 mmol, 44.22% yield) as a white solid. 1H NMR (400 MHz, DMSO-d₆) δ = 13.84-13.73 (m, 1H), 8.20-8.15 (m, 2H), 6.34-6.21 (m, 1H), 4.63-4.58 (m, 1H), 4.19-4.13 (m, 1H), 2.75-2.71 (m, 1H), 2.61-2.56 (m, 1H) ppm. Chiral SFC: AD-3-MeOH(DEA)-5-40-3ML-35T. 1cm. Rt = 1.304 min, ee% = 96.54%. The eluate from peak 2 was concentrated to give a residue. The residue was diluted with HO (50 mL) and adjusted to pH=2 by adding 1N HCl, followed by extraction with DCM (50 mL*2). The combined organic layer was dried over anhydrous NaSO, filtered and concentrated to give (4S)-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid (800 mg, 2.81 mmol, 41.65% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=13.80-13.73(m,1H),8.19-8.15(m,2H),6.34-6.21(m,1H),4.63-4.58(m,1H),4.19-4.13(m,1H),2.85-2.75(m,1H),2.61-2.56(m,1H) ppm.Chiral SFC:AD-3-MeOH(DEA)-5-40-3ML-35T.lcm.Rt=1.410min,ee%=99.25%.
[0245] Preparation of (4R)-N-[[6-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyrazin-2-yl]-3-isoquinolyl]methyl]-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxamide (compound 19) [ka] Step 1: Preparation of (2S,6R)-4-(6-chloropyrazin-2-yl)-2,6-dimethyl-morpholine [ka] To a solution of 2,6-dichloropyrazine (1 g, 6.71 mmol) in ACN (50 mL) was added K2CO3 (2.78 g, 20.14 mmol) and (2S,6R)-2,6-dimethylmorpholine (850.40 mg, 7.38 mmol). The mixture was stirred at 90 °C for 3 h. The reaction mixture was poured into water (100 mL) and extracted with EA (100 mL * 3). The combined organic layers were washed with brine (200 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO2, PE:EA = 20:1 to 1:1), and the fractions were concentrated under reduced pressure to give (2S,6R)-4-(6-chloropyrazin-2-yl)-2,6-dimethylmorpholine (1.2 g, 5.27 mmol, 78.52% yield) as a white solid. LCMS(ESI) m / z:[M+H]+=228.1. 1 H NMR(400MHz,DMSO-d6) δ=8.40-8.23(m,1H),7.91-7.78(m,1H),4.21-4.10(m,2H),3.67-3.52(m,2H),3.31(s,1H),2.53(d,J=2.4Hz,1H),1.17-1.14(m,6H) ppm.
[0246] Step 2: Preparation of tert-butyl N-[[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-isoquinolyl]methyl]carbamate [ka] tert-Butyl N-[(6-bromo-3-isoquinolyl)methyl]carbamate (200 mg, 593.10 μmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (180.73 mg, 711.72 μmol), Pd(dppf)Cl (43.40 mg, 59.31 μmol), and KOAc (174.62 mg, 1.78 mmol) in dioxane (5 mL). The mixture was degassed and purged with N2 three times, and then the mixture was stirred at 100 °C under N2 atmosphere for 2 h. The mixture was diluted with HO (30 mL) and extracted with EA (30 mL * 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated to give tert-butyl N-[[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-isoquinolyl]methyl]carbamate (220 mg, crude) as a brown oil, which was used directly in the next step.
[0247] Step 3: Preparation of tert-butyl N-[[6-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyrazin-2-yl]-3-isoquinolyl]methyl]carbamate [ka] A mixture of (2S,6R)-4-(6-chloropyrazin-2-yl)-2,6-dimethyl-morpholine (from Step 1) (100 mg, 439.19 μmol), N-[[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-isoquinolyl]methyl]carbamic acid (202.53 mg, 527.03 μmol), KPO (279.68 mg, 1.32 mmol), and di-tert-butyl(cyclopentyl)phosphane; dichloropalladium; iron (28.62 mg, 43.92 μmol) in dioxane (2.5 mL) and HO (0.5 mL) was degassed and purged with N three times. After that, the mixture was stirred at 100 °C for 12 h. The reaction mixture was poured into H2O (30 mL) and extracted with EA (30 mL * 3). The combined organic layers were washed with brine (60 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography (SiO2, PE:EA = 20:1 to 1:1), and the fractions were concentrated under reduced pressure to give tert-butyl N-[[6-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyrazin-2-yl]-3-isoquinolyl]methyl]carbamate (150 mg, 333.67 μmol, 75.97% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] + =450.1.
[0248] Step 4: Preparation of [6-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyrazin-2-yl]-3-isoquinolyl]methanamine [ka] To a solution of tert-butyl N-[[6-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyrazin-2-yl]-3-isoquinolyl]methyl]carbamate (150 mg, 333.67 μmol) in dioxane (2 mL) was added HCl / dioxane (4 M, 4 mL). The mixture was stirred at 25 °C for 1 h. The reaction mixture was concentrated to give [6-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyrazin-2-yl]-3-isoquinolyl]methanamine (120 mg, crude, HCl salt) as a pale yellow solid, which was used in the next step without further purification. LCMS (ESI) m / z: [M+H]+ = 350.2
[0249] Step 5: Preparation of (4R)-N-[[6-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyrazin-2-yl]-3-isoquinolyl]methyl]-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxamide (compound 19) [ka] To a solution of [6-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyrazin-2-yl]-3-isoquinolyl]methanamine hydrochloride (70 mg, 200.33 μmol) in DCM (2 mL) was added (4R)-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid (Intermediate 2) (55.74 mg, 200.33 μmol), EDCI (76.81 mg, 400.65 μmol), HOBt (54.14 mg, 400.65 μmol), and DIEA (155.35 mg, 1.20 mmol, 209.36 μL). The mixture was stirred at 25 °C for 2 h. The reaction mixture was poured into water (15 mL) and extracted with EA (15 mL*3). The combined organic layers were washed with brine (20 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by preparative HPLC (column: Phenomenex C18 75*30 mm*3 um; mobile phase: [water (FA)-ACN]; B%: 55% to 8%, 5 min). The fractions were concentrated in vacuo to remove MeCN and lyophilized to give (4R)-N-[[6-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyrazin-2-yl]-3-isoquinolyl]methyl]-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxamide (39.15 mg, 63.38 μmol, 31.64% yield) as a yellow solid. LCMS (ESI) m / z: [M+H]+ = 610.3. 1 H NMR(400MHz,DMSO-d6) δ=9.66-9.58(m,1H),9.36-9.31(m,1H),8.71-8.62(m,2H),8.39-8.19(m,5H),7.87(s,1H),6.41-6.12(m,1H),4.80-4.73(m,2H),4. 65-4.57(m,1H),4.44-4.33(m,2H),4.13-4.15(m,1H),3.71-3.62(m,2H),2.90-2.72(m,1H),2.61-2.55(m,3H),1.20(d,J=6.4Hz,6H) ppm. Chiral SFC: OD-MeOH + CAN(DEA)-40-3mL-35T.lcm, T=0.904, ee%=100%.
[0250] Preparation of (2R)-6-chloro-N-[[6-[6-(difluoromethoxy)-2-pyridyl]-3-isoquinolyl]methyl]-2-fluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxamide (compound 235) [ka] Step 1: Preparation of 2-bromo-6-(difluoromethoxy)pyridine [ka] To a solution of 1-[[bromo(difluoro)methyl]-ethoxy-phosphoryl]oxyethane (3.38 g, 12.64 mmol) in MeCN (20 mL) was added 6-bromopyridin-2-ol (2.00 g, 11.49 mmol) and KF (1.34 g, 22.99 mmol). The mixture was stirred at 25 °C for 16 h. The reaction mixture was concentrated under reduced pressure to give a residue, which was then diluted with HO (100 mL * 3), dried over NaSO, filtered, and concentrated under reduced pressure to give a residue which was purified by column chromatography (SiO, PE / EA = 50 / 1 to 5 / 1). The eluate was concentrated under reduced pressure to give 2-bromo-6-(difluoromethoxy)pyridine (1.2 g, 5.36 mmol, 46.61% yield) as a colorless oil. LCMS (ESI) m / z: [81BrM+H] + =226.2. 1 H NMR(400MHz, CDCl3) δ=7.66-7.43(m,2H),7.32-7.30(m,1H),6.87(d,J=8.0Hz,1H) ppm.
[0251] Step 2: Preparation of 2-(difluoromethoxy)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine [ka] To a solution of XPhos (106.41 mg, 223.21 μmol) in dioxane (5 mL), Pd(dba) (81.76 mg, 89.28 μmol) was added. The mixture was degassed and purged with N three times, and then stirred under a N atmosphere at 25 °C for 30 min. Next, 2-bromo-6-(difluoromethoxy)pyridine (200 mg, 892.85 μmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (272.07 mg, 1.07 mmol), and KOAc (262.88 mg, 2.68 mmol) were added to the mixture. The resulting mixture was stirred at 80 °C for 2 h. The reaction mixture was filtered, and the filter cake was washed with EA (20 mL*3). The combined filtrate was concentrated under reduced pressure to give 2-(difluoromethoxy)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (240 mg, 885.39 μmol, 99.16% yield) as a brown oil, which was used directly in the next step without further purification.
[0252] Step 3: Preparation of tert-butyl N-[[6-[6-(difluoromethoxy)-2-pyridyl]-3-isoquinolyl]methyl]carbamate [ka] To a solution of 2-(difluoromethoxy)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (240 mg, 885.39 μmol) in dioxane (2 mL) and HO (0.2 mL) was added tert-butyl N-[(6-bromo-3-isoquinolyl)methyl]carbamate (149.28 mg, 442.69 μmol), ditert-butyl(cyclopentyl)phosphane; dichloropalladium; iron (28.85 mg, 44.27 μmol), and KPO (281.91 mg, 1.33 mmol). The mixture was degassed and purged with N three times. The mixture was then stirred at 80 °C under a N atmosphere for 16 h. The mixture was diluted with HO (30 mL) and extracted with EA (50 mL x 3). The combined organic phase was washed with brine (50 mL*2), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo to give a residue, which was purified by column chromatography (SiO2, PE / EA = 10 / 1 to 1 / 3). The eluate was concentrated under reduced pressure to give a yellow solid, tert-butyl N-[[6-[6-(difluoromethoxy)-2-pyridyl]-3-isoquinolyl]methyl]carbamate (160 mg, 398.60 μmol, 90.04% yield). LCMS (ESI) m / z: [M+H] + =402.2. 1 H NMR(400MHz, CDCl3) δ=9.25(s,1H),8.39(s,1H),8.20(d,J=8.8Hz,1H),8.06(d,J=8.8Hz,1H),7.91-7.85(m,1H ),7.78-7.49(m,3H),6.95(d,J=8.0Hz,1H),5.53(s,1H),4.62(d,J=5.6Hz,2H),1.49(s,9H) ppm.
[0253] Step 4: Preparation of [6-[6-(difluoromethoxy)-2-pyridyl]-3-isoquinolyl]methanamine [ka] A mixture of tert-butyl N-[[6-[6-(difluoromethoxy)-2-pyridyl]-3-isoquinolyl]methyl]carbamate (160 mg, 398.60 μmol) in HCl / dioxane (4 M) was stirred at 25° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give [6-[6-(difluoromethoxy)-2-pyridyl]-3-isoquinolyl]methanamine (130 mg, 384.90 μmol, 96.56% yield, HCl) as a gray solid, which was used directly in the next step without further purification. LCMS (ESI) m / z: [M+H] + =302.1.
[0254] Step 5: Preparation of (2R)-6-chloro-N-[[6-[6-(difluoromethoxy)-2-pyridyl]-3-isoquinolyl]methyl]-2-fluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxamide [ka] To a mixture of [6-[6-(difluoromethoxy)-2-pyridyl]-3-isoquinolyl]methanamine (30 mg, 88.82 μmol) and (2R)-6-chloro-2-fluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxylic acid (Intermediate 1) (31.41 mg, 106.59 μmol) in DCM (1 mL), EDCI (22.14 mg, 115.47 μmol), HOBt (15.60 mg, 115.47 μmol), and DIEA (68.88 mg, 532.94 μmol) were added. The mixture was stirred at 25 °C for 2 h. The reaction mixture was poured into HO (10 mL) and extracted with DCM (20 mL * 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue that was purified by reverse-phase flash (0.1% FA). The eluate was concentrated under reduced pressure to remove MeCN, and the residue was lyophilized to give (2R)-6-chloro-N-[[6-[6-(difluoromethoxy)-2-pyridyl]-3-isoquinolyl]methyl]-2-fluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxamide (19.12 mg, 33.08 μmol, 37.24% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =578.1 1 H NMR(400MHz,DMSO-d6) δ=9.76-9.73(m,1H),9.35(s,1H),8.73(s,1H),8.58(d,J=1.6Hz,1H),8.50(d,J=1.6Hz,1H),8.39-8.37(m,1H),8.27-7.83(m,5H) ),7.13-7.11(m,1H),6.36-6.10(m,1H),5.41(d,J=14.8Hz,1H),5.09(d,J=14.8Hz,1H),4.78(d,J=5.2Hz,2H),4.52-4.36(m,2H) ppm. Chiral SFC: OD-3-MeOH + ACN(DEA)-40-3ML-35T. 1cm, Rt = 0.853 min, ee% = 97.36%.
[0255] The following examples in Table 4 were prepared using standard chemical manipulations and procedures similar to those used to prepare compound 235. [Table 6-1] [Table 6-2]
[0256] Preparation of (R)-N-((4-((E)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)vinyl)pyridin-2-yl)methyl)-4,9-difluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (Compound 52) [ka] Step 1: Preparation of (2S,6R)-4-(6-bromopyridin-2-yl)-2,6-dimethylmorpholine [ka] To a solution of 2-bromo-6-fluoropyridine (2 g, 11.36 mmol) in DMF (20 mL) was added (2S,6R)-2,6-dimethylmorpholine (1.96 g, 17.05 mmol) and Cs2CO3 (7.41 g, 22.73 mmol). The mixture was stirred at 80 °C for 1 h. The reaction mixture was poured into water (200 mL) and extracted with EA (50 mL * 3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by normal phase flash (column: SiO2, 40 g; PE:EA = 1:0 to 0:1, RF = 0.3). The eluate was concentrated in vacuo to give (2S,6R)-4-(6-bromopyridin-2-yl)-2,6-dimethylmorpholine (2.9 g, 10.30 mmol, 90.63% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =270.8 1H NMR (400 MHz, chloroform-d) δ = 7.31-7.27 (m, 1H), 6.77 (d, J = 7.6 Hz, 1H), 6.50 (d, J = 8.4 Hz, 1H), 4.03-4.00 (m, 2H), 3.76-3.62 (m, 2H), 2.55-2.49 (m, 2H), 1.27 (d, J = 6.2 Hz, 6H) ppm.
[0257] Step 2: Preparation of (2S,6R)-2,6-dimethyl-4-(6-vinylpyridin-2-yl)morpholine [ka] To a solution of (2S,6R)-4-(6-bromopyridin-2-yl)-2,6-dimethylmorpholine (1 g, 3.69 mmol) in dioxane (10 mL) was added potassium hydride; trifluoro(vinyl)boron (988.00 mg, 7.38 mmol), Pd(dtbpf)Cl (240.36 mg, 368.80 mmol), KPO (2.35 g, 11.06 mmol), and HO (2 mL). The mixture was degassed and purged with N three times and stirred at 80 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL * 3). The combined organic layer was washed with brine (30 mL), dried over anhydrous NaSO, filtered, and concentrated in vacuo. The residue was purified by normal phase flash chromatography (column: SiO2, 40 g, PE:EA = 1:0 to 0:1, Rf = 0.4). The eluate was concentrated in vacuo to give (2S,6R)-2,6-dimethyl-4-(6-vinylpyridin-2-yl)morpholine (850 mg, 3.64 mmol, 98.81% yield) as a brown oil. LCMS (ESI) m / z: [M+H] + =218.9. 1 H NMR(400MHz,chloroform-d) δ=7.47-7.43(m,1H),6.73-6.63(m,2H),6.54(d,J=8.4Hz,1H),6.23(d,J=1.8Hz,1H),6.19(d,J=1.8Hz ,1H),5.39-5.36(m,1H),4.15-4.12(m,2H),3.75-3.72(m,2H),2.55-2.49(m,2H),1.28(d,J=6.2Hz,6H) ppm.
[0258] Step 3: Preparation of tert-butyl ((4-bromopyridin-2-yl)methyl)carbamate [ka] To a solution of (4-bromo-2-pyridyl)methanamine (2 g, 10.69 mmol) in DCM (20 mL) was added tert-butoxycarbonyl tert-butyl carbonate (4.20 g, 19.25 mmol, 4.42 mL) and TEA (2.16 g, 21.39 mmol, 2.98 mL). The mixture was stirred at 25 °C for 2 h. The mixture was poured into water (50 mL) and extracted with DCM (50 mL * 3). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by normal phase flash (column: SiO2, 80 g, PE:EA = 1:0 to 1:1, RF = 0.4). The eluate was concentrated to give tert-butyl ((4-bromopyridin-2-yl)methyl)carbamate (3 g, 10.19 mmol, 95.28% yield) as a colorless oil. LCMS (ESI) m / z: [M+H-56] + =230.8. 1 H NMR (400 MHz, chloroform-d) δ = 8.34 (d, J = 5.4 Hz, 1H), 7.46 (d, J = 1.2 Hz, 1H), 7.35-7.27 (m, 1H), 5.51 (br s, 1H), 4.42 (br d, J = 5.2 Hz, 2H), 1.46 (s, 9H) ppm.
[0259] Step 4: Preparation of tert-butyl ((4-((E)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)vinyl)pyridin-2-yl)methyl)carbamate [ka] To a solution of (2S,6R)-2,6-dimethyl-4-(6-vinylpyridin-2-yl)morpholine (100 mg, 458.10 μmol) in DMF (2 mL) was added tert-butyl ((4-bromopyridin-2-yl)methyl)carbamate (197.32 mg, 687.15 μmol), Pd(OAc) (10.28 mg, 45.81 μmol), tris-o-tolylphosphane (34.86 mg, 114.52 μmol), and DIEA (177.61 mg, 1.37 mmol, 239.37 μL). The mixture was degassed, purged with N, and stirred at 100 °C for 1 h. The reaction mixture was poured into water (15 mL) and extracted with EA (10 mL*3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by normal phase flash chromatography (column: SiO2, 12 g, PE:EA = 1:0 to 0:1, Rf = 0.4). The eluate was concentrated to give tert-butyl ((4-((E)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)vinyl)pyridin-2-yl)methyl)carbamate (190 mg, 399.62 μmol, 87.23% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =425.1. 1 H NMR (400MHz, chloroform-d) δ=8.51(br d,J=5.4Hz,1H),7.59-7.39(m,4H),7.28(br s,1H),7.24(br s,1H),6.76(d,J=7.2Hz,1H),6.63(d,J=8.4Hz,1H),5.85-5.70(m,1H),4.52(br d,J=4.8Hz,2H),4.17(br d,J=12.6Hz,2H),3.82-3.73(m,2H),2.61-2.55(m,2H),1.47(s,9H),1.32(d,J=6.2Hz,6H) ppm.
[0260] Step 5: Preparation of (4-((E)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)vinyl)pyridin-2-yl)methanamine [ka] To a mixture of tert-butyl ((4-((E)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)vinyl)pyridin-2-yl)methyl)carbamate (100 mg, 235.55 umol) in DCM (1 mL) was added TFA (0.3 mL). The mixture was stirred at 25° C. for 1 hour. The mixture was poured into saturated NaHCO (5 mL) and extracted with DCM (5 mL*3). The combined organic layers were washed with brine (5 mL), dried over anhydrous NaSO, filtered, and concentrated in vacuo to give (4-((E)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)vinyl)pyridin-2-yl)methanamine (75 mg, crude) as a yellow oil. LCMS (ESI) m / z: [M+H] + =325.0
[0261] Step 6: Preparation of (R)-N-((4-((E)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)vinyl)pyridin-2-yl)methyl)-4,9-difluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (compound 52) [ka] To a solution of (4R)-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid (Intermediate 2) (64.32 mg, 231.18 μmol) in DCM (2 mL) was added HATU (131.85 mg, 346.77 μmol) and DIEA (89.64 mg, 693.55 μmol, 120.80 μL). Then, (4-((E)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)vinyl)pyridin-2-yl)methanamine (75 mg, 231.18 μmol) was added. The mixture was stirred at 25 °C for 2 h. The mixture was poured into water (20 mL) and extracted with EA (10 mL * 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous NaSO, filtered, and concentrated under vacuum. The residue was purified by preparative HPLC (column: Phenomenex luna C18 150*25 mm*10 μm; mobile phase: [water (FA)-ACN]; B%: 30% to 60%, 10 min). The eluate was then concentrated and lyophilized to give (R)-N-((4-((E)-2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)vinyl)pyridin-2-yl)methyl)-4,9-difluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (28.28 mg, 43.20 μmol, 18.69% yield, FA) as a yellow solid. LCMS(ESI) m / z:[M+H] + =585.1. 1H NMR (400 MHz, chloroform-d) δ = 8.53 (d, J = 5.4 Hz, 1H), 8.30-8.26 (m, 1H), 8.15 (s, 1H), 8.08-8.05 (m, 2H), 7.56-7.50 (m, 3H), 7.46-7.44 (m, 1H), 7.30 (s, 1H), 7.26 (br s,1H),6.78(d,J=7.2Hz,1H),6.63(d,J=8.4Hz,1H),5.76-5.38(m,1H),4.80(d,J=5.2Hz,2H),4.67-4.65(m,1H),4.19-4.16 (m,2H),4.11-4.09(m,1H),3.85-3.68(m,2H),3.21-2.96(m,1H),2.59-5.28(m,2H),2.52-2.42(m,1H),1.32(d,J=6.4Hz,7H) ppm. Chiral SFC: OJ-3-EtOH(DEA)-5-40-3ML-35T. 1cm, Rt = 1.847 min, ee% = 100%.
[0262] Preparation of the intermediate 4(2R)-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ6-benzoxathiepin-8-carboxylic acid [ka] Step 1: Preparation of methyl 4-bromo-2-fluoro-6-sulfanyl-benzoate [ka] To a solution of methyl 4-bromo-2,6-difluorobenzoate (100 g, 398.37 mmol) in DMF (1000 mL) was added Na2S (34.54 g, 398.37 mmol, 90% purity), and the mixture was stirred at 30 °C for 16 hours. The reaction mixture was poured into water (1500 mL) and extracted with MTBE (1500 mL * 2). The aqueous phase was adjusted to pH = 2 with 1 N HCl and extracted with MTBE (1500 mL * 3). The combined organic layers were washed with water (2000 mL * 2) and brine (5000 mL), dried over Na2SO4, filtered, and concentrated to give methyl 4-bromo-2-fluoro-6-sulfanylbenzoate (105 g, crude) as a yellow oil. LCMS (ESI) m / z: [Br79 M+H] + =232.9
[0263] Step 2: Preparation of (4-bromo-2-fluoro-6-sulfanyl-phenyl)methanol [ka] To a solution of methyl 4-bromo-2-fluoro-6-sulfanylbenzoate (105 g, 396.08 mmol) in THF (1000 mL) was added LiAlH (15.03 g, 396.08 mmol) at 0 °C under N. The mixture was stirred at 0 °C for 1 h. The mixture was poured into 1 N HCl (1000 mL) and extracted with EtOAc (1000 mL*2). The combined organic phase was washed with brine (2000 mL), dried over anhydrous NaSO, filtered, and concentrated in vacuo to give (4-bromo-2-fluoro-6-sulfanyl-phenyl)methanol (93 g, crude) as a yellow oil, which was used directly in the next step.
[0264] Step 3: Preparation of (4-bromo-2-fluoro-6-vinylsulfanyl-phenyl)methanol [ka] To a solution of (4-bromo-2-fluoro-6-sulfanyl-phenyl)methanol (93 g, 392.26 mmol) in DMF (1800 mL) were added K2CO3 (162.64 g, 1.18 mol) and 1,2-dibromoethane (221.07 g, 1.18 mol, 88.78 mL), and the mixture was stirred at 30 °C for 16 h. The reaction was quenched with water (2000 mL). The mixture was extracted with ethyl acetate (2000 mL*3). The combined organic layers were dried over Na2SO4 and concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10:1 to 1:1), and the solution was concentrated to give (4-bromo-2-fluoro-6-vinylsulfanyl-phenyl)methanol (56 g, 212.83 mmol) as a yellow oil. 1H NMR(400MHz,CDCl3) δ=7.33(s,1H),7.19-7.17(m,1H),6.50-6.44(m,1H),5.54-5.42(m,2H),4.78(d,J=1.2Hz,2H),2.13(s,1H) ppm
[0265] Step 4: Preparation of (4-bromo-2-fluoro-6-vinylsulfinyl-phenyl)methanol [ka] To a solution of (4-bromo-2-fluoro-6-vinylsulfanyl-phenyl)methanol (10 g, 38.00 mmol) in MeOH (100 mL) and HO (100 ml) was added Oxone (11.68 g, 19.00 mmol), and the mixture was stirred at 30 °C for 16 h. The reaction mixture was poured into water (1 L), the solution was extracted with EA (1 L * 3), and the combined organic layers were washed with saturated NaSO (1 L) and brine (1 L), dried over NaSO, filtered, and concentrated to give (4-bromo-2-fluoro-6-vinylsulfinyl-phenyl)methanol (10.61 g, crude) as a yellow oil. LCMS (ESI) m / z: [Br 79 M+H] + =263.0
[0266] Step 5: Preparation of 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide [ka] To a solution of (4-bromo-2-fluoro-6-vinylsulfinyl-phenyl)methanol (10.6 g, 37.98 mmol) in THF (110 mL) was added NaH (3.04 g, 75.95 mmol, purity 60%) at 0 °C, and the mixture was stirred at 20 °C for 1 h. The reaction mixture was poured into NHCl (500 mL), and the solution was extracted with EA (500 mL * 3). The combined organic layers were washed with brine (1000 mL), dried over NaSO, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10:1 to 1:1), and the solution was concentrated to give 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide (5.5 g, 19.70 mmol, 51.89% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=7.78-7.75(m,1H),7.62(s,1H),4.96(d,J=15.2Hz,1H),4.54-4.50(m,1H),4.33-4.24(m,2H),3.41-3.39(m,2H) ppm
[0267] Step 6: Preparation of 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide and 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin [ka] To a solution of 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide (1.9 g, 6.81 mmol) in DCM (40 mL) was added SbCl (46.58 mg, 204.21 μmol), followed by DAST (2.19 g, 13.61 mmol, 1.80 mL). The mixture was stirred at 20 °C for 16 h. Next, DAST (5.49 g, 34.03 mmol, 4.50 mL) was added, and the mixture was stirred at 20 °C for 16 h. SbCl (1.55 g, 6.81 mmol) and DAST (10.97 g, 68.07 mmol, 8.99 mL) were added, and the mixture was stirred at 20 °C for 16 h. The reaction mixture was poured into NaHCO3 solution (200 mL), and the solution was extracted with EA (200 mL * 3). The combined organic layers were washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20:1 to 5:1), and peak 1 eluate was concentrated to give 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide (1.2 g, 4.56 mmol, 67.00% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl) δ = 7.54-7.51 (m, 1H), 7.18-7.15 (m, 1H), 4.91-4.89 (m, 2H), 4.17-4.14 (m, 2H), 2.89-2.86 (m, 2H) ppm. The peak 2 eluate was concentrated to give 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin (600 mg, 2.13 mmol, 31.36% yield) as a yellow solid. 1 H NMR(400MHz, CDCl3) δ=7.55-7.54(m,1H),7.27-7.24(m,1H),5.63-5.51(m,1H),5.25(d,J=13.6Hz,1H),4.69-4.65(m,1H),4.43-4.41(m,1H),4.13-4.05(m,1H) ppm
[0268] Step 7: Preparation of 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin [ka] To a solution of 8-bromo-6-fluoro-3,5-dihydro-2H-4,1λ4-benzoxathiepin 1-oxide (1.2 g, 4.56 mmol) in MeCN (25 mL) was added Select F (2.02 g, 5.70 mmol) followed by DAST (147.02 mg, 912.11 μmol, 120.51 μL) under ice bath. The solution was stirred at 20 °C for 1 h. Next, DIEA (884.11 mg, 6.84 mmol, 1.19 mL) was added to the mixture at 0 °C, and the mixture was stirred at 20 °C for 1 h. The reaction mixture was poured into NaHCO3 solution (200 mL) and extracted with EA (200 mL * 3). The combined organic layer was washed with brine (500 mL), dried over Na2SO4, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 20:1 to 5:1), and the solution was concentrated to give 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiep- ine (500 mg, 1.78 mmol, yield 39.00%) as a yellow solid. 1 H NMR(400MHz, CDCl3) δ=7.54(m,1H),7.27-7.24(m,1H),5.63-5.51(m,1H),5.25(d,J=13.6Hz,1H),4.70-4.66(m,1H),4.43-4.42(m,1H),4.13-4.05(m,1H) ppm
[0269] Step 8: Preparation of 2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin-8-carboxylic acid [ka] To a solution of 8-bromo-2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin (1.3 g, 4.62 mmol) in DMSO (20 mL) and HO (4 mL) was added KCO (958.71 mg, 6.94 mmol), bicyclohexyl(3-bicyclohexylphosphaniumylpropyl)phosphonium; ditetrafluoroborate (283.13 mg, 462.44 µmol), and Pd(OAc) (103.82 mg, 462.44 µmol). The suspension was degassed under vacuum and purged with CO several times. The mixture was stirred at 100 °C under CO (15 psi) for 2 h. The reaction mixture was poured into NaHCO solution (100 mL) and extracted with EA (100 mL * 2). The aqueous phase was adjusted to pH=1 with 1N HCl and extracted with EA (50 mL*2), and the combined organic layers were dried over Na2SO4, filtered, and concentrated to give 2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin-8-carboxylic acid (1.1 g, crude) as a yellow solid, which was used without purification.
[0270] Step 9: 2,6-Difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ 6 Preparation of benzoxathiepin-8-carboxylic acid [ka] To a solution of 2,6-difluoro-3,5-dihydro-2H-4,1-benzoxathiepin-8-carboxylic acid (1.1 g, 4.47 mmol) in MeOH (12 mL) and HO (12 mL) was added Oxone (5.49 g, 8.93 mmol), and the mixture was stirred at 20° C. for 16 h. The reaction mixture was poured into water (100 mL), the solution was extracted with EA (100 mL*3), and the combined organic layers were washed with brine (200 mL), dried over NaSO, filtered, and concentrated to give 2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ as a white solid. 6 -benzoxathiepin-8-carboxylic acid (1.1 g, 3.95 mmol, 88.50% yield). 1H NMR(400MHz,DMSO-d6) δ=14.03-13.95(m,1H),8.34(d,J=1.2Hz,1H),8.13-8.11(m,1H),6.27-6.16(m,1H),5.25-5.21(m,1H),4.91-4.86(m,1H),4.47-4.38(m,2H) ppm.
[0271] Step 10: (2R)-2,6-Difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ 6 -benzoxathiepin-8-carboxylic acid (intermediate 4) and (2S)-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ 6 Preparation of benzoxathiepin-8-carboxylic acid [ka] 2,6-Difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ 6 -Benzoxathiepin-8-carboxylic acid (1.1 g, 3.95 mmol) was separated by chiral SFC (column: Daicel ChiralPak IG (250*30 mm, 10 μm); mobile phase: [0.1% NH3H2O MEOH]; B%: 20% to 20%, 4.75; 310 min) to give two peaks. Peak 1 eluate was concentrated to give a residue, which was diluted with water (100 mL) and adjusted to pH=2 with 4N HCl solution. The solution was extracted with EA (100 mL*2). The combined organic layer was dried over Na2SO4, filtered, and concentrated to give (2R)-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ as a white solid. 6 -benzoxathiepin-8-carboxylic acid (intermediate 4) (350 mg, 1.25 mmol, 31.69% yield) was obtained. 1H NMR (400 MHz, DMSO-d6) δ = 14.17-13.92 (m, 1H), 8.33 (s, 1H), 8.13-8.11 (m, 1H), 6.27-6.17 (m, 1H), 5.25-5.21 (m, 1H), 4.91-4.86 (m, 1H), 4.47-4.35 (m, 2H) ppm. Chiral SFC: IG-3_5CM_MEOH(DEA)_5_40_3ML_T35.M; Rt = 1.408 min, ee% = 98.14%. Peak 2 eluate was concentrated to give a residue. The residue was diluted with water (100 mL) and purified by 4N chromatography. The pH was adjusted to 2 with HCl solution, the solution was extracted with EA (100 mL*2), and the combined organic layers were dried over Na2SO4, filtered, and concentrated to give (2S)-2,6-difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ as a white solid. 6 -benzoxathiepin-8-carboxylic acid (500 mg, 1.66 mmol, 41.94% yield). 1 H NMR(400MHz,DMSO-d6) δ=14.27-13.55(m,1H),8.34(d,J=1.2Hz,1H),8.13-8.10(m,1H),6.27-6.16(m,1H),5.26-5.21(m,1H),4.91-4.86(m,1H),4.47-4.38(m,2H) ppm.Chiral SFC:IG-3_5CM_MEOH(DEA)_5_40_3ML_T35.M;Rt=1.624min,ee%=98.96%
[0272] Preparation of (R)-N-((4-((6-(difluoromethoxy)pyridin-2-yl)ethynyl)pyridin-2-yl)methyl)-2,6-difluoro-3,5-dihydro-2H-benzo[e][1,4]oxathiepin-8-carboxamide 1,1-dioxide (Compound 184) [ka] Step 1: Preparation of 2-bromo-6-(difluoromethoxy)pyridine [ka] To a solution of 6-bromopyridin-2-ol (2 g, 11.49 mmol) in MeCN (20 mL) was added KF (1.34 g, 22.99 mmol, 538.55 μL) and 1-[[bromo(difluoro)methyl]-ethoxy-phosphoryl]oxyethane (3.38 g, 12.64 mmol). The mixture was stirred at 25 °C for 1.5 h. The reaction mixture was poured into water (100 mL) and extracted with DCM (100 mL * 3). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (column: SiO2, 80 g; PE / EA = 1 / 0 to 0 / 1, 40 mL / min, Rf = 0.80). The eluate was concentrated in vacuo to give 2-bromo-6-(difluoromethoxy)pyridine (2.23 g, 9.59 mmol, 83.47% yield) as a yellow oil. LCMS (ESI) m / z: [M+H] + =225.7 1 H NMR(400MHz,DMSO-d6) δ=7.91-7.80(m,1H),7.66-7.54(m,1H),7.50(d,J=28.8Hz,1H),7.15(d,J=8.0Hz,1H) ppm.
[0273] Step 2: Preparation of tert-butyl ((4-((6-(difluoromethoxy)pyridin-2-yl)ethynyl)pyridin-2-yl)methyl)carbamate [ka] To a solution of 2-bromo-6-(difluoromethoxy)pyridine (100 mg, 446.42 μmol) and tert-butyl N-[(4-ethynyl-2-pyridyl)methyl]carbamate (103.69 mg, 446.42 μmol) in DMF (1 mL) was added TEA (451.73 mg, 4.46 mmol, 621.36 μL), Pd(PPh3)2Cl2 (31.33 mg, 44.64 μmol), and CuI (8.50 mg, 44.64 μmol). The mixture was degassed, purged with N2, and stirred at 80 °C for 1.5 h. The reaction mixture was poured into water (5 mL) and extracted with EA (5 mL * 3). The combined organic layers were washed with brine (5 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by flash silica gel chromatography (column: SiO2, 20 g; PE / EA = 1 / 0 to 1 / 0, 40 mL / min, Rf = 0.30). The eluate was concentrated in vacuo to give tert-butyl ((4-((6-(difluoromethoxy)pyridin-2-yl)ethynyl)pyridin-2-yl)methyl)carbamate (116 mg, 289.24 μmol, 64.79% yield) as a yellow oil. LCMS(ESI) m / z:[M+H] + =375.9. 1 H NMR (400 MHz, chloroform-d) δ = 8.77-8.39 (m, 1H), 7.79-7.73 (m, 1H), 7.55 (s, 1H), 7.48-7.47 (m, 1H), 7.37 (d, J = 6.8 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 5.53 (br s, 1H), 4.47 (br s, 2H), 1.48 (s, 9H) ppm.
[0274] Step 3: Preparation of (4-((6-(difluoromethoxy)pyridin-2-yl)ethynyl)pyridin-2-yl)methanamine [ka] To a solution of tert-butyl ((4-((6-(difluoromethoxy)pyridin-2-yl)ethynyl)pyridin-2-yl)methyl)carbamate (110 mg, 293.05 umol) in DCM (1 mL) was added TFA (0.3 mL). The mixture was stirred at 25 °C for 2 h. The reaction mixture was poured into aqueous NaHCO (10 mL) and extracted with EA (10 mL*3). The combined organic layers were dried over NaSO, filtered, and concentrated to dryness to give (4-((6-(difluoromethoxy)pyridin-2-yl)ethynyl)pyridin-2-yl)methanamine (80 mg, 257.81 umol, 87.98% yield) as a yellow solid. LCMS(ESI) m / z:[M+H] + =275.8
[0275] Step 4: Preparation of (R)-N-((4-((6-(difluoromethoxy)pyridin-2-yl)ethynyl)pyridin-2-yl)methyl)-2,6-difluoro-3,5-dihydro-2H-benzo[e][1,4]oxathiepin-8-carboxamide 1,1-dioxide (Compound 184) [ka] (2R)-2,6-Difluoro-1,1-dioxo-3,5-dihydro-2H-4,1λ in DCM (1 mL) 6To a solution of 1-benzoxathiepin-8-carboxylic acid (Intermediate 4) (80.86 mg, 290.64 μmol), EDCI (83.57 mg, 435.96 μmol), HOBt (58.91 mg, 435.96 μmol), and DIEA (112.69 mg, 871.93 μmol, 151.87 μL) were added. Then, (4-((6-(difluoromethoxy)pyridin-2-yl)ethynyl)pyridin-2-yl)methanamine (80 mg, 290.64 μmol) was added. The mixture was stirred at 25° C. for 2 hours. The reaction mixture was poured into water (10 mL) and extracted with EA (10 mL*3). The combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (column: Phenomenex luna C18 150*25mm*10um; mobile phase: [water (FA)-ACN]; B%: 42%-72%, 10 min). The eluate was concentrated and lyophilized to give (R)-N-((4-((6-(difluoromethoxy)pyridin-2-yl)ethynyl)pyridin-2-yl)methyl)-2,6-difluoro-3,5-dihydro-2H-benzo[e][1,4]oxathiepin-8-carboxamide 1,1-dioxide (13.44 mg, 25.10 umol, 8.64% yield) as a yellow solid. LCMS(ESI) m / z:[M+H] + =536.0. 1 H NMR (400MHz, chloroform-d) δ=8.63(d,J=5.2Hz,1H),8.41(s,1H),8.05-8.00(m,1H),7.86(br s,1H),7.77-7.75(m,1H),7.56(s,1H),7.45(d,J=5.2Hz,1H),7.41-7.37(m,1H),6.96(d,J=8.4Hz,1 H),5.44-5.29(m,2H),4.99-4.95(m,1H),4.83(d,J=4.8Hz,2H),4.54-4.49(m,1H),4.48-4.44(m,1H) ppm. Chiral SFC: OJ-3-MeOH(DEA)-5-40-3ML-35T. 1cm, Rt = 1.676 min, ee% = 100%.
[0276] Preparation of intermediate 3(R)-9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide [ka] Step 1: Preparation of 3-chloro-5-(chlorosulfonyl)-4-hydroxybenzoic acid [ka] To HSO3Cl (525.00 g, 4.51 mol, 300.00 mL) was added 3-chloro-4-hydroxybenzoic acid (60 g, 347.69 mmol) at 20 °C. The mixture was stirred at 80 °C for 16 h. The reaction mixture was slowly poured into ice water (2000 mL), and a lot of solid formed. The solid was then collected by filtration and washed with water (1000 mL), and the filter cake was diluted with EA (3000 mL) and washed with water (1000 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to give 3-chloro-5-(chlorosulfonyl)-4-hydroxybenzoic acid (78 g, 244.58 mmol, 70.34% yield, 85% purity) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=12.29-11.14(m,1H),8.01(d,J=2.0Hz,1H),7.86(d,J=2.0Hz,1H) ppm.
[0277] Step 2: Preparation of 3-chloro-4-hydroxy-5-mercaptobenzoic acid [ka] To a solution of 3-chloro-5-(chlorosulfonyl)-4-hydroxybenzoic acid (78 g, 287.74 mmol) in toluene (1600 mL) was added PPh (264.15 g, 1.01 mol, 3.5 equiv). The mixture was stirred at 90 °C for 2 h. The reaction mixture was quenched by adding 10% NaOH (aq) until pH = 9 and then extracted with DCM (1000 mL). The organic layer was discarded, and the aqueous layer was adjusted to pH = 3 with 1 N HCl, then diluted with HO (8000 mL), and extracted with EtOAc (1000 mL * 2). The combined organic layers were washed with brine (500 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give 3-chloro-5-(chlorosulfonyl)-4-hydroxybenzoic acid (70 g, crude) as a white solid, which was used directly in the next step.
[0278] Step 3: Preparation of methyl 3-chloro-4-hydroxy-5-mercaptobenzoate [ka] To a solution of 3-chloro-5-(chlorosulfonyl)-4-hydroxybenzoic acid (70 g, 342.08 mmol, 1 equiv) in MeOH (700 mL) was added H2SO4 (33.55 g, 342.08 mmol, 18.23 mL, 1 equiv). The mixture was stirred at 70 °C for 16 h. The reaction mixture was diluted with HO (2000 mL) and extracted with EtOAc (1000 mL*3). The combined organic layers were washed with brine (1000 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give methyl 3-chloro-4-hydroxy-5-mercaptobenzoate (61.4 g, 280.80 mmol, 82.09% yield) as a white solid, which was used directly in the next step. 1 H NMR(400MHz,DMSO-d6) δ=8.00-7.69(m,2H),3.78(s,3H) ppm.
[0279] Step 4: Preparation of methyl 9-chloro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate [ka] To a mixture of methyl 3-chloro-4-hydroxy-5-mercaptobenzoate (30 g, 137.20 mmol, 1 equiv.) and CsCO (223.51 g, 686.01 mmol, 5 equiv.) in DMF (1200 mL) was added 1,3-dibromopropane (30.47 g, 150.92 mmol, 15.39 mL, 1.1 equiv.). The mixture was stirred at 25 °C for 16 h. The mixture was diluted with water (1500 mL) and extracted with MTBE (methyl tert-butyl ether) (1500 mL × 2). The organic layer was dried over NaSO (1000 mL), filtered, and concentrated. The material was purified by silica gel chromatography using petroleum ether / ethyl acetate (gradient: 0 to 50% ethyl acetate) and the eluent was concentrated in vacuo to give 9-chloro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid (43 g, 56% yield) as a yellow solid. 1 H NMR(400MHz,DMSO-d6) δ=7.90-7.76(m,2H),4.38-4.22(m,2H),3.83(s,3H),3.12-2.97(m,2H),2.26-2.15(m,2H) ppm.
[0280] Step 5: Preparation of methyl 9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate [ka] To a solution of 9-chloro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid (43 g, 166.20 mmol, 1 equiv) in MeCN (800 mL) was added DAST (5.36 g, 33.24 mmol, 4.39 mL, 0.2 equiv), followed by Select F (73.60 g, 207.75 mmol, 1.25 equiv) at 0 °C. The mixture was stirred at 0 °C for 1 h. The reaction mixture was poured into NaHCO (1000 mL) and extracted with EA (1000 mL*2). The combined organic layers were washed with brine (300 mL), dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether / ethyl acetate (gradient: 0 to 50% ethyl acetate) to give methyl 9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate (27 g, 97.57 mmol, 58.71% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=7.98(d,J=2.0Hz,1H),7.90(d,J=2.0Hz,1H),6.37-6.20(m,1H),4.63-4.58 (m,1H),4.07-3.98(m,1H),3.85(s,3H),2.61-2.52(m,1H),2.49-2.46(m,1H) ppm.
[0281] Step 6: Preparation of 9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid [ka] To a solution of methyl 9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate (27 g, 97.57 mmol, 1 equiv.) in THF (280 mL), MeOH (140 mL), and water (70 mL) was added LiOH.HO (8.19 g, 195.15 mmol, 2 equiv.). The mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into ice-cold NaHCO (900 mL) and extracted with EA (300 mL*2). The combined organic layers were washed with brine (100 mL), dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography using petroleum ether / ethyl acetate (gradient: 0 to 50% ethyl acetate) to give 9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid (25.6 g, 97.46 mmol, 99.88% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=13.38(br s,1H),7.95(d,J=2.0Hz,1H),7.88(d,J=2.0Hz,1H),6.43-6.12(m,1H),4 .61-4.57(m,1H),4.09-3.92(m,1H),2.61-2.53(m,1H),2.48-2.44(m,1H) ppm.
[0282] Step 7: Preparation of 9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide [ka] To a solution of 9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid (25.6 g, 97.46 mmol, 1 equiv) in MeOH (500 mL) and water (200 mL) was added Oxone (119.82 g, 194.91 mmol, 2 equiv). The mixture was stirred at 40 °C for 48 h. The mixture was diluted with water (1000 mL) and extracted with EA (1000 mL × 2). The organic layer was washed with a mixture of 1 M HCl (250 mL) and saturated NaSO (250 mL), dried over NaSO, filtered, and concentrated. The residue was purified by silica gel chromatography using petroleum ether / ethyl acetate (gradient: 0 to 80% ethyl acetate) to give 9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide (16 g, 54.30 mmol, 55.71% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=14.40-13.23(m,1H),8.34(d,J=2.0Hz,1H),8.30(d,J=2.0Hz,1H),6.44-6.10(m,1H),4.64-4.58(m,1H) ,4.16-4.04(m,1H),2.93-2.60(m,2H).Chiral SFC:AD-3-MeOH(DEA)-5-40-3ML-35T.lcm,Rt=1.411min,1.640min.
[0283] Step 8: Preparation of (R)-9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide (Intermediate 3) and (S)-9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide [ka] 9-Chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide (1 g, 3.39 mmol) was separated by SFC (Column: DAICEL CHIRALPAK AD-H (250 mm * 30 mm, 5 μm); Mobile phase: [0.1% NH3HO MEOH]; B%: 35% to 35%, 2.4; 80 min) to give peak 1 and peak 2. The eluate of peak 1 was concentrated under reduced pressure to remove MeOH. The residue was diluted with water (30 mL), adjusted to pH 4 with 1 M HCl aqueous solution, and extracted with EA (20 mL * 3). The combined organic layers were washed with brine (50 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give (R)-9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepine-7-carboxylic acid 5,5-dioxide (Intermediate 3) (400 mg, 1.35 mmol, 39.64% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ = 8.34 (d, J = 2.0 Hz, 1H), 8.29 (d, J = 2.0 Hz, 1H), 6.37-6.16 (m, 1H), 4.64-4.58 (m, 1H), 4.16-4.04 (m, 1H), 2.94-2.72 (m, 2H), 2.64-2.53 (m, 1H). Chiral SFC: AD-3-MeOH(DEA)-5-40-3ML-35T. 1cm, Rt = 1.401 min, ee% = 100%. The eluate of peak 2 was concentrated under reduced pressure to remove MeOH. The residue was diluted with water (30 mL), adjusted to pH 4 with 1 M aqueous HCl, and extracted with EA (20 mL*3). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to give (S)-9-chloro-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide. 1H NMR(400MHz,DMSO-d6) δ=8.35(d,J=2.0Hz,1H),8.30(d,J=2.0Hz,1H),6.40-6.15(m,1H),4.64-4.58(m,1H),4.16-4.04(m,1H), 2.92-2.73(m,1H),2.66-2.54(m,1H).Chiral SFC:AD-3-MeOH(DEA)-5-40-3ML-35T.lcm,Rt=1.626min,ee%=99%.
[0284] Preparation of (R)-9-chloro-N-((2-(7-((3R,4R)-3,4-difluoropyrrolidin-1-yl)-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (Compound 258) [ka] Step 1: Preparation of (R)-9-chloro-N-((2-(7-((3R,4R)-3,4-difluoropyrrolidin-1-yl)-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide [ka] To a solution of (4R)-9-chloro-4-fluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid (Intermediate 2, above) (24.41 mg, 82.83 umol) in DCM (1 mL) was added EDCI (21.65 mg, 112.95 umol), HOBt (15.26 mg, 112.95 umol), and DIEA (29.20 mg, 225.90 umol, 39.35 uL). Then, [2-[7-[(3R,4R)-3,4-difluoropyrrolidin-1-yl]-2,3-dihydropyrido[3,2-b][1,4]oxazin-4-yl]-1,6-naphthyridin-7-yl]methanamine (prepared in a manner similar to that described for Example 1) (30 mg, 75.30 umol) was added. The mixture was stirred at 25°C for 2 hours. The mixture was poured into water (10 mL) and extracted with EA (5 mL * 3). The combined organic layer was washed with brine (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (column: Phenomenex C18 150 * 25 mm * 10 um; mobile phase: [water (NH4HCO3)-ACN]; B%: 33% to 63%, 8 min). The eluate was then concentrated and lyophilized to give (R)-9-chloro-N-((2-(7-((3R,4R)-3,4-difluoropyrrolidin-1-yl)-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (4.73 mg, 6.48 μmol, 8.61% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] + =675.0. 1H NMR(400MHz,DMSO-d6) δ=9.62-9.59(m,1H),9.02(s,1H),8.53(d,J=2.0Hz,1H),8.45(d,J=2.0Hz,1H),8.2 4-8.18(m,2H),7.49-7.44(m,2H),6.73(d,J=2.4Hz,1H),6.37-6.17(m,1H),5.58-5 .42(m,2H),4.71(d,J=5.8Hz,2H),4.65-4.59(m,1H),4.37-4.29(m,4H),4.14-4.08 (m,1H),3.77-3.70(m,1H),3.68-3.57(m,3H),2.94-2.75(m,1H),2.61-2.58(m,1H) ppm.Chiral SFC:AS-3-MeOH+ACN(DEA)-50-3mL-35T.lcm,Rt=0.805min,ee%=100%.
[0285] The following examples in Table 5 were prepared using standard chemical manipulations and procedures similar to those used to prepare compound 258. [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4] [Table 7-5] [Table 7-6] [Table 7-7] [Table 7-8] [Table 7-9] [Table 7-10] [Table 7-11] [Table 7-12] [Table 7-13] [Table 7-14] [Table 7-15] [Table 7-16] [Table 7-17]
[0286] Preparation of (R)-9-chloro-N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridine-7-)methyl)-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (Compound 148) [ka] Step 1: Preparation of (2S,6R)-4-(6-bromo-2-pyridyl)-2,6-dimethyl-morpholine [ka] To a solution of 2,6-dibromopyridine (50 g, 211.07 mmol) and (2S,6R)-2,6-dimethylmorpholine (36.46 g, 316.60 mmol) in DMSO (500 mL) was added KCO (87.51 g, 633.20 mmol), and the mixture was stirred at 80 °C for 16 h. The reaction mixture was poured into water (2 L), and the solution was extracted with EA (2 L * 3). The combined organic layers were washed with brine (2 L mL), dried over NaSO, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10:1 to 1:1), and the solution was concentrated to give (2S,6R)-4-(6-bromo-2-pyridyl)-2,6-dimethylmorpholine (54 g, 199.15 mmol, 94.35% yield) as a yellow oil. 1 H NMR(400MHz,DMSO-d6) δ=7.31-7.27(m,1H),6.76(d,J=7.6Hz,1H),6.50(d,J=8.0Hz,1H),4.03-3.99(m,2H),3.69-3.66(m,2H),2.55-2.49(m,2H),1.28-1.25(m,5H) ppm
[0287] Step 2: Preparation of [6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-trimethyl-stannane [ka] To a solution of (2S,6R)-4-(6-bromo-2-pyridyl)-2,6-dimethyl-morpholine (20 g, 73.76 mmol) and trimethyl(trimethylstannyl)stannane (29.00 g, 88.51 mmol) in dioxane (200 mL) was added Pd(PPh3)4 (4.26 g, 3.69 mmol), and the mixture was stirred at 100 °C under N2 for 2 h. The reaction mixture was poured into water (500 mL), and the solution was extracted with EA (500 mL*3). The combined organic layers were washed with brine (1000 mL), dried over Na2SO4, filtered, and concentrated to give [6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-trimethyl-stannane (26.1 g, crude) as a brown oil, which was used directly in the next step.
[0288] Step 3: Preparation of tert-butyl N-[[2-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-1,6-naphthyridin-7-yl]methyl]carbamate [ka] To a mixture of [6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-trimethyl-stannane (26 g, 73.23 mmol) and tert-butyl N-[(2-chloro-1,6-naphthyridin-7-yl)methyl]carbamate (described in Example 1) (10.76 g, 36.61 mmol) in dioxane (120 mL) was added Pd(PPh)Cl (2.57 g, 3.66 mmol), and the mixture was stirred at 100 °C under N for 2 h. The reaction mixture was concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1:1 to 0:1), and the solution was concentrated to give a yellow solid, N-[[2-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-1,6-naphthyridin-7-yl]methyl]carbamic acid (15 g, 32.78 mmol, 89.52% yield). LCMS (ESI) m / z: [ 79 BrM+H] + =450.2. 1H NMR(400MHz,DMSO-d6) δ=9.35(s,1H),8.66-8.59(m,2H),7.93(d,J=7.2Hz,1H),7.79-7.74(m,2H),7.62(7.63-7.61,1H),7.04(d,J=8.4Hz,1H),4.45(br ppm
[0289] Step 4: Preparation of [2-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-1,6-naphthyridin-7-yl]methanamine [ka] To HCl / dioxane (200 mL, 4 M) was added a solution of N-[[2-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-1,6-naphthyridin-7-yl]methyl]carbamic acid (15 g, 33.37 mmol) in DCM (200 mL), and the mixture was stirred at 30 °C for 2 h. The reaction mixture was concentrated to give a residue. The residue was poured into MTBE (100 mL), the solution was filtered, and the filter cake was dried under vacuum to give a yellow solid, [2-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-1,6-naphthyridin-7-yl]methanamine (15.5 g, crude, HCl salt). LCMS (ESI) m / z: [M+H] + =350.1 1 H NMR(400MHz,DMSO-d6) δ=9.56(s,1H),8.82-8.70(m,5H),8.21(s,1H),7.94(d,J=7.6Hz,1H),7.82-7.78(m,1H),7.0 8(d,J=8.4Hz,1H),4.42-4.31(m,4H),3.70-3.65(m,2H),2.54-2.52(m,2H),1.22-1.16(m,6H) ppm
[0290] Step 5: Preparation of (R)-9-chloro-N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide [ka] To a solution of Intermediate 3 (30 mg, 101.80 μmol), [2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-1,6-naphthyridin-7-yl]methanamine (46.71 mg, 101.80 μmol), HOBt (17.88 mg, 132.35 μmol), and EDCI (25.37 mg, 132.35 μmol) in DCM (1 mL) was added DIEA (65.79 mg, 509.02 μmol). The mixture was stirred at 25 °C for 2 h. The reaction mixture was diluted with HO (20 mL) and extracted with DCM (10 mL*3). The combined organic layers were washed with brine (30 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give a residue. The crude product was purified by reverse-phase HPLC (0.1% FA), and the eluate was lyophilized to give (R)-9-chloro-N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (43.55 mg, 69.30 μmol, 68.07% yield) as a yellow solid. LCMS (ESI) m / z: [M+H]+ = 626.2. 1H NMR(400MHz,DMSO-d6) δ=9.74-9.63(m,1H),9.40(s,1H),8.67-8.63(m 2H),8.54(d,J=2.0Hz,1H),8.46(d,J=2.0Hz,1H),8.14(s,1H),7.92(d,J=7.6Hz,1H),7.85(s,1H),7.78-7.7 4(m,1H),7.04(d,J=8.6Hz,1H),6.36-6.17(m,1H),4.81(d,J=5.6Hz,2H),4.69-4.57(m,1H),4.32(d,J=11.6 Hz,2H),4.14-4.08(t,J=11.6Hz,1H),3.71-3.63(m,2H),2.94-2.72(m,1H),2.64-2.56(m,1H),2.53(d,J=2. 4Hz,2H),1.22(d,J=6.0Hz,6H).Chiral SFC:IG-3-MeOH+ACN(DEA)-60-3ML-5MIN-35T.lcm,Rt=1.655min,ee%=100%
[0291] The following examples in Table 6 were prepared using standard chemical manipulations and procedures similar to those used to prepare Example 8. [Table 8-1] [Table 8-2] [Table 8-3] [Table 8-4] [Table 8-5] [Table 8-6] [Table 8-7] [Table 8-8] [Table 8-9] [Table 8-10]
[0292] Preparation of Intermediate 5 (2S,4S)-N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide [ka] Step 1: Preparation of 3-(chlorosulfonyl)-5-fluoro-4-hydroxybenzoic acid [ka] To a solution of HSO3Cl (33.25 g, 285.35 mmol, 19 mL) was added 3-fluoro-4-hydroxy-benzoic acid (4 g, 25.62 mmol) in 10 portions at 0 °C. The mixture was stirred at 30 °C for 2 h and then at 80 °C for 2 h. The reaction mixture was poured into ice water (100 mL). The solid precipitated, collected by filtration, and dried under vacuum to give 3-(chlorosulfonyl)-5-fluoro-4-hydroxybenzoic acid (6.3 g, crude) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=7.89(s,1H),7.64-7.61(m,1H) ppm.
[0293] Step 2: Preparation of 3-fluoro-4-hydroxy-5-mercaptobenzoic acid [ka] To a solution of 3-(chlorosulfonyl)-5-fluoro-4-hydroxybenzoic acid (4.3 g, 16.89 mmol) in toluene (80 mL) was added PPh (15.50 g, 59.11 mmol). The mixture was stirred at 90 °C for 16 h. The reaction mixture was poured into saturated NaHCO (100 mL) and extracted with MTBE (100 mL * 3). The MTBE layer was discarded. The aqueous layer was adjusted to pH = 3 with 12 N HCl aqueous solution and extracted with EA (100 mL * 3). The organic layer was dried over NaSO, filtered, and concentrated under reduced pressure to give 3-fluoro-4-hydroxy-5-mercaptobenzoic acid (3 g, crude) as a white solid. 1 H NMR (400 MHz, methanol-d4) δ = 7.71-7.69 (m, 1H), 7.48-7.45 (m, 1H) ppm.
[0294] Step 3: Preparation of methyl 3-fluoro-4-hydroxy-5-mercaptobenzoate [ka] To a solution of 3-(chlorosulfonyl)-5-fluoro-4-hydroxybenzoic acid (3 g, 15.94 mmol) in MeOH (30 mL) was added H2SO4 (5.52 g, 56.28 mmol, 3 mL). The mixture was stirred at 80 °C for 16 h. The reaction mixture was concentrated under reduced pressure to remove MeOH and diluted with H2O (100 mL). The aqueous layer was adjusted to pH = 3 with saturated NaHCO3 and extracted with EA (500 mL * 2). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by normal phase flash (SiO2 column, 20 g, PE / EA = 1 / 0 to 9 / 1, Rf = 0.5). The eluate was concentrated to give 3-fluoro-4-hydroxy-5-mercaptobenzoic acid (2.4 g, 11.87 mmol, 74.45% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=7.86(s,1H),7.77(s,1H),7.63(br d,J=10.8Hz,1H),7.46-7.43(m,1H),3.80(s,3H),3.78(s,2H) ppm.
[0295] Step 4: Preparation of methyl 9-fluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate [ka] To a solution of methyl 3-fluoro-4-hydroxy-5-mercaptobenzoate (1.2 g, 5.93 mmol) and 1,3-dibromobutane (1.28 g, 5.93 mmol, 719.87 μL) in DMF (50 mL) was added CsCO (9.67 g, 29.67 mmol). The mixture was stirred at 25 °C for 12 h. The mixture was diluted with HO (200 mL) and extracted with MTBE (200 mL * 2). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated. The residue was purified by normal phase flash (SiO column, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1, Rf = 0.4). The eluate was concentrated to give methyl 9-fluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate (1.5 g, 5.54 mmol, 93.43% yield) as a colorless oil. LCMS (ESI) m / z: [M+H] + =256.8. 1 H NMR(400MHz,DMSO-d6) δ=7.69-7.66(m,1H),7.60-7.57(m,1H),4.40-4.30(m,1H),3.83(s,3H),3.31-3.15( m,1H),2.91-2.86(m,1H),2.27-2.20(m,1H),2.09-2.00(m,1H),1.38(d,J=6.4Hz,3H) ppm.
[0296] Step 5: Preparation of methyl 4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate [ka] To a solution of methyl 9-fluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate (1.3 g, 5.07 mmol) in ACN (13 mL) was added Select F (2.70 g, 7.61 mmol) and DAST (163.52 mg, 1.01 mmol, 134.03 μL) at 0° C. The mixture was stirred at 25° C. for 1 hour. Then, DIEA (983.34 mg, 7.61 mmol, 1.33 mL) was added at 0° C. The mixture was stirred at 25° C. for 1 hour. The mixture was added to aqueous NaHCO3 (100 mL) at 0° C. and extracted with DCM (40 mL*3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated to give methyl 4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate (1.3 g, crude) as a yellow oil. LCMS (ESI) m / z: [M+H] + =274.9.
[0297] Step 6: Preparation of (trans)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate methyl 5,5-dioxide and (cis)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate methyl 5,5-dioxide [ka] To a solution of methyl 4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate (1.3 g, 4.74 mmol) in DCM (33 mL) was added m-CPBA (3.37 g, 16.59 mmol, 85% purity) at 0 °C. The mixture was stirred at 25 °C for 2 h. The mixture was poured into water (50 mL) and extracted with EA (50 mL * 3). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by normal-phase flash chromatography (SiO2 column, PE / EA = 1 / 0 to 0 / 1). The eluate was concentrated in vacuo. The residue was purified by reverse-phase flash chromatography (0.1% FA condition). The eluate was concentrated in vacuo to remove MeCN and extracted with EA (50 mL * 3). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The product was purified by normal phase flash (SiO column, PE / EA = 1 / 0 to 0 / 1, Rf = 0.3, 0.2). The eluate was concentrated in vacuo to give the following: (trans)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate 5,5-dioxide (390 mg, 1.27 mmol, 26.87% yield) as a yellow oil. LCMS (ESI) m / z: [M+H] + =306.9, 1 H NMR (400 MHz, DMSO-d6) δ = 8.24-8.16 (m, 2H), 6.35-6.19 (m, 1H), 4.39-4.31 (m, 1H), 3.91 (s, 3H), 2.80-2.60 (m, 2H), 1.50 (d, J = 6.4 Hz, 3H) ppm, and colorless oil of (cis)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylate 5,5-dioxide (60 mg, 195.90 μmol, 4.13% yield). LCMS (ESI) m / z: [M+H] + =306.8, 1 H NMR(400MHz,DMSO-d6) δ=8.25-8.18(m,2H),6.21-6.05(m,1H),4.71-4.61(m,1H),3.91(s,3H),2.78-2.69(m,1H),2.63-2.54(m,1H),1.47(d,J=6.8Hz,3H) ppm.
[0298] Step 7: Preparation of (cis)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide [ka] To a mixture of (cis)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide (60.00 mg, 195.90 μmol) in THF (0.8 mL) and MeOH (0.8 mL), LiOH (14.08 mg, 587.69 μmol) and HO (0.4 mL) were added. The mixture was stirred at 25 °C for 1 h. The reaction mixture was adjusted to pH 3-4 with aqueous HCl (1 N) and extracted with EA (5 mL). The combined organic layers were washed with brine (10 mL), dried over NaSO, filtered, and concentrated in vacuo to give (cis)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide (60 mg, crude) as a yellow oil. 1 H NMR(400MHz,DMSO-d6) δ=8.29-8.12(m,2H),6.24-6.04(m,1H),4.76-4.57(m,1H),3.92(s,3H),2.80-2.55(m,2H),1.48(d,J=6.4Hz,3H) ppm.
[0299] Step 8: Preparation of (2R,4R)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide and (2S,4S)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide [ka] (cis)-4,9-Difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxyl (60 mg, crude) was separated by SFC (Column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 μm); Mobile phase: [MeOH (0.1% IPAm)]; B%: 20% to 20%, A5.4; 54 min). The eluate was concentrated in vacuo to give impure (2S,4S)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide and pure (2R,4R)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide (Intermediate 5) (23 mg, 77.30 μmol, 37.65% yield) as a yellow oil. 1 H NMR(400MHz,DMSO-d6) δ=8.29-8.12(m,2H),6.24-6.04(m,1H),4.76-4.57(m,1H),3.92(s,3H),2.80-2.55(m,2H),1.48(d,J=6.4Hz,3H) ppm.Chiral SFC:G-3-MeOH(DEA)-5-40-3mL-35T.lcm,Rt=1.313min,ee%=100%.
[0300] Preparation of (2R,4R)-N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide [ka] Step 1: Preparation of (2S,6R)-2,6-dimethyl-4-(6-(trimethylstannyl)pyridin-2-yl)morpholine [ka] To a solution of (2R,6S)-4-(6-bromo-2-pyridyl)-2,6-dimethyl-morpholine (prepared according to the method of Example 6) (600 mg, 2.21 mmol) and trimethyl(trimethylstannyl)stannane (869.96 mg, 2.66 mmol, 550.60 uL) in dioxane (7 mL) was added Pd(PPh3)4 (127.85 mg, 110.64 umol). The mixture was degassed, purged with N2, and stirred at 100 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL*3). The combined organic layers were washed with brine (50 mL), dried over anhydrous NaSO, filtered, and concentrated in vacuo to give (2S,6R)-2,6-dimethyl-4-(6-(trimethylstannyl)pyridin-2-yl)morpholine (780 mg, crude) as a yellow oil, which was used directly in the next step. LCMS (ESI) m / z: [M+H] + =356.7.
[0301] Step 2: Preparation of tert-butyl ((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)carbamate [ka] To a solution of (2S,6R)-2,6-dimethyl-4-(6-(trimethylstannyl)pyridin-2-yl)morpholine (779.63 mg, 2.20 mmol) and tert-butyl N-[(2-chloro-1,6-naphthyridin-7-yl)methyl]carbamate (430 mg, 1.46 mmol) in dioxane (5 mL) was added Pd(PPh3)2Cl2 (102.75 mg, 146.38 μmol). The mixture was degassed, purged with N2, and stirred at 100 °C for 2 h. The mixture was poured into water (100 mL) and extracted with EA (30 mL*3). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by normal phase flash chromatography (column: SiO2, PE:EA = 1:0 to 0:1, RF = 0.2). The eluate was concentrated in vacuo to give ((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)carbamate (600 mg, 1.27 mmol, 86.62% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] + =450.0. 1 H NMR(400MHz,DMSO-d6) δ=9.35(s,1H),8.71-8.55(m,2H),7.93(d,J=7.4Hz,1H),7.82-7.73(m,2H),7.60-7.58(m,1H),7.03(d,J=8.4Hz,1H),4.45(br d,J=5.8Hz,2H),4.31(br d,J=12.6Hz,2H),3.76-3.57(m,2H),1.44(s,9H),1.22(d,J=6.2Hz,6H) ppm.
[0302] Step 3: Preparation of (2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methanamine [ka] To a solution of ((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)carbamic acid (200 mg, 444.90 umol) in DCM (2 mL) was added TFA (0.6 mL). The mixture was stirred at 25° C. for 6 hours. The mixture was poured into saturated NaHCO (20 mL) and extracted with DCM (10 ml*3). The combined organic layers were washed with brine (10 mL), dried over anhydrous NaSO, filtered, and concentrated in vacuo to give (2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methanamine (160 mg, crude) as a yellow oil. LCMS (ESI) m / z: [M+H] + =350.0
[0303] Step 4: Preparation of (2S,4S)—N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (compound 34) [ka] To a solution of (2R,4R)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxylic acid 5,5-dioxide (Intermediate 5) (18.40 mg, 62.96 μmol) in DCM (1 mL) was added EDCI (16.46 mg, 85.86 μmol), HOBT (11.60 mg, 85.86 μmol), and DIEA (36.99 mg, 286.20 μmol, 49.85 μL). Next, (2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methanamine (20 mg, 57.24 μmol) was added. The mixture was stirred at 25° C. for 2 hours. The mixture was poured into water (10 mL) and extracted with EA (5 mL * 3). The combined organic layer was washed with brine (5 mL), dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was purified by preparative HPLC (column: Phenomenex luna C18 150 * 25 mm * 10 um; mobile phase: [water (FA)-ACN]; B%: 50% ~ 80%, 10 min). The eluate was then concentrated and lyophilized to give (2S,4S)—N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)-4,9-difluoro-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (7.23 mg, 11.35 μmol, 19.83% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] + =623.9. 1H NMR(400MHz,DMSO-d6) δ=9.68-9.66(m,1H),9.40(s,1H),8.71-8.58(m,2H),8.40-8.30(m,2H),7.91(d,J=7.6H z,1H),7.83(s,1H),7.78-7.75(m,1H),7.04(d,J=8.4Hz,1H),6.24-6.01(m,1H),4.82(br d,J=6.0Hz,2H),4.67-4.56(m,1H),4.32(br d,J=12.0Hz,2H),3.72-3.64(m,2H),2.80-2.56(m,4H),1.49(br d,J=6.2Hz,3H),1.22(d,J=6.2Hz,6H) ppm. Chiral SFC: (S,S)Whelk-O1-IPA+ACN(DEA)-40-3mL-35T.1cm, Rt=2.237min, ee%=97.69%.
[0304] The following examples in Table 7 were prepared using standard chemical manipulations and procedures similar to those used to prepare compound 34. [Table 9]
[0305] Preparation of (S)-N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxamide 1,1-dioxide (Compound 1) [ka] Step 1: Preparation of methyl 4-bromo-2-mercaptobenzoate [ka] To a solution of methyl 4-bromo-2-fluorobenzoate (5 g, 21.46 mmol) in DMF (50 mL) was added Na2S (1.95 g, 22.53 mmol, 90% pure). The mixture was stirred at 25° C. for 12 h. The mixture of methyl 4-bromo-2-mercaptobenzoate (5.3 g, crude) as a brown liquid in DMF (50 mL) was used directly in the next step without further purification. LCMS (ESI) m / z: [Br 81 M+H] + =204.0.
[0306] Step 2: Preparation of 8-bromo-3,4-dihydrobenzo[f][1,4]thiazepin-5(2H)-one [ka] To a solution of methyl 4-bromo-2-mercaptobenzoate (5.3 g, 21.45 mmol) in DMF (50 mL) and THF (50 mL) was added 2-chloroethanamine (4.98 g, 42.90 mmol), and then NaH (2.57 g, 64.34 mmol, 60% purity) was added to the mixture at 0 °C under a N atmosphere. The mixture was stirred at 25 °C for 12 h. The mixture was diluted with NH Cl solution (500 mL) and extracted with EA (500 mL * 2), and the combined organic layer was washed with brine (300 mL * 2). The organic layer was then dried over anhydrous Na SO and concentrated to give a residue. The residue was diluted with MTBE and filtered. The filter cake was dried under vacuum to give 8-bromo-3,4-dihydrobenzo[f][1,4]thiazepin-5(2H)-one (1 g, 3.87 mmol, 18.06% yield) as an off-white solid. LCMS (ESI) m / z: [Br 81 M+H] + =260.2
[0307] Step 3: Preparation of 8-bromo-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine [ka] To a solution of 8-bromo-3,4-dihydrobenzo[f][1,4]thiazepin-5(2H)-one (1 g, 3.87 mmol) in THF (10 mL) was added BH3-Me2S (10 M, 774.79 uL) at 25 °C. The mixture was stirred at 60 °C for 12 h. The reaction mixture was diluted with MeOH (2 mL) and stirred at 60 °C for 12 h. The mixture was concentrated to give 8-bromo-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine (945 mg, crude) as a yellow oil. LCMS (ESI) m / z: [Br 81 M+H] + =246.0.
[0308] Step 4: Preparation of tert-butyl 8-bromo-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-carboxylate [ka] To a solution of 8-bromo-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine (945 mg, 3.87 mmol) in THF (10 mL) was added (Boc)O (1.69 g, 7.74 mmol), DMAP (47.29 mg, 387.06 mmol), and TEA (1.17 g, 11.61 mmol). The mixture was stirred at 25 °C for 4 h. The mixture was diluted with water (20 mL) and extracted with EA (20 mL * 2). The combined organic layers were dried over anhydrous NaSO and concentrated to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® silica flash column, elution with 0 to 100% ethyl acetate / petroleum ether). The eluate was concentrated to give tert-butyl 8-bromo-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-carboxylate (600 mg, 1.74 mmol, 45.03% yield) as a white solid. LCMS (ESI) m / z: [Br 81 M+H] + =290.0. 1HNMR(400MHz,DMSO-d6) δ=7.70-7.64(m,1H),7.52-7.43(m,1H),7.33-7.25(m,1H),4.49-4.39(m,2H),3.79(s,2H),2.89-2.76(m,2H),1.33(s,9H) ppm.
[0309] Step 5: Preparation of 4-(tert-butyl)8-methyl 2,3-dihydrobenzo[f][1,4]thiazepine-4,8(5H)-dicarboxylate [ka] To a solution of tert-butyl 8-bromo-2,3-dihydrobenzo[f][1,4]thiazepine-4(5H)-carboxylate (600 mg, 1.74 mmol) in DMSO (6 mL) and MeOH (279.22 mg, 8.71 mmol), bicyclohexyl(3-bicyclohexylphosphaniumylpropyl)phosphonium; ditetrafluoroborate (106.71 mg, 174.28 mmol), KCO (361.32 mg, 2.61 mmol), and Pd(OAc) (39.13 mg, 174.28 mmol) were added. The mixture was then degassed and purged with CO three times and stirred at 100 °C under a CO atmosphere (15 psi) for 2 h. The mixture was filtered, and the filter cake was washed with EA (100 mL) and water (100 mL). The mixture was then diluted with water (100 mL) and extracted with EA (100 mL*2). The combined organic layers were dried over anhydrous Na2SO4 and concentrated to give the product. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® silica flash column, eluent: 0 to 100% ethyl acetate / petroleum ether). The eluate was concentrated to give 4-(tert-butyl)8-methyl 2,3-dihydrobenzo[f][1,4]thiazepine-4,8(5H)-dicarboxylate (450 mg, 1.39 mmol, 79.84% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =224.1 1HNMR(400MHz,DMSO-d6) δ=8.04-7.98(m,1H),7.88-7.80(m,1H),7.54-7.46(m,1H),4.58-4.49(m,2H),3.88-3.77(m,5H),2.93-2.82(m,2H),1.34-1.29(m,9H) ppm.
[0310] Step 6: Preparation of 4-(tert-butyl) 8-methyl (S)-2-fluoro-2,3-dihydrobenzo[f][1,4]thiazepine-4,8(5H)-dicarboxylate [ka] To 4-(tert-butyl) 8-methyl 2,3-dihydrobenzo[f][1,4]thiazepine-4,8(5H)-dicarboxylate (450 mg, 1.39 mmol) in ACN (6 mL) was added Select F (985.86 mg, 2.78 mmol), followed by DAST (44.86 mg, 278.29 mmol) in an ice bath (0 °C). The solution was stirred at 25 °C for 0.5 h. Next, DIEA (269.75 mg, 2.09 mmol) was added in an ice bath (0 °C), and the solution was stirred at 25 °C for 12 h. The mixture was diluted with water (30 mL) and extracted with DCM (30 mL * 2). The combined organic layers were dried over anhydrous NaSO and concentrated to give 4-(tert-butyl) 8-methyl(S)-2-fluoro-2,3-dihydrobenzo[f][1,4]thiazepine-4,8(5H)-dicarboxylate (475 mg, crude) as a black solid, which was used without purification.
[0311] Step 7: Preparation of 4-(tert-butyl) 8-methyl(S)-2-fluoro-2,3-dihydrobenzo[f][1,4]thiazepine-4,8(5H)-dicarboxylate 1,1-dioxide [ka] To a solution of 4-(tert-butyl) 8-methyl(S)-2-fluoro-2,3-dihydrobenzo[f][1,4]thiazepine-4,8(5H)-dicarboxylate (475 mg, 1.39 mmol) in DCM (6 mL) was added m-CPBA (1.41 g, 6.96 mmol, 85% purity) at 0 °C. The mixture was stirred at 25 °C for 12 h. The mixture was diluted with water (30 mL) and extracted with DCM (30 mL * 2). The combined organic layers were then washed with saturated Na2SO3 (30 mL * 2) and saturated NaHCO3 solution (30 mL * 2), then dried over Na2SO4, filtered, and concentrated to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® silica flash column, elution with 0 to 100% ethyl acetate / petroleum ether). The eluate was concentrated to give 4-(tert-butyl)8-methyl(S)-2-fluoro-2,3-dihydrobenzo[f][1,4]thiazepine-4,8(5H)-dicarboxylic acid 1,1-dioxide (180 mg, 448.32 μmol, 32.22% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =318.0. 1 HNMR(400MHz,DMSO-d6) δ=8.48(d,J=2.8Hz,1H),8.38-8.28(m,1H),7.85-7.73(m,1H),6.28-6.10(m,1 H),4.91-4.79(m,1H),4.69-4.49(m,2H),3.99-3.81(m,4H),1.35-1.26(m,9H) ppm.
[0312] Step 8: Preparation of methyl 2-fluoro-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide [ka] To a solution of 4-(tert-butyl) 8-methyl (S)-2-fluoro-2,3-dihydrobenzo[f][1,4]thiazepine-4,8(5H)-dicarboxylate 1,1-dioxide (180 mg, 482.06 μmol) in DCM (2 mL) was added TFA (1.10 g, 9.64 mmol). The mixture was stirred at 25 °C for 2 h. The mixture was diluted with ice water (10 mL) and adjusted to pH = 8 with saturated NaHCO solution. The mixture was then extracted with DCM (10 mL * 2). The combined organic layers were dried over anhydrous NaSO and concentrated to give methyl 2-fluoro-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide (130 mg, 475.70 μmol, 98.68% yield) as a yellow solid. LCMS(ESI) m / z:[M+H] + =274.0
[0313] Step 9: Preparation of methyl 2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide [ka] To a solution of methyl 2-fluoro-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide (130 mg, 475.70 μmol) in MeOH (2 mL) was added HCHO (115.83 mg, 1.43 mmol, 37% purity) and AcOH (2.86 mg, 47.57 μmol), followed by NaBHCN (89.68 mg, 1.43 mmol) at 0° C. The mixture was stirred at 25° C. for 2 h. The mixture was diluted with water (10 mL) and extracted with EA (10 mL*2). The combined organic layers were dried over anhydrous NaSO and concentrated to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® silica flash column, elution with 0 to 100% ethyl acetate / petroleum ether). The eluate was concentrated to give methyl 2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide (120 mg, 417.67 μmol, 87.80% yield) as a brown oil. LCMS (ESI) m / z: [M+H] + =288.1. 1 HNMR(400MHz,DMSO-d6) δ=8.48(d,J=1.6Hz,1H),8.29-8.26(m,1H),7.77(d,J=7.6Hz,1H),6.12-6.08(m,1H) ),4.50-4.44(m,1H),4.10-4.06(m,1H),3.92(s,3H),3.61-3.53(m,2H),2.52(s,3H) ppm.
[0314] Step 10: Preparation of (R)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate methyl 1,1-dioxide and (S)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate methyl 1,1-dioxide [ka] Methyl 2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide (120 mg, 417.67 μmol) was separated by SFC. The solid was separated by SFC (column: DAICEL CHIRALPAK AD (250 mm * 30 mm, 10 μm); mobile phase: [0.1% NH3HO MEOH]; B%: 25% to 25%, 6.8 min). The eluate from peak 1 was concentrated to give (R)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide and methyl 2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide (30 mg, 104.42 μmol, 25.00% yield) as a white solid. Chiral SFC: AD-3-MeOH(DEA)-5-40-3 mL-35 T.1 cm; Rt = 1.127 min, ee% = 100%. The eluate from peak 2 was concentrated to give (S)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide (35 mg, 118.17 µmol, 28.29% yield) as a white solid. Chiral SFC: AD-3-MeOH(DEA)-5-40-3 mL-35 T. 1 cm; Rt = 1.957 min, ee% = 99.49%.
[0315] Step 11: Preparation of (R)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylic acid 1,1-dioxide [ka] To a solution of (R)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylate 1,1-dioxide and methyl (20 mg, 69.61 μmol) in THF (0.2 mL) and water (0.1 mL) was added LiOH·HO (8.76 mg, 208.84 μmol). The mixture was stirred at 25 °C for 2 h. The reaction mixture was adjusted to pH = 5 with 1 N HCl, and then the mixture was adjusted to pH = 9 with solid NaHCO. The mixture was then concentrated to give (R)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylic acid 1,1-dioxide (19 mg, 69.53 μmol, 99.88% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] + =274.1.
[0316] Step 12: Preparation of (R)-N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxamide 1,1-dioxide (Compound 1) [ka] To a solution of (R)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxylic acid 1,1-dioxide (19 mg, 69.53 μmol) and [2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-1,6-naphthyridin-7-yl]methanamine (26.83 mg, 69.53 μmol) (prepared according to the method of Example 9) in DMF (0.5 mL) was added HOBt (14.09 mg, 104.29 μmol), EDCI (19.99 mg, 104.29 μmol), and DIPEA (26.96 mg, 208.58 μmol). The mixture was stirred at 25° C. for 12 hours. The reaction mixture was diluted with water (10 mL) and extracted with DCM (10 mL*2). The combined organic layers were dried over anhydrous NaSO and concentrated to give a residue. The residue was purified by reverse-phase HPLC (0.1% NH H0). The eluate was concentrated to remove ACN and lyophilized to give (R)-N-((2-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-1,6-naphthyridin-7-yl)methyl)-2-fluoro-4-methyl-2,3,4,5-tetrahydrobenzo[f][1,4]thiazepine-8-carboxamide 1,1-dioxide (2.65 mg, 4.38 μmol, 6.30% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] + =605.3. 1H NMR(400MHz,DMSO-d6) δ=9.70-9.61(m,1H),9.40(s,1H),8.70-8.60(m,2H),8.58(s,1H),8.32(d,J=7.6Hz,1H),7. 92(d,J=7.6Hz,1H),7.84(s,1H),7.78-7.72(m,2H),7.03(d,J=8.0Hz,1H),6.11-5.94(m,1H ),4.82(d,J=5.6Hz,2H),4.47(d,J=14.8Hz,1H),4.31(d,J=12.8Hz,2H),4.14-4.03(m,1H), 3.75-3.62(m,3H),3.57-3.48(m,1H),2.63-2.56(m,2H),2.30(s,3H),1.21(d,J=6.0Hz,6H) ppm.Chiral SFC:IA-3-ETOH(DEA)-40_1ML_T35.M;Rt=4.133min,ee%=100%.
[0317] The following examples in Table 8 were prepared using standard chemical manipulations and procedures similar to those used to prepare Compound 1. [Table 10]
[0318] Preparation of (R)-9-bromo-4-fluoro-N-((2-(7-((S)-2-(fluoromethyl)azetidin-1-yl)-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (Compound 210) [ka] Step 1: Preparation of N'-(3-(benzyloxy)cyclobutylidene)-4-methylbenzenesulfonohydrazide [ka] To a solution of 3-benzyloxycyclobutanone (10 g, 56.75 mmol) in MeOH (100 mL) was added 4-methylbenzenesulfonohydrazide (10.57 g, 56.75 mmol). The mixture was stirred at 25° C. for 5 minutes. The reaction mixture was filtered, and the filter cake was washed with MeOH (20 mL) and dried under reduced pressure to give N'-(3-(benzyloxy)cyclobutylidene)-4-methylbenzenesulfonohydrazide (13.88 g, 40.30 mmol, 71.01% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=10.34(s,1H),7.69(d,J=8.4Hz,2H),7.39(d,J=8.0Hz,3H),7.34-7.30(m, 5H),4.39(d,J=2.8Hz,2H),4.16-4.13(m,1H),3.12-2.98(m,3H),2.38(s,4H) ppm.
[0319] Step 2: Preparation of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile [ka] To a solution of 4-bromopyridine-2-carbonitrile (20 g, 109.29 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (83.26 g, 327.86 mmol) in dioxane (200 mL) was added KOAc (32.18 g, 327.86 mmol) and Pd(dppf)Cl (8.00 g, 10.93 mmol). The mixture was stirred at 130 °C under N for 2 h. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, PE:EA = 1:0 to 3:1). The eluate was concentrated to give 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile (20 g, 86.93 mmol, 79.54% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =231.4. 1H NMR(400MHz,CDCl3) δ=8.75-8.74(m,1H),8.04(s,1H),7.84-7.83(m,1H),1.37(s,12H) ppm.
[0320] Step 3: Preparation of 4-(3-(benzyloxy)cyclobutyl)picolinonitrile [ka] To a solution of N'-(3-(benzyloxy)cyclobutylidene)-4-methylbenzenesulfonohydrazide (12.88 g, 37.40 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinonitrile (12.91 g, 56.09 mmol) in dioxane (260 mL) was added CsCO (36.55 g, 112.19 mmol). The mixture was stirred at 130 °C for 48 h. The mixture was concentrated to give a residue. The residue was purified by column chromatography (SiO, PE:EA = 1:0 to 3:1). The eluate was concentrated to give 4-(3-(benzyloxy)cyclobutyl)picolinonitrile (1.53 g, 5.79 mmol, 15.48% yield) as a red oil, which was used directly in the next step. LCMS(ESI) m / z:[M+H] + =265.2;
[0321] Step 4: Preparation of 4-(3-hydroxycyclobutyl)picolinonitrile [ka] To a solution of 4-(3-(benzyloxy)cyclobutyl)picolinonitrile (1.53 g, 5.79 mmol) in DCM (45 mL) and HO (4.5 mL) was added DDQ (7.23 g, 31.84 mmol). The mixture was stirred at 30 °C for 12 h. The mixture was diluted with aqueous NaSO (100 mL) and extracted with DCM (100 mL * 2). The combined organic layer was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, PE:EA = 1:0 to 0:1). The eluate was concentrated to give 4-(3-hydroxycyclobutyl)picolinonitrile (670 mg, 3.85 mmol, 66.45% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] + =175.1.
[0322] Step 5: Preparation of 4-(3-oxocyclobutyl)picolinonitrile [ka] To a solution of 4-(3-hydroxycyclobutyl)picolinonitrile (670 mg, 3.85 mmol) in DCM (7 mL) was added Dess-Martin (4.89 g, 11.54 mmol) at 0 °C. The mixture was stirred at 30 °C for 4 h. The mixture was added to aqueous NaHCO3 to adjust the pH to 9 and extracted with DCM (50 mL * 2). The combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, PE:EA = 10:1). The eluate was concentrated to give 4-(3-oxocyclobutyl)picolinonitrile (576 mg, 3.35 mmol, 86.98% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =173.2. 1 H NMR(400MHz,CDCl3) δ=8.71(d,J=4.8Hz,1H),7.65(s,1H),7.47-7.46(m,1H),3.74-3.66(m,1H),3.62-3.59(m,2H),3.32-3.25(m,2H) ppm.
[0323] Step 6: Preparation of 4-(3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-3-hydroxycyclobutyl)picolinonitrile [ka] To a solution of (2S,6R)-4-(6-bromo-2-pyridyl)-2,6-dimethyl-morpholine (629.92 mg, 2.32 mmol) (EW9303-1833-P1) in THF (4 mL) was added n-BuLi (2.5 M, 929.24 μL) at −78 °C under N, and the mixture was stirred at −78 °C for 0.5 h. Next, the mixture was added to a solution of 4-(3-oxocyclobutyl)picolinonitrile (200 mg, 1.16 mmol) in THF (4 mL) at −78 °C under N, and the mixture was stirred at −78 °C for 2 h. The mixture was poured into aqueous NHCl (50 mL) and then extracted with EA (50 mL*2). The combined organic layers were dried over NaSO, filtered, and concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO2, PE:EA = 1:0 to 1:1). The eluate was concentrated to give 4-(3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-3-hydroxycyclobutyl)picolinonitrile (455 mg, crude) as a yellow solid. LCMS (ESI) m / z: [M+H] + =365.1. 1 H NMR(400MHz,DMSO-d6) δ=8.67(d,J=4.4Hz,1H),8.08(s,1H),7.71-7.69(m,1H),7.57-7.53(m,1H),6.92(d,J=7.2Hz,1H),6.73(d,J=8.8Hz,1H),5 .82(s,1H),4.20-4.17(m,2H),3.66-3.63(m,2H),3.50(m,1H),2.97-2.92(m,2H),2.42-2.37(m,4H),1.18(d,J=6.0Hz,6H) ppm.
[0324] Step 7: Preparation of O-(3-(2-cyanopyridin-4-yl)-1-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)S-methyl carbonodithioate [ka] To a solution of NaH (111.12 mg, 2.78 mmol, purity 60%) in THF (4 mL) was added dropwise a solution of 4-(3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)-3-hydroxycyclobutyl)picolinonitrile (405 mg, 1.11 mmol) in THF (4 mL) at 0 °C under N2. The mixture was stirred at 0 °C for 0.5 h under N2. Then, CS2 (359.27 μL, 5.95 mmol) was added dropwise at 0 °C, and the mixture was stirred at 0 °C for 1 h. Next, MeI (179.88 μL, 2.89 mmol) was added dropwise to the mixture at 0 °C, and the mixture was stirred at 0 °C for 1 h. The mixture was poured into aqueous NH4Cl (50 mL) and extracted with EA (50 mL * 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, PE:EA = 1:0 to 3:1). The eluate was concentrated to give O-(3-(2-cyanopyridin-4-yl)-1-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)S-methylcarbonodithioate (490 mg, 1.08 mmol, 96.99% yield) as a yellow solid. LCMS(ESI) m / z:[M+H] + =455.0. 1 H NMR(400MHz, CDCl3) δ=8.66(d,J=5.2Hz,1H),7.61(s,1H),7.51-7.47(m,1H),7.43-7.42(m,1H),6.65(d,J=7.6Hz,1H),6.55(d,J=8.4Hz,1H),4.1 2-4.08(m,2H),3.77-3.76(m,2H),3.69(s,1H),3.43-3.40(m,2H),2.80-2.74(m,2H),2.61-2.55(m,5H),1.30(d,J=6.0Hz,6H) ppm.
[0325] Step 8: Preparation of 4-(3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)picolinonitrile [ka] To a solution of O-(3-(2-cyanopyridin-4-yl)-1-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)S-methylcarbonodithioate (300 mg, 659.91 μmol) in toluene (7.5 mL) was added BuSnH (663.64 μL, 2.51 mmol), followed by the addition of AIBN (21.67 mg, 131.98 μmol). The reaction mixture was stirred at 110 °C for 2 h. The mixture was quenched with 50 mL of saturated KF and extracted with EA (50 mL * 3). The combined organic layers were dried over NaSO, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by column chromatography (SiO, PE:EA = 1:0 to 3:1). The eluate was concentrated to give 4-(3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)picolinonitrile (150 mg, 430.49 μmol, 65.23% yield) as a yellow solid. LCMS (ESI) m / z: [M+H] + =349.2. 1 H NMR(400MHz, CDCl3) δ=8.65-8.61(m,1H),7.65-7.64(m,1H),7.48-7.41(m,2H),6.56-6.47(m,2H),4.14-4 .09(m,2H),3.77-3.74(m,2H),2.78-2.75(m,2H),2.55-2.49(m,4H),1.31-1.28(m,6H) ppm.
[0326] Step 9: Preparation of tert-butyl ((4-(3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridin-2-yl)methyl)carbamate [ka] To a solution of 4-(3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)picolinonitrile (150 mg, 430.49 μmol) in MeOH (3 mL) was added BocO (197.80 μL, 860.98 μmol), TEA (179.76 μL), and Raney-Ni (100 mg, 1.17 mmol). The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred at 25 °C under H2 (15 psi) for 2 h. The mixture was diluted with MeOH (10 mL), allowed to stand for 10 min, and then the supernatant was removed and filtered. This process was repeated three times. The filtrate was concentrated to give the crude product. The crude product was purified by column chromatography (SiO2, PE:EA = 1:0 to 1:1). The eluate was concentrated to give tert-butyl ((4-(3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridin-2-yl)methyl)carbamate (140 mg, 309.33 μmol, 71.86% yield) as a colorless oil. LCMS (ESI) m / z: [M+H] + =453.3. 1 H NMR(400MHz,CDCl3) δ=8.48-8.44(m,1H),7.44-7.40(m,1H),7.22-7.15(m,2H),6.57-6.45(m,2H),5.59(br d,J=2.4Hz,1H),4.45-4.43(m,2H),4.14-4.10(m,2H),3.77-3.73(m,2H),2.77-2.72(m,2H),2.54-2.46(m,4H),1.31-1.27(m,6H) ppm.Chiral SFC:AD-3_5CM_ETOH(DEA)_5_40_3ML_T35.M,Rt=1.198 min, 1.504 min.
[0327] Step 10: Preparation of tert-butyl ((4-((1R,3r)-3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridin-2-yl)methyl)carbamate and tert-butyl ((4-((1S,3s)-3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridin-2-yl)methyl)carbamate [ka] 4-(3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)picolinonitrile (140 mg, 309.33 µmol) was separated by chiral SFC (column: DAICEL CHIRALPAK AD (250 mm x 30 mm, 10 µm); mobile phase: [0.1% NH₃HO / ETOH]; B%: 30% to 30%, 4.3 min). The eluate of peak 1 was concentrated to give tert-butyl and tert-butyl ((4-((1R,3r)-3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridin-2-yl)methyl)carbamate (40 mg, 88.38 µmol, 28.57% yield) as a colorless oil. LCMS(ESI) m / z:[M+H] + =453.3. 1 H NMR(400MHz,CDCl3) δ=8.47(d,J=4.8Hz,1H),7.47-7.43(m,1H),7.21(s,1H),7.14(d,J=5.2Hz,1H),6.57-6.48(m,2H),5.58(br s,1H),4.45(br d,J=5.2Hz,2H),4.16(br d,J=11.6Hz,2H),3.79-3.75(m,3H),2.81-2.77(m,2H),2.56-2.51(m,4H),1.48(s,9H),1.30(d,J=6.4Hz,6H) ppm.Chiral SFC:AD-3_5CM_ETOH(DEA)_5_40_3ML_T35.M;Rt=1.177min,ee%=98.82%.
[0328] The eluate of peak 2 was concentrated to give tert-butyl ((4-((1S,3s)-3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridin-2-yl)methyl)carbamate (86 mg, 189.11 μmol, 61.13% yield) as a colorless oil. LCMS (ESI) m / z: [M+H] + =453.3. 1H NMR(400MHz,CDCl3) δ=8.45(d,J=4.8Hz,1H),7.44-7.40(m,1H),7.17(d,J=5.2Hz,1H),7.13(s,1H),6.53-6.45(m,2H),5.57(br s,1H),4.43(br d,J=5.2Hz,2H),4.13-4.10(m,2H),3.75-3.73(m,2H),2.74-2.71(m,2H),2.54-2.46(m,4H),1.47(s,9H),1.28(d,J=6.4Hz,6H) ppm.Chiral SFC:AD-3_5CM_ETOH(DEA)_5_40_3ML_T35.M;Rt=1.505 min,ee%=100%.
[0329] Step 11: Preparation of 4-((1R,3r)-3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridine-2-methamine [ka] A solution of ((4-((1R,3r)-3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridin-2-yl)methyl)carbamate and tert-butyl ether (40 mg, 88.38 umol) in HCl / dioxane (4 M, 1 mL). The mixture was stirred at 25° C. for 1 hour. The mixture was concentrated to give 4-((1R,3r)-3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridine-2-methamine (35 mg, crude, HCl) as a colorless oil. LCMS (ESI) m / z: [M+H] + =353.3.
[0330] Step 12: Preparation of compound 210 (R)-9-bromo-4-fluoro-N-((2-(7-((S)-2-(fluoromethyl)azetidin-1-yl)-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide [ka] 4-((1R,3r)-3-(6-((2S,6R)-2,6-dimethylmorpholino)pyridin-2-yl)cyclobutyl)pyridin-2-amine (35 mg, 89.99 umol) and (4R)-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ in DCM (1 mL) 6 To a solution of 1-benzoxathiepin-7-carboxylic acid (25 mg, 89.85 μmol) (Intermediate 2), HOBt (18.21 mg, 134.78 μmol), DIEA (78.25 μL, 449.27 μmol), and EDCI (25.84 mg, 134.78 μmol) were added. The mixture was stirred at 25° C. for 3 hours. The mixture was diluted with aqueous NaHCO (5 mL) and extracted with DCM (5 mL * 3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by reverse phase (0.1% FA condition). The eluate was concentrated to remove ACN and lyophilized to give (R)-9-bromo-4-fluoro-N-((2-(7-((S)-2-(fluoromethyl)azetidin-1-yl)-2,3-dihydro-4H-pyrido[3,2-b][1,4]oxazin-4-yl)-1,6-naphthyridin-7-yl)methyl)-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (14.02 mg, 21.95 μmol, 24.43% yield) as a white solid. LCMS (ESI) m / z: [M+H] + =613.2; 1H NMR(400MHz,DMSO-d6) δ=9.50-9.47(m,1H),8.46-8.45(m,1H),8.29-8.24(m,2H),7.49-7.45(m,1H),7.30(s,2H),6.67- 6.59(m,2H),6.32-6.21(m,1H),4.61-4.58(m,3H),4.20-4.16(m,3H),3.64-3.60(m,1H),2.61(br s,4H),2.46-2.34(m,3H),1.14(d,J=6.4Hz,6H) ppm.Chiral SFC:IC-3-MeOH+ACN(DEA)-40-3ML-35T.lcm;Rt=1.113min,ee%=100%.
[0331] Preparation of (R)-9-chloro-N-((2-(6-(difluoromethyl)-2-ethoxypyridin-3-yl)-1,6-naphthyridin-7-yl)methyl)-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (Compound 331) [ka] Step 1: Preparation of methyl 5-bromo-6-ethoxypicolinate [ka] To a solution of methyl 5-bromo-6-hydroxypyridine-2-carboxylate (100 g, 430.98 mmol) in DMF (1000 mL) was added K2CO3 (119.13 g, 861.95 mmol) and iodoethane (73.94 g, 474.07 mmol, 37.92 mL). The mixture was stirred at 25 °C for 14 h. The reaction mixture was diluted with HO (1000 mL) and extracted with MTBE (1000 mL) and EA (1000 mL * 2). The combined organic layers were washed with brine (800 mL * 3), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 20 / 1 to 10 / 1). The fractions were concentrated under reduced pressure to give methyl 5-bromo-6-ethoxypicolinate (54 g, 140.44 mmol, 48.17% yield) as an off-white solid. LCMS(ESI) m / z:[ 81 Br M+H] + =262.1. 1 H NMR(400MHz,DMSO-d6) δ=8.20(d,J=8.0Hz,1H),7.56(d,J=8.0Hz,1H),4.44-4.39(m,2H),3.86(s,3H),1.43-1.28(m,3H) ppm
[0332] Step 2: Preparation of (5-bromo-6-ethoxypyridin-2-yl)methanol [ka] To a solution of methyl 5-bromo-6-ethoxypicolinate (54 g, 207.63 mmol) in DCM (550 mL) was added DIBAL-H (1 M, 415.25 mL) dropwise at −78° C. After the addition was complete, the mixture was stirred at 25° C. for 3 h. The reaction mixture was poured into HCl (1 M) (1500 mL) and then adjusted to pH=8 with saturated NaHCO. The mixture was extracted with DCM (2000 mL*3), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give (5-bromo-6-ethoxypyridin-2-yl)methanol (46 g, 130.01 mmol, 62.62% yield) as a yellow oil. 1 H NMR(400MHz,DMSO-d6) δ=7.97(d,J=8.0Hz,1H),6.98(d,J=8.0Hz,1H),5.66-5.12(m,1H),4.43(s,2H),4.36-4.31(m,2H),1.33-1.30(m,3H) ppm.
[0333] Step 3: Preparation of 5-bromo-6-ethoxypicolinaldehyde [ka] To a solution of (5-bromo-6-ethoxypyridin-2-yl)methanol (46 g, 198.21 mmol) in DCM (460 mL) was added Dess-Martin (100.88 g, 237.86 mmol) at 0 °C. The mixture was stirred at 25 °C for 14 h. The reaction mixture was filtered to remove a white solid. The filtrate was then diluted with saturated NaHCO (1000 mL) and extracted with DCM (1000 mL * 3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 20 / 1 to 10 / 1). The fractions were concentrated under reduced pressure to give 5-bromo-6-ethoxypicolinaldehyde (35 g, 152.14 mmol, 76.75% yield) as an off-white solid. 1 H NMR(400MHz,DMSO-d6) δ=9.84(s,1H),8.27(d,J=8.0Hz,1H),7.46(d,J=8.0Hz,1H),4.49-4.44(m,2H),1.40-1.36(m,3H) ppm
[0334] Step 4: Preparation of 3-bromo-6-(difluoromethyl)-2-ethoxypyridine [ka] To a solution of 5-bromo-6-ethoxypicolinaldehyde (35 g, 152.14 mmol) in DCM (350 mL) was added DAST (60.30 mL, 456.41 mmol). The mixture was stirred at 25 °C for 14 h. The reaction mixture was poured into saturated NaHCO (500 mL) and extracted with DCM (500 mL * 3). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10 / 1 to 3 / 1). The fractions were concentrated in vacuo to give 3-bromo-6-(difluoromethyl)-2-ethoxypyridine (29 g, 100.21 mmol, 65.87% yield) as a yellow oil. LCMS(ESI) m / z:[ 81 Br M+H] + =252.1. 1 H NMR(400MHz,DMSO-d6) δ=8.20(d,J=8.0Hz,1H),7.20(d,J=8.0Hz,1H),7.07-6.66(m,1H),4.42-4.37(m,2H),1.37-1.33(m,3H) ppm.
[0335] Step 5: Preparation of 6-(difluoromethyl)-2-ethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine [ka] To a solution of 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (BPD) (34.96 g, 137.66 mmol) and 3-bromo-6-(difluoromethyl)-2-ethoxypyridine (29 g, 115.05 mmol) in dioxane (400 mL) was added AcOK (33.77 g, 344.15 mmol) and cyclopentyl(diphenyl)phosphane; dichloropalladium; and iron (4.20 g, 5.74 mmol) under N. The reaction mixture was stirred at 80 °C under N for 2 h. The reaction mixture was diluted with EA (100 mL) and then filtered. The filtrate was concentrated in vacuo to give 6-(difluoromethyl)-2-ethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (33.5 g, 111.99 mmol, 97.63% yield) as a brown oil. LCMS(ESI) m / z:[M+H] + =300.3.
[0336] Step 6: Preparation of tert-butyl ((2-(6-(difluoromethyl)-2-ethoxypyridin-3-yl)-1,6-naphthyridin-7-yl)methyl)carbamate [ka] A mixture of (2-chloro-1,6-naphthyridin-7-yl)methanamine (25 g, 85.11 mmol), 6-(difluoromethyl)-2-ethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (33.09 g, 110.64 mmol), KPO (54.20 g, 255.32 mmol), and ditert-butyl(cyclopentyl)phosphane; dichloropalladium; iron (2.77 g, 4.26 mmol) in dioxane (400 mL) and HO (40 mL) was degassed and purged with N three times. The mixture was then stirred at 80 °C under N for 2 h. The reaction mixture was diluted with HO (300 mL) and extracted with EA (300 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 1 / 3). The fractions were concentrated under reduced pressure to give a brown solid. PE (100 mL) was then added to the brown solid, and the mixture was stirred for 30 minutes. The mixture was filtered to give a solid. The solid was washed with PE (40 mL * 2), filtered, and concentrated under reduced pressure to give tert-butyl ((2-(6-(difluoromethyl)-2-ethoxypyridin-3-yl)-1,6-naphthyridin-7-yl)methyl)carbamate (21 g, 41.77 mmol, 49.08% yield) as a yellow solid. LCMS(ESI) m / z:[M+H] + =431.3. 1 H NMR(400MHz,DMSO-d6) δ=9.37(s,1H),8.62(d,J=8.8Hz,1H),8.46(d,J=7.6Hz,1H),8.21(d,J=8.8Hz,1H),7.74(s,1H),7.63-7.61(m,1H) ),7.48(d,J=8.0Hz,1H),7.15-6.80(m,1H),4.53-4.47(m,2H),4.47-4.43(m,2H),1.43(s,9H),1.38-1.35(m,3H) ppm.
[0337] Step 7: Preparation of (2-(6-(difluoromethyl)-2-ethoxypyridin-3-yl)-1,6-naphthyridin-7-yl)methanamine [ka] A mixture of tert-butyl ((2-(6-(difluoromethyl)-2-ethoxypyridin-3-yl)-1,6-naphthyridin-7-yl)methyl)carbamate (21 g, 48.79 mmol) in HCl / dioxane (4 M, 180 mL) was stirred for 0.5 h at 25° C. The reaction mixture was concentrated under reduced pressure to give (2-(6-(difluoromethyl)-2-ethoxypyridin-3-yl)-1,6-naphthyridin-7-yl)methanamine (17.5 g, 47.71 mmol, 97.80% yield, HCl salt) as a yellow solid. LCMS(ESI) m / z:[M+H] + = 331.3.
[0338] Step 8: Preparation of (R)-9-chloro-N-((2-(6-(difluoromethyl)-2-ethoxypyridin-3-yl)-1,6-naphthyridin-7-yl)methyl)-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide [ka] To a solution of (4R)-9-chloro-4-fluoro-5,5-dioxo-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylic acid (15.47 g, 52.48 mmol) in DCM (30 mL) was added (2-(6-(difluoromethyl)-2-ethoxypyridin-3-yl)-1,6-naphthyridin-7-yl)methanamine (17.5 g, 47.71 mmol), EDCI (13.72 g, 71.57 mmol), HOBt (9.67 g, 71.57 mmol), and DIEA (41.55 mL, 238.55 mmol). The reaction mixture was stirred at 25 °C for 14 h. The reaction mixture was diluted with HO (100 mL) and extracted with DCM (100 mL * 2). The combined organic layers were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 330 g SepaFlash® silica flash column, 0 to 80% ethyl acetate / petroleum ether gradient elution @ 200 mL / min). The fractions were then concentrated under reduced pressure to give a residue. The residue was dissolved in MeCN (20 mL) and HO (200 mL), and then the mixture was concentrated under reduced pressure to remove MeCN and then lyophilized to give compound 331, (R)-9-chloro-N-((2-(6-(difluoromethyl)-2-ethoxypyridin-3-yl)-1,6-naphthyridin-7-yl)methyl)-4-fluoro-3,4-dihydro-2H-benzo[b][1,4]oxathiepin-7-carboxamide 5,5-dioxide (21.37 g, 35.21 mmol, 73.79% yield) as an off-white solid. LCMS(ESI) m / z:[M+H] + = 607.2. 1H NMR(400MHz,DMSO-d6) δ=9.69-9.66(m,1H),9.41(s,1H),8.64(d,J=8.8Hz,1H),8.52(d,J=2.0Hz,1H),8. 50-8.42(m,2H),8.24(d,J=8.8Hz,1H),7.85(s,1H),7.45(d,J=7.6Hz,1H),7.13-6. 78(m,1H),6.34-6.14(m,1H),4.81(d,J=5.6Hz,2H),4.63-4.58(m,1H),4.51-4.46 (m,2H),4.12-4.06(m,1H),2.93-2.71(m,1H),2.64-2.55(m,1H),1.38-1.34(m,3H) ppm. Chiral SFC: OJ-3-IPA(DEA)-5-40-3ML-35T. 1cm, Rt=2.084 min, ee%=100%.
[0339] Preparation of (4R)-N-[[2-[2-(cyclopropylmethoxy)-6-(difluoromethyl)-3-pyridyl]-1,6-naphthyridin-7-yl]methyl]-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxamide (compound 332) [ka] Step 1: Preparation of methyl 5-bromo-6-(cyclopropylmethoxy)pyridine-2-carboxylate [ka] To a solution of methyl 5-bromo-6-hydroxypyridine-2-carboxylate (146 g, 629.23 mmol) and bromomethylcyclopropane (254.84 g, 1.89 mol, 180.23 mL) in CHCl (1500 mL), AgCO (208.21 g, 755.07 mmol) was added, and the mixture was stirred at 60 °C for 12 h. The reaction mixture was filtered, and the filter cake was washed with EA (200 mL × 2) to obtain a yellow filtrate. The filtrate was concentrated under reduced pressure to obtain a yellow oil, which was purified by column chromatography (SiO, PE / EA = 20:1). The eluate was concentrated under reduced pressure to obtain methyl 5-bromo-6-(cyclopropylmethoxy)picolinate (166 g, 580.17 mmol, 92.20% yield) as a pale yellow oil. 1 H NMR(400MHz,DMSO-d6) δ=8.20(d,J=7.6Hz,1H),7.55(d,J=7.6Hz,1H),4.22(d,J=7.2Hz,2H),3.86(s,3H),1.30-1.28(m,1H),0.64-0.50(m,2H),0.47-0.31(m,2H) ppm.
[0340] Step 2: Preparation of 5-bromo-6-(cyclopropylmethoxy)-2-pyridyl]methanol [ka] To a solution of methyl 5-bromo-6-(cyclopropylmethoxy)picolinate (83000 mg, 290.09 mmol) in DCM (850 mL) was added DIBAL-H (1 M, 638.19 mL) at −60° C. under N2, and the mixture was warmed to 0° C. over 2 h. The reaction mixture was slowly poured into 1 N HCl (1600 mL) and extracted with DCM (500 mL*2), and the combined organic layers were concentrated under reduced pressure to give (5-bromo-6-(cyclopropylmethoxy)pyridin-2-yl)methanol (140 g, crude) as a pale yellow oil, which was used directly in the next step without further purification.
[0341] Step 3: Preparation of 5-bromo-6-(cyclopropylmethoxy)picolinaldehyde [ka] To a solution of (5-bromo-6-(cyclopropylmethoxy)pyridin-2-yl)methanol (140 g, 542.40 mmol) in DCM (1500 mL) was added MnO (398.92 g, 4.59 mol), and the mixture was warmed to 40° C. for 12 h. The reaction mixture was filtered, the filter cake was washed with DCM (2 L), and the filtrate was concentrated under reduced pressure to give 5-bromo-6-(cyclopropylmethoxy)picolinaldehyde (144 g, crude) as a pale yellow oil, which was used directly in the next step without further purification. 1 H NMR(400MHz,DMSO-d6) δ=9.84(s,1H),8.27(d,J=7.6Hz,1H),7.46(d,J=7.6Hz,1H),4.27(d,J=7.2Hz,2H),1.42-1.21(m,1H),0.65-0.35(m,4H) ppm.
[0342] Step 4: Preparation of 3-bromo-2-(cyclopropylmethoxy)-6-(difluoromethyl)pyridine [ka] To a solution of 5-bromo-6-(cyclopropylmethoxy)picolinaldehyde (144 g, 562.29 mmol) in DCM (1500 mL) was added DAST (226.59 g, 1.41 mol) at 0 °C, and the mixture was stirred at 20 °C for 12 h. The reaction mixture was slowly poured into saturated NaHCO (2 L) and extracted with DCM (500 mL * 2). The combined organic layer was dried over NaSO, filtered, and concentrated under reduced pressure to give a residue, which was purified by column chromatography (SiO, PE). The eluate was concentrated under reduced pressure to give 3-bromo-2-(cyclopropylmethoxy)-6-(difluoromethyl)pyridine (130 g, 466.39 mmol, 82.95% yield) as a pale yellow oil. LCMS(ESI) m / z:[ 79 BrM+H] + =278.0. 1H NMR(400MHz,DMSO-d6) δ=8.21(d,J=7.6Hz,1H),7.20(d,J=8.0Hz,1H),7.03-6.64(m,1H),4.21( d,J=7.2Hz,2H),1.34-1.20(m,1H),0.63-0.50(m,2H),0.44-0.29(m,2H) ppm.
[0343] Step 5: Preparation of 2-(cyclopropylmethoxy)-6-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine [ka] To a solution of 3-bromo-2-(cyclopropylmethoxy)-6-(difluoromethyl)pyridine (20 g, 71.92 mmol) in dioxane (400 mL) was added 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (21.92 g, 86.30 mmol), Pd(dppf)Cl (5.26 g, 7.19 mmol), and KOAc (21.17 g, 215.76 mmol). The mixture was degassed and purged with N three times, and the mixture was stirred at 110 °C under N for 2 h. The reaction mixture was filtered, and the filter cake was washed with EA (30 mL). The combined filtrate was concentrated under reduced pressure to give 2-(cyclopropylmethoxy)-6-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (23.38 g, crude) as a brown oil, which was used directly in the next step without further purification.
[0344] Step 6: Preparation of 2-[[2-[2-(cyclopropylmethoxy)-6-(difluoromethyl)-3-pyridyl]-1,6-naphthyridin-7-yl]methyl]isoindoline-1,3-dione [ka] To a solution of 2-(cyclopropylmethoxy)-6-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (22.60 g, 69.50 mmol) in dioxane (300 mL) and HO (30 mL) was added 4,2-[(2-chloro-1,6-naphthyridin-7-yl)methyl]isoindoline-1,3-dione (15 g, 46.33 mmol), di-tert-butyl(cyclopentyl)phosphane; dichloropalladium; iron (3.02 g, 4.63 mmol), and KPO (29.51 g, 139.00 mmol). The mixture was degassed and purged with N three times, and the mixture was stirred at 80 °C under N for 12 h. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was diluted with HO (200 mL) and extracted with EA (300 mL*2). The combined layers were washed with brine (500 mL*2), dried over NaSO, filtered, and concentrated under reduced pressure to give a crude material, which was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10 / 1 to 1 / 1). The eluate was concentrated under reduced pressure to give 2-((2-(2-(cyclopropylmethoxy)-6-(difluoromethyl)pyridin-3-yl)-1,6-naphthyridin-7-yl)methyl)isoindoline-1,3-dione (16.31 g, 33.53 mmol, 72.36% yield) as a yellow solid. LCMS(ESI) m / z:[M+H] + =487.2. 1 H NMR(400MHz,DMSO-d6) δ=9.35(s,1H),8.64-8.62(m,1H),8.47(d,J=7.6Hz,1H),8.29-8.26(m,1H),8.02-7.84(m,5H),7.45(d,J=7.6Hz,1 H),7.14-6.78(m,1H),5.12(s,2H),4.31-4.29(m,2H),1.34-1.26(m,1H),0.60-0.50(m,2H),0.42-0.35(m,2H)ppm.
[0345] Step 7: Preparation of [2-[2-(cyclopropylmethoxy)-6-(difluoromethyl)-3-pyridyl]-1,6-naphthyridin-7-yl]methanamine [ka] To a solution of 2-((2-(2-(cyclopropylmethoxy)-6-(difluoromethyl)pyridin-3-yl)-1,6-naphthyridin-7-yl)methyl)isoindoline-1,3-dione (16.31 g, 33.53 mmol) in THF (200 mL) was added NH2NH2.HO (35.62 g, 697.31 mmol). The mixture was stirred at 25 °C for 12 h. The reaction mixture was poured into HO (300 mL) and extracted with EA (200 mL*3). The combined organic layers were washed with brine (300 mL*2), dried over Na2SO4, filtered and concentrated under reduced pressure to give (2-(2-(cyclopropylmethoxy)-6-(difluoromethyl)pyridin-3-yl)-1,6-naphthyridin-7-yl)methanamine (11.71 g, 32.86 mmol, 98.01% yield) as a yellow solid, which was used directly in the next step without further purification. LCMS(ESI) m / z:[M+H] + =357.1. 1H NMR(400MHz,DMSO-d6) δ=9.36(s,1H),8.63-9.61(m,1H),8.48(d,J=7.6Hz,1H),8.25-8.23(m,1H),7.99(s,1H),7.50-7.48(m,1H),7.21-6.77( m,1H),4.32-4.30(m,2H),4.09-3.98(m,2H),2.23-2.00(m,2H),1.41-1.24(m,1H),0.67-0.49(m,2H),0.40-0.39(m,2H) ppm.
[0346] Step 8: Preparation of (4R)—N-[[2-[2-(cyclopropylmethoxy)-6-(difluoromethyl)-3-pyridyl]-1,6-naphthyridin-7-yl]methyl]-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxamide [ka] To a solution of (4R)-9-chloro-4-fluoro-5,5-dioxo-3,4-dihydro-2H-1,5-benzoxathiepin-7-carboxylic acid (9.14 g, 32.86 mmol) in DCM (150 mL) was added EDCI (8.19 g, 42.72 mmol), HOBt (5.77 g, 42.72 mmol), and DIEA (12.74 g, 98.58 mmol), followed by (2-(2-(cyclopropylmethoxy)-6-(difluoromethyl)pyridin-3-yl)-1,6-naphthyridin-7-yl)methanamine (11.71 g, 32.86 mmol). The mixture was stirred at 25 °C for 12 h. The reaction mixture was diluted with HO (200 mL) and extracted with DCM (100 mL * 2). The combined organic layers were washed with brine (300 mL*2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue, which was purified by column chromatography (SiO2, PE / EA = 10 / 1 to 1 / 2). The eluate was concentrated under reduced pressure to give a yellow gum. The gum was dissolved in MeCN (100 mL) and HO (300 mL), and the solution was concentrated under reduced pressure to remove MeCN. The mixture was lyophilized to give the title compound 332 (16.34 g, 26.37 mmol, 80.24% yield) as an off-white solid. LCMS(ESI) m / z:[M+H] + =617.3. 1 H NMR(400MHz,DMSO-d6) δ=9.69-9.67(m,1H),9.41(s,1H),8.65(d,J=8.4Hz,1H),8.46(d,J=7.6Hz,1H),8.38- 8.23(m,3H),7.84(s,1H),7.46-7.44(m,1H),7.17-6.76(m,1H),6.41-6.16(m,1H),4. 81(d,J=5.6Hz,2H),4.63-4.59(m,1H),4.31-4.29(m,2H),4.19-4.16(m,1H),2.93-2. 71(m,1H),2.65-2.53(m,1H),1.39-1.22(m,1H),0.59-0.51(m,2H),0.40-0.37(m,2H) ppm. Chiral SFC: AD-3-IPA + ACN(DEA)-40-3ML-35T. 1cm, Rt = 0.836 min, ee% = 100.00%
[0347] Step 9: Preparation of (2-chloro-1,6-naphthyridin-7-yl)methanamine [ka] A mixture of tert-butyl ((2-chloro-1,6-naphthyridin-7-yl)methyl)carbamate (30 g, 102.13 mmol) in HCl / dioxane (4 M, 100 mL) was stirred for 6 hours at 25° C. The reaction mixture was concentrated under reduced pressure to give (2-chloro-1,6-naphthyridin-7-yl)methanamine (23.5 g, 102.13 mmol, 100.00% yield, HCl salt) as a brown solid, which was used directly in the next step without further purification. LCMS(ESI) m / z:[M+H] + =294.1. 1 H NMR(400MHz,DMSO-d6) δ=9.53(s,1H),8.73-8.70(m,3H),8.05(s,1H),7.82(d,J=8.8Hz,1H),4.39-4.34(m,2H) ppm.
[0348] Step 10: Preparation of Intermediate 4, 2-[(2-chloro-1,6-naphthyridin-7-yl)methyl]isoindoline-1,3-dione [ka] To a solution of (2-chloro-1,6-naphthyridin-7-yl)methanamine (23.5 g, 102.13 mmol) in toluene (700 mL) was added TEA (31.00 g, 306.40 mmol) and isobenzofuran-1,3-dione (15.13 g, 102.13 mmol). The mixture was heated at 120 °C for 2 h. The reaction mixture was concentrated under reduced pressure to remove toluene, and the residue was diluted with HO (100 mL) and extracted with EA (200 mL x 3). The combined organic layers were washed with brine (500 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give the residue, which was purified by column chromatography (SiO, PE / EA = 10 / 1 to 1 / 1). The eluate was concentrated under reduced pressure to give 9 (25.35 g, 78.31 mmol, 76.67% yield) as a yellow solid. LCMS(ESI) m / z:[M+H] + =324.1. 1 H NMR(400MHz,DMSO-d6) δ=9.35(s,1H),8.62-8.60(m,1H),8.06-7.83(m,5H),7.75-7.73(m,1H),5.10(s,2H) ppm.
[0349] Preparation of (4R)-N-[[2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]methyl]-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxamide (compound 405) [ka] Step 1: Preparation of [6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-trimethyl-stannane [ka] To a solution of (2R,6S)-4-(6-bromo-2-pyridyl)-2,6-dimethyl-morpholine (prepared according to the method of FG-A4398) (500 mg, 1.84 mmol) and trimethyl(trimethylstannyl)stannane (0.94 g, 2.87 mmol) in dioxane (5 mL) was added Pd(PPh3)4 (106.54 mg, 92.20 mmol), and the reaction was stirred at 100 °C under N2 for 2 h. EA (10 mL) was added to the reaction mixture, and after filtration, the filtrate was concentrated to give [6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]-trimethyl-stannane (650 mg, crude) as a yellow solid, which was used in the next step without further purification. LCMS(ESI) m / z:[M+H] + =357.0.
[0350] Step 2: Preparation of methyl [2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]acetate [ka] To a solution of 4 (650 mg, 1.83 mmol) in dioxane (6 mL) was added methyl (2-chloropyrido[3,4-b]pyrazin-7-yl)acetate (290.03 mg, 1.22 mmol) and dichloropalladium; triphenylphosphane (85.66 mg, 122.04 mmol), and the reaction was stirred at 100 °C under N for 12 h. The reaction mixture was poured into water (10 mL), and the solution was extracted with EA (10 mL*3). The combined organic layers were washed with brine (10 mL), dried over NaSO, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10:1 to 5:1), and the solution was concentrated to give methyl [2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]acetate (160 mg, crude) as a yellow solid. LCMS(ESI) m / z:[M+H] + =294.1.
[0351] Step 3: Preparation of [2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]methanol [ka] To a solution of 5 (160 mg, 406.67 μmol) in MeOH (3 mL) was added NaOMe (43.94 mg, 813.34 μmol), and the reaction was stirred at 25 °C under N for 2 h. The reaction mixture was poured into water (10 mL), and the solution was extracted with EA (10 mL * 3). The combined organic layers were washed with brine (10 mL), dried over NaSO, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10:1 to 5:1), and the solution was concentrated to give [2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]methanol (100 mg, 284.57 μmol, 69.98% yield) as a yellow solid. LCMS(ESI) m / z:[M+H] + =352.2.
[0352] Step 4: Preparation of 2-[[2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]methyl]isoindoline-1,3-dione [ka] To a solution of 6 (100 mg, 284.57 μmol) and isoindoline-1,3-dione (46.06 mg, 313.03 μmol) in THF (2 mL) was added PPh (89.57 mg, 341.49 μmol), then DIAD (86.31 mg, 426.86 μmol) was added to the mixture at 0 °C, and the reaction was stirred at 25 °C under N for 2 h. The reaction mixture was poured into water (20 mL), the solution was extracted with EA (20 mL*3), and the combined organic layers were washed with brine (20 mL*3), dried over NaSO, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 10:1 to 5:1), and the solution was concentrated to give a yellow solid, 2-[[2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]methyl]isoindoline-1,3-dione (90 mg, 187.30 μmol, yield 65.82%). LCMS(ESI) m / z:[M+H] + =481.0.
[0353] Step 5: Preparation of [2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]methanamine [ka] To a solution of 8 (50 mg, 104.05 μmol) in THF (0.5 mL) was added hydrazine hydrate (0.14 g, 2.74 mmol) at 25° C., and the reaction was stirred at 25° C. for 12 h. The reaction mixture was poured into water (10 mL), and the solution was extracted with EA (10 mL*3). The combined organic layers were washed with brine (20 mL), dried over NaSO, filtered, and concentrated to give [2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]methanamine (35 mg, crude) as a yellow solid, which was used directly in the next step. LCMS(ESI) m / z:[M+H] + =351.1.
[0354] Step 6: Preparation of Compound 405 (4R)-N-[[2-[6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-2-pyridyl]pyrido[3,4-b]pyrazin-7-yl]methyl]-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxamide [ka] To a solution of 9 (35 mg, 99.88 μmol) in DCM (1.5 mL) was added (4R)-4,9-difluoro-5,5-dioxo-3,4-dihydro-2H-1,5λ6-benzoxathiepin-7-carboxylic acid (prepared according to the method of FG-A5321A) (27.79 mg, 99.88 μmol), EDCI (28.72 mg, 149.82 μmol), HOBt (20.24 mg, 149.82 μmol), and DIEA (64.54 mg, 499.41 μmol), and the reaction was stirred at 25 °C for 12 h. The reaction mixture was diluted with HO (10 mL), and the solution was extracted with EA (10 mL * 3). The combined organic layers were washed with brine (10 mL), dried over NaSO, filtered, and concentrated to give a residue. The residue was purified by reverse-phase HPLC (0.1% FA condition). The solution was lyophilized to give compound 405 (12.96 mg, 19.74 μmol, 19.76% yield, FA) as a yellow solid. LCMS(ESI) m / z:[M+H] + =611.4. 1H NMR(400MHz,DMSO-d6) δ=9.96(s,1H),9.75-9.69(m,1H),9.50(s,1H),8.44(s,1H),8.39-8.28(m,2H),7.94(s,1H) ),7.90-7.84(m,1H),7.83-7.76(m,1H),7.11(d,J=8.4Hz,1H),6.37-6.19(m,1H),4.85(br d,J=5.6Hz,2H),4.66-4.56(m,1H),4.35(br ppm. Chiral SFC: OJ-3-IPA(DEA)-5-40-3ML-35T. 1cm, Rt=2.121 min, ee%=100%.
[0355] Step 7: Preparation of (4,5-diaminopyridin-2-yl)methanol [ka] To a solution of methyl 4,5-diaminopyridine-2-carboxylate (8 g, 47.86 mmol) in THF (80 mL) was added LiBH (2 M, 103.98 mL) dropwise at 0 °C. The mixture was stirred at 25 °C for 12 h. The reaction mixture was slowly poured into aqueous NaHCO (300 mL). The suspension was filtered. The filtrate was concentrated to remove THF and then lyophilized to give the crude material. The crude material was washed with a column (Al2O3, DCM / MeOH=10:1 to 2:1) to give (4,5-diaminopyridin-2-yl)methanol (12 g, crude) as a white solid. LCMS(ESI) m / z:[M+H] + =140.4
[0356] Step 8: Preparation of 7-(hydroxymethyl)pyrido[3,4-b]pyrazin-2-ol [ka] To a solution of 2A (5 g, 35.93 mmol) in n-BuOH (50 mL) was added ethyl 2-oxoacetate (7.70 g, 37.73 mmol, 50% in toluene), and the mixture was stirred at 100° C. for 8 hours. The reaction mixture was filtered. The filter cake was washed with MeOH (50 mL) to give Solution A and Filter Cake B. Filtrate A was concentrated to give a residue. The residue was triturated with PE:EA (1:1, 100 mL) and then MeOH (20 mL) to give 7-(hydroxymethyl)pyrido[3,4-b]pyrazin-2-ol (3.3 g, 18.63 mmol, 51.84% yield) as an off-white solid. 1 H NMR(400MHz,DMSO-d6) δ=8.81(s,1H),8.15(s,1H),7.33(s,1H),5.79-5.46(m,1H),4.62(s,2H) ppm.
[0357] Step 9: Preparation of methyl (2-hydroxypyrido[3,4-b]pyrazin-7-yl)acetate [ka] To a solution of 4A (150 mg, 846.69 μmol) and DMAP (51.72 mg, 423.35 μmol) in DCM (3 mL) was added AcO (259.31 mg, 2.54 mmol) and TEA (128.51 mg, 1.27 mmol). The mixture was stirred at 25 °C for 2 h. The reaction was concentrated to give a residue. The residue was purified by column chromatography (SiO, petroleum ether / ethyl acetate = 2 / 1 to 1 / 1) to give methyl (2-hydroxypyrido[3,4-b]pyrazin-7-yl)acetate (100 mg, 456.21 μmol, 53.88% yield) as a yellow solid. 1 H NMR(400MHz,DMSO-d6) δ=12.65(br s,1H),8.89(s,1H),8.21(s,1H),7.22(s,1H),5.20(s,2H),2.15(s,3H) ppm.
[0358] Step 10: Preparation of methyl (2-chloropyrido[3,4-b]pyrazin-7-yl)acetate [ka] To a solution of PPh3 (344.62 mg, 1.31 mmol) in toluene (4 mL), trichloroisocyanuric acid (101.79 mg, 437.96 μmol) was added. The resulting mixture was stirred at 25 °C for 12 h. To the above mixture, 5A (60 mg, 273.73 μmol) was added. The resulting mixture was stirred at 110 °C for 5 h. The reaction was concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 5 / 1) to give a crude product. Methyl (2-chloropyrido[3,4-b]pyrazin-7-yl)acetate (40 mg, 164.95 μmol, yield 60.26%) was obtained as a white solid. LCMS(ESI) m / z:[M+H] + =238.1 1 H NMR(400MHz,DMSO-d6) δ=9.52(s,1H),9.14(s,1H),7.97(s,1H),5.39(s,2H),2.18(s,3H) ppm.
[0359] Preparation of (2R)-N-[[2-[3-(difluoromethoxy)-4-fluoro-pyrazol-1-yl]-1,6-naphthyridin-7-yl]methyl]-6-(difluoromethyl)-2-fluoro-1,1-dioxo-3,5-dihydro-2H-4,1benzoxathiepin-8-carboxamide (compound 514) [ka] Step 1: Preparation of 1-(3-hydroxy-1H-pyrazol-1-yl)ethan-1-one [ka] To a solution of 1H-pyrazol-3-ol (3 g, 35.68 mmol) in PYRIDINE (50 mL) was added AcO (3.82 g, 37.47 mmol) in PYRIDINE (20 mL) at 95 °C for 30 minutes, and then the mixture was stirred at 95 °C for 2 hours. The reaction mixture was concentrated to give a residue. The residue was triturated with MeOH (100 mL) and filtered. The filter cake was washed with MeOH (20 mL*3) and dried to give 1-(3-hydroxy-1H-pyrazol-1-yl)ethan-1-one (4 g, 31.72 mmol, 88.89% yield) as a yellow solid.
[0360] Step 2: 1-(3-(difluoromethoxy)-1H-pyrazol-1-yl)ethan-1-one [ka] To a solution of 1-(3-hydroxy-1H-pyrazol-1-yl)ethan-1-one (2 g, 15.86 mmol) in ACN (20 mL) was added 1-[[bromo(difluoro)methyl]-ethoxy-phosphoryl]oxyethane (8.47 g, 31.72 mmol) and KF (1.84 g, 31.72 mmol). The mixture was stirred at 25 °C for 6 h. The reaction was diluted with water (100 mL) and extracted with EA (20 mL * 4). The combined organic layers were dried over Na2SO4, filtered, and concentrated to give a residue. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 10 / 1 to 3 / 1) to give 1-(3-(difluoromethoxy)-1H-pyrazol-1-yl)ethan-1-one (860 mg, 4.88 mmol, 30.79% yield) as a colorless oil. 1 H NMR(400MHz,DMSO-d6) δ=8.41(d,J=2.8Hz,1H),7.64-7.28(m,1H),6.48(d,J=3.2Hz,1H),2.57(s,3H) ppm.
[0361] Step 3: Preparation of 3-(difluoromethoxy)-1H-pyrazole [ka] To a solution of 1-(3-(difluoromethoxy)-1H-pyrazol-1-yl)ethan-1-one (700 mg, 3.97 mmol) in MeOH (10 mL) was added NaOMe (429.44 mg, 7.95 mmol). The mixture was stirred at 25 °C for 1 h. The reaction was diluted with water (100 mL) and extracted with EA (50 mL*3). The combined organic layers were dried over NaSO, filtered, and concentrated to give 3-(difluoromethoxy)-1H-pyrazole (460 mg, 3.43 mmol, 86.32% yield) as a colorless oil. 1 H NMR(400MHz,DMSO-d6) δ=12.49(br s,1H),7.69(s,1H),7.41-7.04(m,1H),5.97(s,1H) ppm.
[0362] Step 4: Preparation of 3-(difluoromethoxy)-4-fluoro-1H-pyrazole [ka] To a solution of 3-(difluoromethoxy)-1H-pyrazole (400 mg, 2.98 mmol) in ACN (10 mL) was added Select F (1.27 g, 3.58 mmol). The mixture was stirred at 80° C. for 3 hours. The reaction mixture was filtered to obtain a filtrate. The filtrate was purified by reverse-phase HPLC (0.1% FA condition). The fractions were concentrated to remove MeCN. The liquid was extracted with EA (20 mL*3). The combined organic layers were dried over Na2SO4, filtered, and concentrated to obtain 3-(difluoromethoxy)-4-fluoro-1H-pyrazole (180 mg, 1.18 mmol, 39.68% yield) as a colorless oil. 1 H NMR(400MHz,DMSO-d6) δ=12.56(br s,1H),7.91-7.90(m,1H),7.41-7.05(m,1H) ppm.
[0363] Step 5: Preparation of tert-butyl ((2-(3-(difluoromethoxy)-4-fluoro-1H-pyrazol-1-yl)-1,6-naphthyridin-7-yl)methyl)carbamate [ka] A mixture of tert-butyl N-[(2-chloro-1,6-naphthyridin-7-yl)methyl]carbamate (prepared according to the method of FG-A3432C) (120 mg, 408.51 μmol), 3-(difluoromethoxy)-4-fluoro-1H-pyrazole (68.34 mg, 449.36 μmol), Pd(dba) (37.41 mg, 40.85 μmol), Xantphos (47.27 mg, 81.70 μmol), and CsCO (399.30 mg, 1.23 mmol) in dioxane (2 mL) was degassed and purged with N three times. The mixture was then stirred at 100 °C under a N atmosphere for 2 h. The reaction was diluted with water (10 mL) and extracted with EA (5 mL * 3). The combined organic layers were dried over NaSO, filtered, and concentrated to give a residue. The residue was purified by preparative HPLC (column: Phenomenex luna C18 150*25mm*10um; mobile phase: [water (FA)-ACN]; B%: 47%~77%, 10 min). The fractions were concentrated to remove MeCN. The liquid was extracted with DCM (5 mL*3). The combined organic layer was dried over Na2SO4, filtered, and concentrated to give tert-butyl ((2-(3-(difluoromethoxy)-4-fluoro-1H-pyrazol-1-yl)-1,6-naphthyridin-7-yl)methyl)carbamate (120 mg, 293.14 μmol, 71.76% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6) δ=9.33(s,1H),9.08(d,J=4.0Hz,1H),8.74(d,J=8.8Hz,1H),8.08(d,J=9.2Hz,1H),7.75-7.36(m,3H),4.42(br d,J=6.0Hz,2H),1.43(s,9H) ppm.
[0364] Step 6: Preparation of (2-(3-(difluoromethoxy)-4-fluoro-1H-pyrazol-1-yl)-1,6-naphthyridin-7-yl)methanamine [ka] tert-Butyl ((2-(3-(difluoromethoxy)-4-fluoro-1H-pyrazol-1-yl)-1,6-naphthyridin-7-yl)methyl)carbamate (80 mg, 195.43 μmol) in TFA (0.2 mL) and DCM (1 mL) was stirred at 25° C. for 1 h. The reaction mixture was diluted with aqueous NaHCO (5 mL) and extracted with EA (3 mL*5). The combined organic layers were dried over NaSO, filtered, and concentrated to give (2-(3-(difluoromethoxy)-4-fluoro-1H-pyrazol-1-yl)-1,6-naphthyridin-7-yl)methanamine (60 mg, 194.02 μmol, 99.28% yield) as a yellow solid. LCMS(ESI) m / z:[M+H] + =310.0
[0365] Step 7: Preparation of (2R)-N-[[2-[3-(difluoromethoxy)-4-fluoro-pyrazol-1-yl]-1,6-naphthyridin-7-yl]methyl]-6-(difluoromethyl)-2-fluoro-1,1-dioxo-3,5-dihydro-2H-4,1benzoxathiepin-8-carboxamide [ka] To a solution of (2R)-6-(difluoromethyl)-2-fluoro-1,1-dioxo-3,5-dihydro-2H-4,1-benzoxathiepin-8-carboxylic acid (60.19 mg, 194.02 μmol) in DCM (1 mL), EDCI (37.19 mg, 194.02 μmol), HOBt (26.22 mg, 194.02 μmol), and DIEA (62.69 mg, 485.05 μmol) were added, followed by [2-[3-(difluoromethoxy)-4-fluoropyrazol-1-yl]-1,6-naphthyridin-7-yl]methanamine (50 mg, 161.68 μmol). The mixture was stirred at 25 °C for 12 hours. The reaction mixture was filtered, and the filter cake was washed with PE (1 mL * 3). The resulting solid was filtered under reduced pressure to give compound 514 (54.32 mg, 90.31 μmol, yield 55.86%) as a white solid. LCMS(ESI) m / z:[M+H] + =602.1. 1 H NMR(400MHz,DMSO-d6) δ=9.91-9.88(m,1H),9.38(s,1H),9.05(d,J=4.4Hz,1H),8.83-8.71(m,2H),8.60(s,1H),8.11-8.09(m,1H),7. 77-7.33(m,3H),6.35-6.12(m,1H),5.31-5.27(m,1H),5.12-5.08(m,1H),4.83-4.82(m,2H),4.58-4.41(m,2H) ppm. Chiral SFC: OJ-3-EtOH(DEA)-5-40-3ML-35T. 1cm, Rt=2.043 min, ee%=100%.
[0366] The following examples in Table 9 were prepared using standard chemical manipulations and procedures similar to those described herein. [Table 11-1] [Table 11-2] [Table 11-3] [Table 11-4] [Table 11-5] [Table 11-6] [Table 11-7] [Table 11-8] [Table 11-9] [Table 11-10] [Table 11-11]
[0367] Example 2. Assay of ATPase catalytic activity of BRM and BRG-1 The ATPase catalytic activity of BRM or BRG-1 was measured by an in vitro biochemical assay using ADP-Glo™ (Promega, V9102). After the reaction was completed, the ADP-Glo™ kinase assay was performed in two steps. The first step was to deplete any ATP not consumed during the reaction. The second step was to convert the reaction product, ADP, to ATP, which was used by luciferase to generate luminescence and detected by a luminescence reader such as Envision.
[0368] The assay reaction mixture (10 μL) contained 30 nM BRM or BRG-1, 20 nM salmon sperm DNA (Invitrogen, UltraPure™ Salmon Sperm DNA Solution, Catalog No. 15632011), and 400 μM ATP in ATPase assay buffer, which consisted of 20 mM Tris (pH 8), 20 mM MgCl, 50 mM NaCl, 0.1% Tween-20, and 1 mM fresh DTT (Pierce™ DTT (dithiothreitol), Catalog No. 20290). The reaction was initiated by adding 2.5 μL of ATPase solution to 2.5 μL of the ATP / DNA solution in a small white Proxiplate-384 Plus plate (PerkinElmer, Catalog No. 6008280) and incubated at room temperature for 1 hour. Next, 5 μL of the ADP-Glo™ reagent provided in the kit is added, and the reaction mixture is incubated at room temperature for 40 minutes.Next, 10 μL of the kinase detection reagent provided in the kit is added to convert ADP to ATP, and the reaction mixture is incubated at room temperature for 60 minutes.Finally, luminescence readings are collected using a plate-reading luminometer such as Envision.
[0369] BRM and BRG-1 were synthesized from the High Five insect cell line with greater than 90% purity. IC values from the ATPase catalytic activity assay described herein were 50 The data is shown in Table 10 below. [Table 12-1] [Table 12-2] [Table 12-3] [Table 12-4]
[0370] Example 3. Assay of inhibitory effects on BRG1- and BRM-dependent transcription The potential inhibitory effects of compounds on BRG1- and BRM-dependent transcription were investigated by testing their activity against the BRG1-mutant lung cancer cell line A549 and the MDA cell line in which BRM had been ablated using CRISPR. Both cell lines were genetically engineered with a BRG1- or BRM-dependent mouse mammary tumor virus luciferase reporter. Luciferase transcription was induced by dexamethasone in the presence of various concentrations of compounds, and luminescence was measured using a plate reader 6 hours after stimulation.
[0371] IC from the assay described herein 50 The data are shown in Table 11 below. [Table 13-1] [Table 13-2] [Table 13-3]
[0372] Example 4. Synthesis of Compound A Compound A, a BRG1 / BRM inhibitor, has the following structure: [ka] Compound A was synthesized as shown in Scheme 1 below.
[0373] Scheme 1. Synthesis of Compound A [ka] The ATPase catalytic activity of BRM or BRG-1 in the presence of Compound A was measured by the in vitro biochemical assay using ADP-Glo™ (Promega, V9102) described above. Compound A had an IC of 10.4 nM for BRM and 19.3 nM for BRG1 in the assay. 50 It was found to have the following structure:
[0374] Example 5. Effect of BRG1 / BRM ATPase inhibition on the proliferation of uveal melanoma and hematological cancer cell lines Procedure: Uveal melanoma cell lines (92-1, MP41, MP38, MP46), prostate cancer cell line (LNCAP), lung cancer cell line (NCI-H1299), and immortalized embryonic kidney cell line (HEK293T) were seeded into 96-well plates containing growth medium (see Table 9). Compound A, a BRG1 / BRM ATPase inhibitor, was dissolved in DMSO and added to the cells at the time of seeding in a concentration gradient ranging from 0 to 10 micromolar. Cells were incubated at 37°C for 3 days. After 3 days of treatment, the medium was removed from the cells, and 30 microliters of TrypLE (Gibco) was added to the cells for 10 minutes. Cells were detached from the plate and resuspended in 170 microliters of growth medium. Cells from the two DMSO-treated control wells were counted, and the initial number of cells seeded at the beginning of the experiment was replated into fresh compound-containing plates for an additional 4 days at 37°C. On day 7, cells were harvested as described above. On days 3 and 7, relative cell proliferation was measured by adding Cell-titer glo (Promega) and measuring luminescence with an Envision plate reader (Perkin Elmer). The compound concentrations at which proliferation of each cell line was inhibited by 50% (GI 50 ) was calculated using Graphpad Prism and is plotted below. The above-mentioned method was used for multiple myeloma cell lines (OPM2, MM1S, LP1), ALL cell lines (TALL1, JURKAT, RS411), DLBCL cell lines (SUDHL6, SUDHL4, DB, WSUDCL2, PFEIFFER), AML cell line (OCIAML5), MDS cell line (SKM1), ovarian cancer cell lines (OV7, TYKNU), esophageal cancer cell line (KYSE150), rhabdoid tumor cell lines (RD, G402, G401, HS729, A204), liver cancer cell lines (HLF, HLE, PLCRPF5), and lung cancer cell lines (SW1573, NCIH2444) with the following modification: cells were seeded in 96-well plates. The next day, compound A, a BRG1 / BRM ATPase inhibitor, was dissolved in DMSO and added to the cells at a concentration gradient of 0 to 10 micromolar. At the time of cell splitting on days 3 and 7, cells were split into new 96-well plates and new compounds were added 4 hours after reseeding.
[0375] Table 12 lists the cell lines tested and the growth media used. [Table 14]
[0376] Results: As shown in Figure 1, uveal melanoma and hematological cancer cell lines were more sensitive to BRG1 / BRM inhibition than the other cell lines tested. Inhibition of uveal melanoma and hematological cancer cell lines was maintained for up to 7 days.
[0377] Example 6. Comparison of BRG1 / BRM inhibitors with clinical PKC and MEK inhibitors in uveal melanoma cell lines Procedure: Uveal melanoma cell lines, 92-1 or MP41, were seeded in 96-well plates in the presence of growth medium (see Table 12). A BAF ATPase inhibitor (Compound A), a PKC inhibitor (LXS196; MedChemExpress), or a MEK inhibitor (Selumetinib; Selleck Chemicals) was dissolved in DMSO and added to the cells at the time of seeding in a 0-10 micromolar concentration gradient. Cells were incubated at 37°C for 3 days. After 3 days of treatment, cell proliferation was measured using a Cell-titer glow (Promega) and luminescence was read using an Envision plate reader (Perkin Elmer).
[0378] Results: As shown in Figures 2A and 2B, Compound A exhibited comparable growth inhibition of uveal melanoma cells as clinical PKC inhibitors and clinical MEK inhibitors. Furthermore, Compound A was found to exhibit a faster onset of inhibition than clinical PKC inhibitors and clinical MEK inhibitors.
[0379] Example 7. Synthesis of Compound B Compound B, a BRG1 / BRM inhibitor, has the following structure: [ka] Compound B was synthesized as shown in Scheme 2 below.
[0380] Scheme 2. Synthesis of Compound B [ka]
[0381] Preparation of (S)-1-(methylsulfonyl)-N-(4-(methylthio)-1-oxo-1-((4-(3-(pyridin-4-yl)phenyl)thiazol-2-)yl)amino)butan-2-yl)-1H-pyrrole-3-carboxamide (Compound B) [ka] To a mixture of (2S)-2-amino-4-methylsulfanyl-N-[4-[3-(4-pyridyl)phenyl]thiazol-2-yl]butanamide (2 g, 4.75 mmol, HCl salt) and 1-methylsulfonylpyrrole-3-carboxylic acid (898.81 mg, 4.75 mmol) in DMF (20 mL), EDCI (1.37 g, 7.13 mmol), HOBt (962.92 mg, 7.13 mmol), and DIEA (2.46 g, 19.00 mmol, 3.31 mL) were added, and the mixture was stirred at 25 °C for 3 h. The mixture was poured into HO (100 mL), and the precipitate was collected by filtration. The solid was triturated with MeOH (20 mL), and the precipitate was collected by filtration. After dissolving the solid in DMSO (10 mL), the mixture was poured into MeOH (50 mL) and the precipitate formed was collected by filtration and lyophilized to give compound B (2.05 g, 3.66 mmol, 77.01% yield) as a white solid. LCMS (ESI) m / z [M+H] + =555.9. 1H NMR(400MHz,DMSO) δ 12.49(s,1H),8.68-8.66(m,2H),8.46(d,J=7.2Hz,1H),8.31-8.30(m,1H),8.02-8. 00(m,1H),7.94-7.96(m,1H),7.83(s,1H),7.73-7.74(m,3H),7.61-7.57(m,1H),7. 31-7.29(m,1H),6.79-6.77(m,1H),4.74-4.69(m,1H),3.57(s,3H),2.67-2.53(m,2 H),2.13-2.01(m,5H).SFC:AS-3-MeOH(DEA)-40-3mL-35T.lcm,t=0.932min,ee%=100%.
[0382] Example 8. Effect of BRG1 / BRM ATPase inhibition on the proliferation of uveal melanoma, hematological cancer, prostate cancer, breast cancer, and Ewing's sarcoma cell lines Procedure: All of the cell lines described above in Example 4 were also tested with Compound B as described above. In addition, the following cell lines were also tested as follows: Briefly, Ewing's sarcoma cell lines (CADOES1, RDES, SKES1), retinoblastoma cell line (WERIRB1), ALL cell line (REH), AML cell line (KASUMI1), prostate cancer cell lines (PC3, DU145, 22RV1), melanoma cell lines (SH4, SKMEL28, WM115, COLO829, SKMEL3, A375), breast cancer cell lines (MDAMB415, CAMA1, MCF7, BT474, HCC14), and leukemia cell lines (VEGF, ... The above method was performed for the following cell lines: B-ALL cell line (SUPB15), CML cell line (K562, MEG01), Burkitt's lymphoma cell line (RAMOS2G64C10, DAUDI), mantle cell lymphoma cell line (JEKO1, REC1), bladder cancer cell line (HT1197), and lung cancer cell line (SBC5). The cells were seeded into 96-well plates. The following day, compound B, a BRG1 / BRM ATPase inhibitor, was dissolved in DMSO and added to the cells at a concentration gradient of 0 to 10 micromolar. On days 3 and 7, the cells were split into new 96-well plates, and new compound was added 4 hours after reseeding.
[0383] Table 13 lists the cell lines tested and the growth media used. [Table 15]
[0384] Results: As shown in Figure 3, uveal melanoma, hematological cancer, prostate cancer, breast cancer, and Ewing's sarcoma cell lines were more sensitive to BRG1 / BRM inhibition than the other cell lines tested. Inhibition of uveal melanoma, hematological cancer, prostate cancer, breast cancer, and Ewing's sarcoma cell lines was maintained for up to 7 days.
[0385] Example 9. Effect of BRG1 / BRM ATPase inhibition on the proliferation of uveal melanoma and hematological cancer cell lines Procedure: Pooled cell viability assays were performed using PRISM (simultaneous profiling of relative inhibition in mixtures) as previously described (Yu et al., "High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines," Nature Biotechnology 34, 419-423, 2016), with the following modifications. Cell lines were obtained from the Cancer Cell Line Encyclopedia (CCLE) collection and adapted to phenol red-free RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) to apply a unique infection and pooling protocol to this large catalog of cell lines. A lentiviral spin-infection protocol was performed to introduce a 24-nucleotide barcode into each cell line, using blasticidin as a selection marker at an estimated multiplicity of infection (MOI) of 1 for all cell lines. Next, over 750 stably barcoded PRISM cancer cell lines were pooled together into 25 pools according to their doubling times. To perform the screening, instead of seeding a pool of 25 cell lines per well as previously described (Yu et al.), we seeded all adherent or all suspension cell line pools together in T25 flasks (100,000 cells / flask) or 6-well plates (50,000 cells / well), respectively. Cells were treated with either DMSO or compound in triplicate, 3-fold dose-response assays, starting at a top concentration of 10 μM. As a control for assay robustness, cells were treated in parallel with two previously validated compounds, the pan-Raf inhibitor AZ-628 and the proteasome inhibitor bortezomib, using top concentrations of 2.5 μM and 0.039 μM, respectively.
[0386] After 3 days of compound treatment, cells were lysed, genomic DNA was extracted, and barcodes were amplified by PCR and detected using next-generation sequencing. Cell viability was determined by comparing the counts of cell line-specific barcodes in treated samples with those in the DMSO control and day 0 control. Dose-response curves were fitted for each cell line, and the corresponding area under the curve (AUC) was calculated and compared to the median AUC of all cell lines (Figure 4). Cell lines with AUCs below the median were considered the most sensitive.
[0387] Example 10. Effect of BRG1 / BRM ATPase inhibitors on the proliferation of uveal melanoma cell lines Procedure: Uveal melanoma cell lines (92-1, MP41, MP38, MP46) and non-small cell lung cancer cells (NCI-H1299) were seeded into 96-well plates containing growth medium (see Table 9). Compound 67, a BRG1 / BRM ATPase inhibitor, was dissolved in DMSO and added to the cells at the time of seeding in a concentration gradient ranging from 0 to 10 micromolar. Cells were incubated at 37°C for 3 days. After 3 days of treatment, cell proliferation was measured using a Cell-titer glow (Promega) and luminescence was read using an Envision plate reader (Perkin Elmer).
[0388] Results: As shown in Figure 5, Compound B produced potent growth inhibition in uveal melanoma cell lines.
[0389] Example 11. Comparison of BRG1 / BRM inhibitors with clinical PKC and MEK inhibitors in uveal melanoma cell lines Procedure: Uveal melanoma cell lines, 92-1 or MP41, were seeded in 96-well plates in the presence of growth medium (see Table 9). A BAF ATPase inhibitor (Compound B), a PKC inhibitor (LXS196; MedChemExpress), and a MEK inhibitor (Selumetinib; Selleck Chemicals) were dissolved in DMSO and added to the cells at the time of seeding in a concentration gradient ranging from 0 to 10 micromolar. Cells were incubated at 37°C for 3 days. After 3 days of treatment, cell proliferation was measured using a Cell-titer glow (Promega) and luminescence was read using an Envision plate reader (Perkin Elmer).
[0390] Results: As shown in Figures 6A and 6B, Compound B exhibited more potent growth inhibition effects on uveal melanoma cells than clinical PKC inhibitors and clinical MEK inhibitors. Furthermore, Compound B was found to induce faster growth inhibition than clinical PKC inhibitors and clinical MEK inhibitors.
[0391] Example 12. BRG1 / BRM ATPase inhibitors are effective in inhibiting the growth of PKC inhibitor-resistant cells. Procedure: MP41 uveal melanoma cells were made resistant to a PKC inhibitor (LXS196, MedChemExpress) by long-term culture in growth medium containing increasing concentrations of the compound up to 1 μM (see Table 9). After 3 months, the sensitivity of parental MP41 cells and PKC inhibitor (PKCi)-resistant cells to the PKC inhibitor (LXS196) or the BRG1 / BRM ATPase inhibitor (Compound B) was tested in a 7-day growth inhibition assay as described above in Example 6.
[0392] Results: Although PKCi-resistant cells could tolerate growth at higher concentrations of LXS196 than the parental MP41 cell line (Figure 7A), the BRG1 / BRM ATPase inhibitor (compound B) still produced strong growth inhibition of both the PKCi-resistant and parental cell lines (Figure 7B). PKCi-resistant cells were more sensitive to compound B than the parental MP41 cells (Figure 7B).
[0393] Example 13. Synthesis of Compound C [ka] Step 1. Preparation of 6-fluoropyridine-2-carbonyl chloride (intermediate B) [ka] To a cooled (0 °C) solution of 6-fluoropyridine-2-carboxylic acid (50.00 g, 354.36 mmol) in dichloromethane (500 mL) and N,N-dimethylformamide (0.26 mL, 3.54 mmol) was added oxalyl chloride (155.10 mL, 1.77 mol). After all the oxalyl chloride was added, the reaction mixture was warmed to room temperature and stirred for an additional 0.5 h. The mixture was concentrated in vacuo to give Intermediate B (56.50 g) as a white solid, which was used in the next step without further purification.
[0394] Step 2. Preparation of 2-chloro-1-(6-fluoro-2-pyridyl)ethenone (Intermediate C) [ka] To a cooled (0 °C) mixture of Intermediate B (56.00 g, 351.00 mmol) in 1,4-dioxane (800 mL) was added dropwise a 2 M solution of trimethylsilyldiazomethane in hexane (351 mL). The resulting reaction mixture was stirred at 25 °C for 10 h. Subsequently, the reaction mixture was quenched with a solution of 4 M HCl in 1,4-dioxane (500 mL). After stirring for 2 h, the reaction solution was concentrated in vacuo to give an oil. The residue was diluted with saturated aqueous NaHCO (500 mL) and extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (300 mL × 2), dried over NaSO, filtered, and concentrated under reduced pressure to give Intermediate C (35.50 g) as a white solid, which was used directly in the next step. LCMS (ESI) m / z: [M+H] + =173.8.
[0395] Step 3. Preparation of 4-(6-fluoro-2-pyridyl)thiazol-2-amine (Intermediate E) [ka] To a solution of intermediate C (35.50 g, 204.53 mmol) and thiourea (14.01 g, 184.07 mmol) in a mixture of MeOH (250 mL) and HO (250 mL) was added NaF (3.56 g, 84.82 mmol) at room temperature. After stirring for 0.5 h, the reaction mixture was partially concentrated in vacuo to remove MeOH, and the resulting solution was acidified to pH ∼3 with 2 M aqueous HCl. After 15 min, the solution was extracted with ethyl acetate (200 mL × 3), the organic layer was discarded, and the aqueous phase was made alkaline with NaHCO (500 mL). After stirring for 30 min, it was extracted with ethyl acetate (325 mL × 3). The combined organic layer was washed with brine (225 mL × 3), dried over NaSO, filtered, and concentrated under reduced pressure. The residue was triturated with petroleum ether (300 mL), stirred at 25 °C for 10 min, and filtered. The resulting solid was dried under vacuum to give intermediate E (28.00 g, 143.43 mmol, yield 70.13%, purity 100%) as a white solid. LCMS (ESI) m / z: [M+H] + =195.8.; 1 H NMR(400MHz,DMSO-d6) δ 8.00-7.96(m,1H),7.72(d,J=7.2Hz,1H),7.24(s,1H),7.16(s,2H),7.02(d,J=8.0Hz,1H).
[0396] Step 4. Preparation of tert-butyl N-[2-[[4-(6-fluoro-2-pyridyl)thiazol-2-yl]amino]-2-oxo-ethyl]carbamate (Intermediate G) [ka] To a solution of N-Boc-glycine (5.92 g, 33.81 mmol), HATU (12.86 g, 33.81 mmol), and DIEA (15.89 g, 122.94 mmol, 21.41 mL) in dichloromethane (100 mL) was added Intermediate E (6.00 g, 30.74 mmol). After stirring for 2 hours, the reaction mixture was concentrated, then diluted with water (100 mL), and extracted with ethyl acetate (60 mL × 4). The combined organic layers were washed with brine (100 mL × 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to give a residue. The residue was triturated with a 1:1 mixture of petroleum ether and MeOH (40 mL). After stirring at 25° C. for 20 min, the suspension was filtered, and the filter cake was washed with MTBE (20 mL) and dried in vacuo to give intermediate G (7.7 g, 21.63 mmol, 70.4% yield, 99.0% purity) as a white solid. LCMS (ESI) m / z: [M+H] + =353.1.
[0397] Step 5. Preparation of 2-((4-(6-fluoropyridin-2-yl)thiazol-2-yl)amino)-2-oxoethan-1-aminium chloride (Intermediate H) [ka] A solution of intermediate G (5.40 g, 15.32 mmol) in 4 M HCl in 1,4-dioxane (35 mL) was stirred at 25° C. for 1.5 h. The mixture was concentrated in vacuo to give intermediate H (4.42 g) as a white solid, which was used directly in the next step without further purification. LCMS (ESI) m / z: [M+H] + =252.9.
[0398] Step 6. Preparation of 1-tert-butyl-N-[2-[[4-(6-fluoro-2-pyridyl)thiazol-2-yl]amino]-2-oxo-ethyl]pyrrole-3-carboxamide (Intermediate J) [ka] To a solution of Intermediate H (3.00 g, 10.39 mmol), 1-tert-butylpyrrole-3-carboxylic acid (1.74 g, 10.39 mmol), and DIEA (6.71 g, 51.95 mmol, 9.05 mL) in dichloromethane (40 mL) were added HOBt (1.68 g, 12.47 mmol) and EDCI (2.39 g, 12.47 mmol) sequentially. After stirring for 4 h, the mixture was concentrated in vacuo. The residue was diluted with water (250 mL) and extracted with ethyl acetate (200 mL × 3). The combined organic layers were washed with brine (300 mL × 3), dried over Na2SO4, filtered, and concentrated under reduced pressure. The resulting solid was triturated with a 1:1 mixture of MTBE / ethyl acetate (400 mL), and after 30 min, the suspension was filtered. The solid was washed with MTBE (85 mL×3) and then dried in vacuo to obtain intermediate J (3.10 g, 7.64 mmol, yield 73.6%, purity 99.0%) as a white solid. LCMS(ESI) m / z:[M+H] + =402.3. 1 H NMR(400MHz,DMSO-d6) δ 12.40(s,1H),8.18-8.15(m,1H),8.09-8.08(m,1H),7.87-7.83(m,2H),7.52(s,1H), 7.11(d,J=8.0Hz,1H),6.97(m,1H),6.47(s,1H),4.10(d,J=5.6Hz,2H),1.49(s,9H).
[0399] Step 7. Preparation of 1-(tert-butyl)-N-(2-((4-(6-(cis-2,6-dimethylmorpholino)pyridin-2-yl)thiazol-2-yl)amino)-2-oxoethyl)-1H-pyrrole-3-carboxamide (Compound C) [ka] To a solution of intermediate J (0.100 g, 0.249 mmol) in DMSO (1 mL) were added DIEA (0.130 mL, 0.747 mmol) and cis-2,6-dimethylmorpholine (0.057 g, 0.498 mmol), and the mixture was stirred at 120 °C. After 12 h, the solution was cooled to room temperature, and the reaction mixture was diluted with MeOH (3 mL). The residue was purified by preparative HPLC (0.1% TFA; column: Luna C18 150*25 5u; mobile phase: [water (0.075% TFA)-ACN]; B%: 30% to 60%, 2 min). The appropriate fractions were collected and lyophilized to give compound C (0.079 g, 0.129 mmol, 51.94% yield, 100% purity) as a white solid. LCMS (ESI) m / z: [M+H] + =497.5. 1 H NMR(400MHz,DMSO-d6) δ 12.27(s,1H),8.17-8.14(m,1H),7.75(s,1H),7.63-7.59(m,1H),7.51(s,1H),7.25(d,J=7.2Hz,1H),6.96(s,1H),6.79(d,J=8.8Hz,1H ),6.47(s,1H),4.24(d,J=12.4Hz,2H),4.08(d,J=5.6Hz,2H),3.64-3.61(m,2H),2.44-2.38(m,2H),1.49(s,9H),1.18(d,J=5.6Hz,6H).
[0400] Example 14. BRG1 / BRM ATPase inhibitors cause inhibition of uveal melanoma tumor growth in vivo. Procedure: Nude mice (Envigo) were cultured at 5 × 10 6 92-1 uveal melanoma cells were used to implant subcutaneously in the axillary region. Tumors averaged approximately 200 mm 3The tumors were allowed to grow until the tumor size reached 100 μg / kg, at which point the mice were grouped and dosing was initiated. Mice were dosed once daily by oral gavage with vehicle (20% 2-hydroxypropyl-β-cyclodextrin) or increasing doses of Compound C. Tumor volume and body weight were measured over a 3-week period, and the dose was adjusted according to body weight to obtain the appropriate dose in mg / kg. At this point, the animals were sacrificed, and the tumors were dissected and imaged.
[0401] Results: Treatment with Compound C resulted in tumor growth inhibition in a dose-dependent manner, with tumor regression observed at the highest dose (50 mg / kg) (Figures 8A and 8B). Both treatments were well tolerated, and no weight loss was observed (Figure 8C).
[0402] Other embodiments While the invention has been described in relation to particular embodiments thereof, it will be understood that the invention is capable of further modifications, and this application is intended to cover any variations, uses, or adaptations of the invention which generally follow the principles of the invention and include departures from the present disclosure which come within known or customary practice within the art to which this invention pertains, and which may be applied to the essential features set forth herein above, and which fall within the scope of the appended claims.
[0403] Other embodiments are within the scope of the following claims.
Claims
1. A compound having the structure: 【Chemistry 1】 During the ceremony, m is 0, 1, 2, or 3; n is 0, 1, 2, 3, or 4; p is 0, 1, 2, or 3. X 1 But, O, NR 5 , or (C(R 5 ) (R 6 )) and Z 1 and Z 2 Each of is independently absent or (C(R 9 ) 2 ) or O, except that X 1 When is O, Z 1 and Z 2 Each of is independently absent or (C(R 9 ) 2 ) and X 2 But N or CR 8 and Each R X1 are independently deuterium, optionally substituted C 1 -C 6 alkyl, halo, or two geminal R X1 The groups combine with the atoms to which they are attached to form a carbonyl, L 1 is an optionally substituted 9- or 10-membered bicyclic heterocyclyl, an optionally substituted 9- or 10-membered bicyclic heteroaryl, an optionally substituted 6-membered monocyclic heteroarylvinyl, an optionally substituted 6-membered monocyclic heteroaryl-C 3 -C 8 -cycloalkyl or an optionally substituted monocyclic 6-membered heteroarylethynyl; L 2 is absent or optionally substituted C 3 -C 10 Cycloalkyl, optionally substituted C 6 -C 10 aryl, optionally substituted 5-10 membered heteroaryl, or optionally substituted 4-10 membered heterocyclyl; R 1 is hydrogen or optionally substituted C 1 -C 6 is alkyl, Each R 2 And each R 3 are independently hydrogen, optionally substituted C 1 -C 6 Alkyl, or optionally substituted C 1 -C 6 is heteroalkyl, R 4 is hydrogen, halo, optionally substituted C 1 -C 6 Alkyl, or optionally substituted C 3 -C 10 is cycloalkyl, R 5 is hydrogen, deuterium, or optionally substituted C 1 -C 6 is alkyl, R 6 is hydrogen, deuterium, optionally substituted C 1 -C 6 alkyl, or halo; 9 are independently hydrogen, deuterium, optionally substituted C 1 -C 6 alkyl, or halo, or R 6 and one adjacent R 9 taken together with the atom to which they are attached, optionally substituted C 3 -C 8 Form a cycloalkyl, and the remaining R 9 Groups, if present, are independently deuterium, optionally substituted C 1 -C 6 alkyl or halo; Each R 7 is independently an optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6 Heteroalkyl, halo, optionally substituted C 3 -C 10 cycloalkyl, optionally substituted 5- to 10-membered heteroaryl, optionally substituted 4- to 10-membered heterocyclyl, -N(R 7A ) 2 , or -OR 7A and each R 7A is independently H, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 1 -C 6 Heteroalkyl, optionally substituted C 3 -C 10 Cycloalkyl, optionally substituted C 6 -C 10 aryl, optionally substituted 5- to 10-membered heteroaryl, or optionally substituted 4- to 10-membered heterocyclyl, or two geminal R 7A groups combine together with the atoms to which they are attached to form an optionally substituted 5- to 10-membered heteroaryl or an optionally substituted 4- to 10-membered heterocyclyl; R 8 is hydrogen, halo, cyano, optionally substituted C 1 -C 6 Alkyl, optionally substituted C 2 -C 6 Alkynyl, optionally substituted C 1 -C 6 Heteroalkyl or optionally substituted C 3 -C 10 is cycloalkyl, R 10 is hydrogen or halo, or a pharma- ceutically acceptable salt thereof.
2. Z 1 But (C(R 9 ) 2 2. The compound of claim 1, wherein R is H, or a pharma- ceutically acceptable salt thereof.
3. Z 1 or a pharma- ceutically acceptable salt thereof, according to claim 1, wherein:
4. Z 1 is O, or a pharma- ceutically acceptable salt thereof.
5. Z 2 But (C(R 9 ) 2 5. The compound according to claim 1, wherein R is an integer from 1 to 4, or a pharma- ceutically acceptable salt thereof.
6. Z 2 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein
7. Z 2 The compound according to any one of claims 1 to 3, wherein is O, or a pharma- ceutically acceptable salt thereof.
8. X 1 is O; or a pharma- ceutically acceptable salt thereof.
9. X 1 But, N.R. 5 The compound according to any one of claims 1 to 7, wherein:
10. X 1 But (C(R 5 ) (R 6 8. The compound according to claim 1, wherein R is an integer from 1 to 7;
11. X 2 But, CR 8 11. The compound according to any one of claims 1 to 10, wherein:
12. 【Chemical Formula 2】 is a group having the following structure: 【Chemistry 3】 2. The compound of claim 1, wherein:
13. 【Chemical Formula 4】 is a group having the following structure: 【Chemistry 5】 2. The compound of claim 1, wherein:
14. 【Chemical Formula 6】 is a group having the following structure: 【Chemistry 7】 14. The compound of claim 13, wherein:
15. 【Fig. 8】 is a group having the following structure: 【Chemistry 9】 2. The compound of claim 1, wherein:
16. 【Fig. 10】 is a group having the following structure: 【Chemistry 11】 2. The compound of claim 1, wherein:
17. 【Fig. 12】 is a group having the following structure: 【Chemistry 13】 2. The compound of claim 1, wherein:
18. 【Fig. 14】 is a group having the following structure: 【Chemistry 15】 2. The compound of claim 1, wherein:
19. 【Fig. 16】 is a group having the following structure: 【Chemistry 17】 2. The compound of claim 1, wherein:
20. 【Fig. 18】 is a group having the following structure: 【Chemistry 19】 2. The compound of claim 1, wherein:
21. 【Fig. 20】 is a group having the following structure: 【Chemistry 21】 2. The compound of claim 1, wherein:
22. R 8 The compound according to any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.
23. R 8 or a pharma- ceutically acceptable salt thereof. The compound according to any one of claims 1 to 21, wherein: is halo.
24. R 8 or a pharma- ceutically acceptable salt thereof.
25. R 8 is optionally substituted C 2 -C 6 22. The compound of any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, which is alkynyl.
26. R 8 is optionally substituted C 1 -C 6 22. The compound of any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, which is heteroalkyl.
27. R 8 is optionally substituted C 3 -C 10 22. The compound of any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, which is cycloalkyl.
28. X 2 The compound according to any one of claims 1 to 10, wherein is N, or a pharma- ceutically acceptable salt thereof.
29. 【Fig. 22】 is a group having the following structure: 【Chemistry 23】 2. The compound of claim 1, wherein:
30. R 4 The compound according to any one of claims 1 to 29, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.
31. R 4 The compound according to any one of claims 1 to 29, or a pharma- ceutically acceptable salt thereof, wherein is halogen.
32. R 10 The compound according to any one of claims 1 to 31, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.
33. R 10 The compound according to any one of claims 1 to 31, or a pharma- ceutically acceptable salt thereof, wherein is halogen.
34. At least one R X1 is optionally substituted C 1 -C 6 34. The compound according to any one of claims 1 to 33, or a pharma- ceutically acceptable salt thereof, which is alkyl.
35. At least one R X1 or a pharma- ceutically acceptable salt thereof. The compound of any one of claims 1 to 33, wherein: is halo.
36. At least one R X1 The compound according to any one of claims 1 to 33, or a pharma- ceutically acceptable salt thereof, wherein is deuterium.
37. The compound according to any one of claims 1 to 36, wherein p is 3, or a pharma- ceutically acceptable salt thereof.
38. The compound according to any one of claims 1 to 36, wherein p is 2, or a pharma- ceutically acceptable salt thereof.
39. The compound according to any one of claims 1 to 36, wherein p is 1, or a pharma- ceutically acceptable salt thereof.
40. The compound according to any one of claims 1 to 36, wherein p is 0, or a pharma- ceutically acceptable salt thereof.
41. L 1 41. The compound or pharma- ceutically acceptable salt of any one of claims 1 to 40, wherein is an optionally substituted 9 or 10 membered bicyclic heteroaryl.
42. L 1 but: 【Chemistry 24】 During the ceremony, X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 each independently represents N or CR L1 and Each R L1 is independently H, halo, optionally substituted C 1 -C 6 is alkyl, A 1 But -(C(R 2 ) (R 3 )) m - is a bond to A 2 But, L 2 or a pharma- ceutically acceptable salt thereof.
42. The compound of any one of claims 1 to 41, wherein
43. L 1 but the following: 【Chemistry 25】 42. The compound according to any one of claims 1 to 41, or a pharma- ceutically acceptable salt thereof.
44. R L1 or a pharma- ceutically acceptable salt thereof.
44. The compound of claim 43, wherein:
45. L 1 but the following: 【Chemistry 26】 42. The compound according to any one of claims 1 to 41, or a pharma- ceutically acceptable salt thereof.
46. L 1 but the following: 【Chemistry 27】 42. The compound according to any one of claims 1 to 41, or a pharma- ceutically acceptable salt thereof.
47. L 1 or a pharma- ceutically acceptable salt thereof. The compound of any one of claims 1 to 40, wherein is an optionally substituted monocyclic 6-membered heteroarylvinyl; or a pharma- ceutically acceptable salt thereof.
48. L 1 but: 【Chemistry 28】 During the ceremony, X 3 , X 4 , and X 5 each independently represents N or CR L1 and Each R L1 is independently H, halo, optionally substituted C 1 -C 6 is alkyl, A 1 But -(C(R 2 ) (R 3 )) m - is a bond to A 2 But, L 2 or a pharma- ceutically acceptable salt thereof.
49. L 1 but the following: 【Chemical 29】 41. The compound according to any one of claims 1 to 40, wherein:
50. L 1 or a pharma- ceutically acceptable salt thereof. The compound of any one of claims 1 to 40, wherein: is an optionally substituted monocyclic 6-membered heteroarylethynyl; or a pharma- ceutically acceptable salt thereof.
51. L 1 but: 【Chemistry 30】 During the ceremony, X 3 , X 4 , and X 5 each independently represents N or CR L1 and Each R L1 is independently H, halo, optionally substituted C 1 -C 6 is alkyl, A 1 But -(C(R 2 ) (R 3 )) m - is a bond to A 2 But, L 2 or a pharma- ceutically acceptable salt thereof.
52. L 1 but the following: 【Chemistry 31】 41. The compound according to any one of claims 1 to 40, wherein:
53. L 1 is an optionally substituted monocyclic 6-membered heteroaryl-C 3 -C 8 41. The compound according to any one of claims 1 to 40, or a pharma- ceutically acceptable salt thereof, wherein: -cycloalkyl.
54. L 1 but: 【Chemistry 32】 During the ceremony, X 3 , X 4 , and X 5 each independently represents N or CR L1 and Each R L1 is independently H, halo, optionally substituted C 1 -C 6 is alkyl, A 1 But -(C(R 2 ) (R 3 )) m - is a bond to A 2 But, L 2 or a pharma- ceutically acceptable salt thereof.
55. L 1 but the following: 【Chemical 33】 41. The compound according to any one of claims 1 to 40, wherein:
56. L 1 41. The compound or pharma- ceutically acceptable salt of any one of claims 1 to 40, wherein is an optionally substituted 9- or 10-membered bicyclic heterocyclyl.
57. 2. The compound of claim 1, wherein the compound has the structure: or a pharma- ceutically acceptable salt thereof. 【Chemical 34】
58. L 2 58. The compound of any one of claims 1 to 57, or a pharma- ceutically acceptable salt thereof, wherein is optionally substituted 5-10 membered heteroaryl.
59. -L 2 - (R 7 ) n or a pharma- ceutically acceptable salt thereof. The compound of any one of claims 1 to 58, wherein: 【Chemistry 35】
60. -L 2 - (R 7 ) n or a pharma- ceutically acceptable salt thereof. 【Chemical 36】
61. -L 2 - (R 7 ) n or a pharma- ceutically acceptable salt thereof. 【Chemical 37】
62. -L 2 - (R 7 ) n or a pharma- ceutically acceptable salt thereof. 【Chemical 38】
63. -L 2 - (R 7 ) n or a pharma- ceutically acceptable salt thereof. 【Chemical Formula 39】
64. -L 2 - (R 7 ) n or a pharma- ceutically acceptable salt thereof. 【Chemistry 40】
65. -L 2 - (R 7 ) n or a pharma- ceutically acceptable salt thereof. 【Chemistry 41】
66. L 2 is optionally substituted C 6 -C 10 59. The compound of any one of claims 1 to 58, or a pharma- ceutically acceptable salt thereof, which is aryl.
67. L 2 67. The compound of claim 66, or a pharma- ceutically acceptable salt thereof, wherein is optionally substituted phenyl.
68. 68. The compound according to any one of claims 1 to 67, or a pharma- ceutically acceptable salt thereof, wherein n is 1.
69. 68. The compound according to any one of claims 1 to 67, or a pharma- ceutically acceptable salt thereof, wherein n is 2.
70. 68. The compound according to any one of claims 1 to 67, or a pharma- ceutically acceptable salt thereof, wherein n is 3.
71. R 7 is optionally substituted C 1 -C 6 71. The compound of any one of claims 1 to 70, or a pharma- ceutically acceptable salt thereof, which is alkyl.
72. R 7 is optionally substituted C 1 -C 6 71. The compound of any one of claims 1 to 70, or a pharma- ceutically acceptable salt thereof, which is heteroalkyl.
73. R 7 or a pharma- ceutically acceptable salt thereof. The compound of any one of claims 1 to 70, wherein is optionally substituted 4-10 membered heterocyclyl; or a pharma- ceutically acceptable salt thereof.
74. R 7 74. The compound of claim 73, wherein is optionally substituted azetidinyl or optionally substituted morpholinyl, or a pharma- ceutically acceptable salt thereof.
75. R 7 is optionally substituted C 3 -C 10 71. The compound of any one of claims 1 to 70, or a pharma- ceutically acceptable salt thereof, which is cycloalkyl.
76. R 7 76. The compound of claim 75, or a pharma- ceutically acceptable salt thereof, wherein is optionally substituted cyclopropyl or optionally substituted cyclobutyl.
77. R 7 But -N(R 7A ) 2 71. The compound according to any one of claims 1 to 70, or a pharma- ceutically acceptable salt thereof.
78. R 7 78. The compound of claim 77, wherein is optionally substituted N-azetidinyl or optionally substituted N-morpholinyl, or a pharma- ceutically acceptable salt thereof.
79. Two Germinal R 7 71. The compound of any one of claims 1 to 70, wherein the groups combine with the atom to which they are attached to form an optionally substituted 4-10 membered heterocyclyl, or a pharma- ceutically acceptable salt thereof.
80. At least one R 7 But, -OR 7A 80. The compound according to any one of claims 1 to 79, or a pharma- ceutically acceptable salt thereof.
81. R 7A is optionally substituted C 1-6 81. The compound of claim 80, or a pharma- ceutically acceptable salt thereof, which is alkyl.
82. 82. The compound according to any one of claims 1 to 81, wherein n is 0, or a pharma- ceutically acceptable salt thereof.
83. At least one R 7 difluoromethyl, cyclopropyl, 2,2-difluorocyclopropyl, difluoromethoxy, 2,6-dimethylmorpholin-4-yl, N-azetidinyl, 3-fluorocyclobutyl, 2-methoxyethyl, ethoxy, methoxy, 2,2-difluoroethoxy, 2,2-difluoroethyl, trifluoromethyl, isopropyl, methyl, acetyl, fluoro, chloro, 1-methylpyrazol-3-yl, dimethylamino, N-methyl-N-(2-methoxyethyl)-amino, N-ethyl-N-(2-methoxyethyl)-amino , N-(2-propyl)-N-(2-methoxyethyl)-amino, 2-methoxyethylamino, 3-aza-8-oxa-bicyclo[4.3.0]non-3-yl, 3-aza-7-oxa-bicyclo[4.3.0]non-3-yl, 1-fluorocyclobut-1-yl, 3-fluoropyrrolidin-1-yl, 3-methoxypyrrolidin-1-yl, oxetan-3-yl, N-methylindolin-4-yl, 2,2-difluoro-3-methylcycloprop-1-yl, 3-methoxyazetidin-1-yl, 3-methoxypiperidin-1-yl , 1,2-dimethyl-7-azaindole-4-yl, 1-methyl-7-azaindole-4-yl, 2,3-methylenedioxyphenyl, N-methyl-N-(3-oxetanyl)amino, 3-oxetanyloxy, 1,1-difluoro-5-azaspiro[2.3]hex-5-yl, 1-fluoromethyl-cyclopropyl, N-(3-tetrahydrofuranyl)methylamino, N-indolinyl, N-1,4-oxazepanyl, 2-fluoro-2-propyl, 1,1-difluoro-2-propyl, 2,2-difluoro-1-methylsilyl cycloprop-1-yl, 1-methylcyclopropyl, 4,4-difluoropiperidin-1-yl, 2-methoxyethoxy, 3,3-difluorocyclobut-1-yl, N-methyl-N-1-methoxyprop-2-ylamino, 1-methoxyprop-2-ylamino, 1-methoxyethyl, 4-methylpiperazinyl, 3-methylmorpholinyl, 2,2-difluoropropoxy, 3-methoxycyclobutyl, methylamino, 4-dimethylamino-3,3-difluoropiperidinyl, 4-methylamino-3,3-difluoropiperidinyl, 3,The compound according to any one of claims 1 to 82, which is 3-difluoropyrrololidinyl, N-methyl-N-3-methoxycyclobutylamino, 1-methylpyrazol-5-yl, 6-oxa-3-azabicyclo[3.1.1]hept-3-yl, cyclopropyloxy, 2,6-dimethylpyrid-4-yl, 2-methylpyrrololidinyl, 4-oxabicyclo[4.1.0]hept-1-yl, N-methyl-N-(2,6-dimethyltetrahydropyran-4-yl)amino, or N-methyl-N-3-methyloxetan-3-ylmethylamino, or a pharma- ceutically acceptable salt thereof.
84. R 1 The compound according to any one of claims 1 to 56 and 58 to 83, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.
85. 【Chemical Formula 42】 is a group having the following structure: 【Chemistry 43】 85. The compound according to any one of claims 1 to 84, wherein:
86. 【Chemical Formula 44】 is a group having the following structure: 【Chemistry 45】 85. The compound according to any one of claims 1 to 84, wherein:
87. A compound selected from the group consisting of compounds 1 to 523, and pharma- ceutically acceptable salts thereof.
88. The compound is a BRG1 IC 50 and BRM IC 50 or a pharma- ceutically acceptable salt thereof, wherein the ratio of
89. The compound is a BRG1 IC 50 and BRM IC 50 or a pharma- ceutically acceptable salt thereof, wherein the ratio of
90. The compound is a BRG1 IC 50 and BRM IC 50 The compound according to any one of claims 1 to 89, or a pharma- ceutically acceptable salt thereof, wherein the ratio of
91. The compound is a BRG1 IC 50 and BRM IC 50 The compound according to any one of claims 1 to 90, or a pharma- ceutically acceptable salt thereof, wherein the ratio of
92. A pharmaceutical composition comprising a compound according to any one of claims 1 to 91 and a pharma- ceutically acceptable excipient.
93. 93. A method for treating a BAF complex-associated disorder in a subject in need of such treatment, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 91 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 92.
94. 94. The method of claim 93, wherein the BAF complex-associated disorder is cancer or a viral infection.
95. A method for treating a disorder associated with a loss-of-function mutation in BRG1 in a subject in need of such treatment, comprising administering to the subject an effective amount of a compound described in any one of claims 1 to 91 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition described in claim 92.
96. 96. The method of claim 95, wherein the disorder associated with a loss-of-function mutation in BRG1 is cancer.
97. 93. A method of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 91 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 92.
98. The method of any one of claims 93 to 97, wherein the cancer is non-small cell lung cancer, colon cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, esophageal and gastric cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin's lymphoma, small cell lung cancer, prostate cancer, embryonal tumors, germ cell tumors, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumors, uterine sarcoma, gastrointestinal stromal tumors, CNS cancer, thymic tumors, adrenal cortical cancer, appendix cancer, small intestine cancer, or penile cancer.
99. 99. The method of claim 98, wherein the cancer is non-small cell lung cancer, colorectal cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, soft tissue sarcoma, or penile cancer.
100. 100. The method of claim 99, wherein the cancer is non-small cell lung cancer.
101. 100. The method of claim 99, wherein the cancer is a soft tissue sarcoma.
102. 93. A compound according to any one of claims 1 to 91, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 92, for use in the treatment of cancer.
103. The compound or its pharmacologic acceptable salt, or pharmaceutical composition for use according to claim 102, wherein the cancer is non-small cell lung cancer, colon cancer, bladder cancer, cancer of unknown primary site, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, esophageal and gastric cancer, pancreatic cancer, hepatobiliary cancer, soft tissue sarcoma, ovarian cancer, head and neck cancer, renal cell carcinoma, bone cancer, non-Hodgkin's lymphoma, small cell lung cancer, prostate cancer, embryonal tumors, germ cell tumors, cervical cancer, thyroid cancer, salivary gland cancer, gastrointestinal neuroendocrine tumors, uterine sarcoma, gastrointestinal stromal tumors, CNS cancer, thymic tumors, adrenal cortical carcinoma, appendix cancer, small intestine cancer, or penile cancer.
104. 103. The compound or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition for use according to claim 102, wherein the cancer is non-small cell lung cancer, colon cancer, bladder cancer, cancer of unknown primary, glioma, breast cancer, melanoma, non-melanoma skin cancer, endometrial cancer, or penile cancer.
105. 103. The compound or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition for use according to claim 102, wherein the cancer is non-small cell lung cancer.
106. 103. The compound or a pharma- ceutically acceptable salt thereof, or pharmaceutical composition for use according to claim 102, wherein the cancer is soft tissue sarcoma.
107. 107. The compound or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition for use according to any one of claims 102 to 106, wherein the cancer is metastatic.
108. 108. The compound or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition for use according to any one of claims 102 to 107, further comprising an anti-cancer therapy.
